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ABSTRACT 
Melea Ward: A comparative effectiveness analysis of patients newly initiating tyrosine kinase inhibitor 
therapy for chronic myeloid leukemia 
(Under the direction of Susan Blalock) 
 
There are currently three tyrosine kinase inhibitors (TKI) approved for first-line treatment of 
chronic myeloid leukemia (CML).  Historically, imatinib, a first-generation TKI (1GTKI), was the 
standard of care for patients with CML.  Both nilotinib and dasatinab, second-generation TKIs (2GTKI), 
received FDA approval as first-line options for CML in 2010.  This study examined the association 
between patients newly initiating a 1GTKI compared to a 2GTKI and treatment patterns, adherence, 
health services utilization and healthcare costs. 
A retrospective cohort study of commercial and Medicare patients newly initiating TKI therapy 
between June 1, 2010 and December 31, 2011 were identified.  Patients who were new users, 
continuously enrolled for 4 months during the baseline period, between the ages of 18 and 89 years old at 
the index date, and had a diagnosis for CML were included.  Risk adjustment methods were used to 
evaluate time to treatment interruption and regimen change.  Multivariate logistic regression was used to 
investigate the association between TKI therapy and adherence.  Generalized linear models were used to 
examine the association between TKI therapy and (1) health services utilization and (2) healthcare costs 
during the 12 months follow-up period.  
Of the 368 patients newly initiated on TKI therapy, 237 (64%) initiated therapy on 1GTKI.  
Initiating a 2GTKI was associated with a higher risk of treatment interruption (HR: 1.59, 95% CI 1.18-
2.12, unadjusted model; HR: 1.48, 95% CI 1.08-2.02, multivariable model; HR 1.50, 95% CI 1.10-2.04, 
propensity score quintiles model).  Although the majority of patients with a treatment interruption re-
initiated the index medication or changed medications, 15% of patients who initiated a 1GTKI and 30% 
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of patients who initiated a 2GTKI discontinued treatment for the remainder of the study period.  There 
was no association between initiating a 2GTKI versus 1GTKI and regimen change or adherence.  
Although mean adherence was higher for the 1GTKI cohort compared to the 2GTKI cohort, mean 
adherence was low in both cohorts (PDC=0.79 and PDC=0.68, respectively, p=0.007).  Patients who 
initiated 2GTKI incurred more inpatient hospitalizations and ER visits compared to 1GTKI.  Regression 
models demonstrated that initiating therapy with a 2GTKI was associated with higher total and TKI-
related costs. 
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CHAPTER I: INTRODUCTION 
1.1 Overview 
Chronic myeloid leukemia (CML) accounts for 15% of all leukemias, with a median age at 
diagnosis of 64 years.1  In 2013, it was estimated that 5,920 people would be diagnosed with CML and 
610 would die from the disease in the United States.2  CML is classified into three phases (i.e. chronic, 
accelerated and blast crisis) and is typically diagnosed in the chronic phase.3  Untreated chronic phase 
CML typically will evolve into advanced phase disease in 3-5 years.4 
There are currently three oral oncology agents known as tyrosine kinase inhibitors (TKIs) 
approved for the first-line treatment of CML: imatinib, dasatinib, and nilotinib.5-7  Imatinib was approved 
for the treatment of CML in 2001 and has been the standard of care for newly diagnosed patients. The 
introduction of this targeted cancer therapy changed CML from a fatal condition to one that can be 
managed as a chronic illness in many patients.  Although this novel agent has been a significant advance 
in treating CML, it has some limitations.  Major limitations of imatinib therapy include toxicity, lack of 
efficacy, and poor adherence.8   
Dasatinib and nilotinib are second-generation TKIs, initially approved by the FDA as second-line 
therapy for patients with CML who are resistant or intolerant to imatinib.  With the aim of improving 
responses achieved with first-line therapy, head-to-head randomized control trials (RCTs) were conducted 
to compare the second-generation TKIs to imatinib for patients newly diagnosed with chronic phase 
CML.9-13  Both nilotinib and dasatinib had superior efficacy over imatinib during the first year of therapy, 
with higher rates of complete cytogenetic response and major molecular response and similar safety 
profiles.9,11  Subsequently, nilotinib received FDA approval as a first-line option for CML in June 2010 
and dasatinib received approval in October 2010.
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The rationale for initiating a second-generation TKI as first-line therapy is remarkable rates of 
early responses, excellent event-free survival, and overall survival.14-16  The counterargument is that 
approximately two-thirds of patients have an acceptable response to imatinib based on the results of the 
IRIS study17 and other reports.18,19  Regardless of what agent is chosen as first-line therapy, physicians 
will continue to have to consider adherence as well as cost.  Long-term continuous exposure to TKI 
therapy is required to achieve and maintain favorable treatment outcomes.  Specifically, adherence greater 
than 90% has been correlated with clinical end points that are associated with prolonged survival.17,20-22   
Cost is another important consideration.  The price of a 1-year supply of a first-generation TKI 
(i.e. imatinib) and a second-generation TKI (i.e. dasatinib, and nilotinib) is between $80,000 to $90,000 
and $115,000 to $124,000, respectively.23  These medications are typically placed in the highest tier, the 
specialty tier, which requires a 20% co-insurance, placing a large financial burden on the patient.  Thus, 
member cost-share may be an important barrier to medication adherence and persistence that should be 
considered for treatment with TKI therapy.  Cost will continue to be an important health care issue to 
consider when generic imatinib becomes available in 2015.  The expected price differential between 
generic imatinib and the second-generation TKIs will be considerable ($2,000 to $10,000 vs. >$100,000, 
respectively).23 
1.2 Specific Aims 
Because there is no consensus on whether to start patients on a first compared to a second-
generation TKI therapy as first-line therapy and there is limited ability to generalize RCT evidence to 
clinical practice, it is critical to use observational data to evaluate the effectiveness of first-generation TKI 
(i.e. imatinib) versus second-generation TKI (i.e. dasatinib and nilotinib) in patients newly initiating 
therapy.  The proposed study used a comprehensive healthcare administrative database from Humana Inc. 
which is a national health plan representing over 6 million covered lives with a wide geographic 
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distribution covering all 50 states.  The database includes the most current pharmacy claims, medical 
claims, and member enrollment data for all commercial fully-insured and Medicare members.   
The specific aims of the study are to:  
Aim 1: Identify factors associated with newly initiating therapy for CML with a second-generation versus 
a first-generation TKI.  
Aim 2: Examine differences in treatment interruption and regimen change between patients newly 
initiating a second-generation versus a first-generation TKI. 
Aim 3: Determine if adherence is higher among patients newly initiating a second-generation versus a 
first-generation TKI. 
Aim 4: Determine if rates of health services utilization (i.e. number of outpatient physician visits, number 
of inpatient hospital admissions, length of inpatient hospital stays, and number of emergency 
room visits) and healthcare costs differ between patients initiating a second-generation versus a 
first-generation TKI. 
Aim 5: Perform exploratory analyses to determine if adherence, health services utilization, and healthcare 
costs differ between patients newly initiating dasatinib versus nilotinib. 
1.3 Significance 
Although there have been clinical trials comparing each of the second-generation TKIs to 
imatinib in the first-line setting, no comparative effectiveness data exist comparing first and second-
generation TKIs as first-line therapy using real world data.  The results from the proposed study will be 
used to inform clinicians and payers through a comparative effectiveness analysis.   
As survival increases and lifelong treatment is anticipated for the treatment of CML, payers are 
instituting more restrictive covered and preferred therapies.  Payers may consider two strategies moving 
forward in managing CML treatment.  First, payers may consider preferring a second-generation TKI 
therapy.  Recent guidance issued by the National Institute for Health and Clinical Excellence (NICE) 
recommends imatinib and nilotinib, both made by Novartis, for first-line treatment of CML.24  Dasatinib, 
   
4 
 
 
made by Bristol-Myers Squibb, is not recommended.  NICE concluded from indirect comparisons that 
dasatinib and nilotinib could be considered equally effective in treatment of CML and accepted an 
undisclosed patient access scheme reducing the cost to approve nilotinib on the formulary in the United 
Kingdom.  NICE guidance is referred to by other countries because of the perceived robust methodology 
of their review process.  In the case of first-line use of TKI therapy for CML, there is not currently robust 
data to support excluding coverage for dasatinib.   However, U.S. payers may consider following a similar 
strategy as the United Kingdom and prefer imatinib and nilotinib as first-line treatment for CML.  Second, 
payers and oncology clinical pathway partners may consider an imanitib first strategy for patients with 
chronic phase CML with the availability of generic imatinib in 2015.  Developing a pathway involves 
evaluating efficacy, tolerability, and cost.  If agents are considered equally efficacious and tolerable, the 
least costly agent is preferred.25  
The proposed study is a first step in evaluating treatment patterns and comparing adherence and 
outcomes among patients newly initiating first and second-generation TKI therapies for the treatment of 
CML. 
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CHAPTER II: LITERATURE REVIEW 
2.1 Chronic Myeloid Leukemia: the disease 
2.1.1 Overview 
 Leukemia is a cancer of the bone marrow or blood.  CML is one of four major types of 
leukemia.  It is a slow growing leukemia that results from a chromosomal translocation ultimately 
resulting in an increased clonal population of white blood cells that carry this genetic mutation.  CML 
occurs in all age groups but is typically diagnosed in older adults.26  Being exposed to high-dose 
radiation is the only known environmental risk factor.27  The risk of CML has not been shown to be 
affected by smoking, diet, exposure to chemicals, or infections.   A recent study suggests that CML 
may occur in at least three different settings: 1) sporadic; 2) genetic heterogeneity with polygenetic 
and environmental impact; and 3) a familial phenotype following an autosomal dominant 
inheritance.28  Most patients do not report symptoms of the disease.26  CML is typically detected 
when the patient is being tested for another disease or as part of a routine physical exam.   
2.1.2 Epidemiology  
2.1.2.1 Incidence 
 CML is a rare disease.29  Between 2005-2009, the incidence rate of CML was 1.6 per 100,000 
men and women.30  In 2013, the American Cancer Society estimated that 5,920 people would be 
diagnosed with CML and 610 would die from the disease in the U.S.2  The incidence increases with 
advancing age.  There is some evidence suggesting CML occurs with greater frequency in men than 
women with a male to female incidence ratio ranging from 1.3 to 1.8.31  The incidence of CML may 
also vary by race and ethnicity.  In a U.S. study, the incidence of CML was lower in individuals of 
Asian/Pacific Islander ethnicity compared to other races.32  
2.1.2.2 Prevalence 
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 Little CML specific prevalence data are published because CML is often reported within  the 
broader category of leukemia.31   Although prevalence information is lacking, it is well accepted that 
patients with chronic phase CML experience long periods of disease remission on current therapies, 
increasing disease prevalence.  Huang et al. estimated the prevalence of CML in the U.S. was 70,000 
cases in 2010 and will increase to 112,000 in 2020 and 181,000 cases in 2050.33 
2.1.2.3 Survival Outcomes 
2.1.2.3.1 Definitions 
There are several different survival measures assessed and reported for cancer patients.  
Overall survival refers to the proportion of cancer patients who survive during a specific time period 
beginning at the time of diagnosis (e.g. five-year period).  Relative survival measures the ratio of the 
proportion of observed survivors in a cohort of cancer patients to the proportion of expected survivors 
in a comparable set of cancer-free individuals, matched on age, gender, race but not region or 
exposure.30  For young persons, observed and relative survival are typically similar.  However, for 
older persons, due to competing causes of death, relative survival rates are higher than observed 
survival rates.  Progression-free survival (PFS)  for CML has been defined as the time that elapses 
before a doubling of the white blood cell count to more than 20x109 per liter in the absence of 
complete hematologic response; a loss of complete hematologic response; an increase in Philadelphia 
positive bone marrow metaphases to more than 35%; progression to accelerated or blast-crisis phase 
CML; or death from any cause.34  
2.1.2.3.2 Overview 
When evaluating cancer outcomes, it is important to consider the likely survival among the 
patients being studied.  Imatinib was approved for the treatment of CML over a decade ago. The 
introduction of this targeted cancer therapy changed CML from a fatal condition to one that can be 
managed as a chronic illness in many patients.  In newly diagnosed patients with CML, overall 
survival at 3 years for patients initiating therapy with imatinib, dasatinib, and nilotinib have been 
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above 93%.13,35   The proposed study will follow patients for up to one year following initiation of 
TKI therapy.  Based on the overall survival data from the clinical trial data, it is unlikely that a more 
than 5% of patients will die during the follow-up period.   
2.1.3 Pathophysiology 
 In a disease-free individual, hematopoietic stem cells, which are produced in the bone 
marrow, eventually develop into mature blood cells.  A blood stem cell may become a myeloid stem 
cell or a lymphoid stem cell.  Lymphoid stem cells develop into T and B lymphocytes.  Myeloid stem 
cells develop into one of the following three types of mature blood cells36: 
x Red blood cells that carry oxygen to the tissues of the body 
x Platelets that cause blood clots to form and prevent bleeding 
x Granulocytes (white blood cells) that have a role in fighting infection and disease 
In CML, there is an excess of clonal blood stem cells developing into abnormal granulocytes (referred 
to as leukemic cells).36  These leukemic cells do not become healthy white blood cells.  Instead they 
build up in the blood and bone marrow, leaving less room for the development of healthy white blood 
cells (WBCs), red blood cells, and platelets.  
The buildup of leukemic cells is the result of an abnormal gene mutation causing activation of 
pathways that lead to increased cellular proliferation, or too many stem cells that develop into 
leukemic WBCs.  In 95% of CML cases, patients acquire a gene mutation known as the Philadelphia 
chromosome and 5% have an alternative abnormal chromosomal arrangement where the Philadelphia 
chromosome is undetectable.37-39  The Philadelphia chromosome is the product of reciprocal 
translocation (t[9;22]) that fuses the breakpoint cluster region (BCR) gene on chromosome 22 at band 
q11 and the Abelson murine leukemia (ABL) gene located on chromosome 9 at band q34 
(t[9;22][q34;q11]), resulting in the creation of the fusion protein BCR-ABL.40  Specifically, the BCR-
ABL fusion protein contains an active tyrosine kinase region of ABL that deregulates cell growth, 
motility, angiogenesis, and apoptosis, leading to the development of leukemia.41   
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2.1.4 Diagnosis and staging 
2.1.4.1 Diagnosis 
The diagnosis of CML can be accomplished through peripheral blood.  An elevated white 
blood cell (WBC) count with left shift (i.e. increase in the number of immature WBCs) and an 
enlarged spleen is suggestive of CML.  In all patients with suspected CML, the initial work-up for 
CML consists of a bone marrow aspiration with differential count and cytogenetic analysis as well as 
fluorescence in situ hybridization (FISH) and polymerase chain reaction (PCR).42  Table 2.1 describes 
the tests used to confirm CML diagnosis.  The Philadelphia chromosome is undetectable in 5% of 
patients and diagnosis relies on the defection of the BCR-ABL fusion protein.  FISH and PCR are used 
to detect the BCR-ABL fusion gene in the blood or bone marrow (preferred).  PCR has the same role 
as FISH but quantifies the number of BCR-ABL transcripts.  Bone marrow aspiration and cytogenetic 
analysis are necessary to assess staging.  Additionally, cytogenetic examination is used to assess 
whether additional chromosomal abnormalities exist besides the Philadelphia chromosome. 
Table 2.1 Tests used to Diagnose and Monitor CML 
Test Specimen Used Purpose Related CML Endpoint 
Standard cytogenetics Bone marrow Detection of the Philadelphia 
chromosome and other 
abnormal chromosomal 
arrangements 
Cytogenetic 
FISH Blood or bone 
marrow 
Detects BCR-ABL gene Cytogenetic 
RT-PCR Blood or bone 
marrow 
Detects and quantifies levels 
of BCR-ABL transcripts 
Molecular 
BCR-ABL=breakpoint cluster region-Abelson murine leukemia; FISH=fluorescence in situ hybridization; RT-
PCR=reverse transcriptase polymerase chain reaction 
Source: National Comprehensive Cancer Network (NCCN) v3.2013   
2.1.4.2 Staging  
CML occurs in three phases: chronic (CP), accelerated (AP), and blast crisis (BC). The stage 
reflects the severity of the disease.  The percentage of blast cells in the blood and bone marrow 
determine the phase of disease36 (Figure  2.1).  Approximately 90% of patients diagnosed with CML 
are diagnosed in the chronic phase by routine blood tests.  Clinical presentation of symptomatic 
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disease includes fatigue, unexplained weight loss, night sweats, fever, splenomegaly, and bleeding.43  
In 45% of cases, CML presents asymptomatically.44  Treatment improves WBC counts, chronic phase 
symptoms resolve, and patients are able to return to their usual activities.  Untreated CP-CML 
typically leads to advanced terminal blastic phase in 3 to 6 years with signs and symptoms similar to 
acute leukemia.4  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Clinical Course of Untreated CML 
Note: Median duration of disease assumes the patient is left untreated 
Source: Frazer et al., 200745 
 
2.1.5 Clinical Endpoints 
Management of CML involves periodic disease monitoring to assess response to therapy and 
detection of early relapse.  Three different types of responses in CML are monitored: hematologic, 
Definition 
Accelerated 
Phase (AP) 
Blast Crisis 
(BC) 
Chronic 
Phase (CP) 
Hemoglobin 
Platelets 
Symptoms 
Median Disease 
Duration  
<10% of the cells in 
blood and bone 
marrow are blast cells 
10%-19% of the cells 
in blood and bone 
marrow are blast cells 
≥20% of the cells in 
blood and bone marrow 
are blast cells 
Normal/slightly low Low Very low 
Normal/High/Low High/Low Low 
Fatigue, bleeding, 
purpura, weight loss, 
abdominal fullness 
Unexplained fever, 
splenomegaly, 
hepatomegaly, bone 
pain 
Severe anemia, 
bleeding, increased 
infections, CNS disease, 
lymphadenopapthy 
3-5 years 6-9 months 3-6 months 
Disease Progression 
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cytogenetic, and molecular.  Each type of response is outlined in detail in Table 2.2.  Early 
achievement of deeper molecular and cytogenetic responses confers a favorable long-term outcome.42  
Additionally, an accepted goal of CML therapy is to achieve complete cytogenetic response (CCyR), 
which means no Philadelphia positive cells can be detected, within 18 months after initiating 
therapy.46   
2.1.5.1 Hematologic Response 
 A complete hematologic response is a return of blood cells to normal levels and a 
disappearance of blast cells and other immature cells in peripheral blood. 
2.1.5.2 Cytogenetic Response 
Although a CCyR means that Philadelphia positive cells can no longer be detected,  patients 
who achieve CCyR may still carry as many as 109 leukemic cells.47  Cytogenetic response is an 
independent prognostic factor for improved survival and has become a therapeutic target for clinical 
studies.43  Jabbour et al. reported that achievement of early CCyR is a major surrogate endpoint in 
patients newly diagnosed with chronic phase CML that correlates with survival improvement 
regardless of TKI.48   
2.1.5.3 Molecular Response 
 Although the majority of patients treated with TKI therapy will achieve CCyR, a smaller 
proportion of patients go on to achieve complete molecular response (CMR).  CMR indicates there is 
no detectable BCR-ABL mRNA.  Major molecular response (MMR) indicates there is at least a 3-log 
reduction in BCR-ABL mRNA which is assessed based on the standardized baseline and not a 
reduction from the actual individual patient’s baseline level.  MMR is associated with long-term 
remission rates and progression-free survival (PFS).  In the 5-year follow-up IRIS study, patients who 
achieved CCyR and MMR at 12 months did not progress to accelerated or blast crisis.22  Additionally, 
molecular responses also predict the duration of CCyR.49-52  In the 7-year follow-up IRIS study, the 
probability of loss of cytogenetic remission by 7 years was 3% among patients achieving MMR at 18 
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months compared to 26% for patients who achieved CCyR but not MMR (p<0.001).49  Additionally, 
patients with stable MMR have a lower probability of loss of cytogenetic remission compared to 
unstable MMR or not achieving MMR.51,52  
 
Table 2.2 National Comprehensive Cancer Network (NCCN) Response Criteria 
Response Type Degree of Response Definitions 
Hematologic Complete x Complete normalization of peripheral blood counts 
with leukocyte count < 10 x 109/L 
x Platelet count < 450 x 109/L 
x No immature cells, such as myelocytes, 
promyelocytes, or blasts, in peripheral blood 
x No signs and symptoms of disease with 
disappearance of palpable splenomegaly 
Cytogenetic Minor > 35% Ph+ metaphases 
 Major 0%-35% Ph+ metaphases (complete + partial) 
 Partial 1%-35% Ph+ metaphases  
 Complete No Ph+ metaphases 
Molecular Major ≥3-log reduction in International Scale of BCR-ABL mRNA 
 Complete No detectable BCR-ABL mRNA by QPCR (International 
Scale) using an assay with a sensitivity of at least 4.5 logs 
below standardized baseline 
BCR-ABL=breakpoint cluster region-Abelson murine leukemia; mRNA=messenger RNA; Ph+=Philadelphia 
chromosome-positive; QPRC=quantitative reverse transcriptase polymerase chain reaction 
Source: NCCN v3.2013 
2.1.6 Risk classification 
Prognostic scores are used to stratify patients into risk groups based on age, spleen size, and 
blood cell counts.  The prognostic classification systems proposed by Sokal and Hasford are used to 
calculate the risk of progression and death based on baseline characteristics, without consideration for 
treatment response.53,54  The calculations are used to categorize patients as low, intermediate, and high 
risk (Table 2.3).  The Sokal score predicts the likelihood of achieving CCyR at 2 years as follows: 
low-risk patients 91%, intermediate-risk patients 84%, and high-risk patients 69%.55   
Table 2.3 Risk Calculations in CML 
Classification System Calculations Risk Definition 
Sokal Exp 0.0116 x (age in years – 43.4) + 0.0345 x 
(spleen - 7.51) + x [(platelet count ÷ 700)2 – 
0.563] + 0.0887 x (blast cells – 2.10) 
Low: < 0.8 
Intermediate: 0.8-1.2 
High: > 1.2 
Hasford 0.666 when age ≥ 50 years + (0.042 x spleen) 
+ 1.0956 when platelet count > 1,500 x 109/L 
+ (0.0584 x blast cells) + 0.20399 when 
Low: ≤ 780 
Intermediate: 781-1,480 
High: > 1,480 
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basophils > 3% + (0.0413 x eosinophils) x 
100 
CML=chronic myelogenous leukemia 
Note: For the equations, age is measured in years; spleen in centimeters below the costal margin; and blast cells, 
eosinophils, and basophils are in percents of peripheral blood differential. All factors must be collected before 
any treatment. 
Source: National Comprehensive Cancer Network (NCCN) v3.2013 
2.2 Current Approaches to Treatment 
2.2.1 First-Line Therapy 
2.2.1.1 Overview 
There are currently three oral oncology agents known as tyrosine kinase inhibitors (TKIs) 
approved for the first-line treatment of CML, imatinib, dasatinib, and nilotinib (Table 2.4).  In the 
United States, imatinib was approved for the treatment of chronic phase CML in 2002.  The 
introduction of this targeted cancer therapy changed CML from a fatal condition to one that can be 
managed as a chronic illness.  Although this novel agent was a significant advance in treating CML, it 
has some limitations, including toxicity, lack of efficacy and poor adherence.8  Specifically, one-third 
of newly diagnosed CP-CML patients treated with imatinib had inadequate responses or did not 
experience long-term benefit in an intention-to-treat analysis.18   
Two second-generation TKIs, dasatinib and nilotinib, were initially approved by the FDA as 
second-line agents for patients with CML who fail imatinib.  With the aim of improving responses 
achieved with first-line therapy, head-to-head RCTs were conducted to compare the second-
generation TKIs to imatinib for patients newly diagnosed with CP-CML.9-13  Both nilotinib and 
dasatinib had superior efficacy over imatinib during the first year of therapy with higher rates of 
complete cytogenetic response (CCyR) and major molecular response (MMR) rate and similar safety 
profiles.9,11  Subsequently, nilotinib received FDA approval as a first-line option for CP-CML in June 
2010 and dasatinib received approval in October 2010. These recent changes have been reflected in 
National Comprehensive Cancer Network (NCCN) Guidelines for Chronic Myelogenous Leukemia, 
which has changed the landscape for treating newly diagnosed patients with CML.56  The pivotal 
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trials for imatinib, dasatinib, and nilotinib in the first-line setting are described below and compared 
in Table 2.5. 
Table 2.4 First-line treatment for CML 
Current TKI Therapies Description Dose 
First-generation TKI 
Gleevec (imatinib)5 FDA approved for: 
Newly diagnosed Ph+ CP-CML 
Ph+ CML in CP, AP, BC after failure of 
interferon-alpha 
CP: 400 mg once daily 
AP or BC: 600 mg one daily or 
400 mg twice daily 
Second-generation TKIs 
Sprycel (dasatinib)6 FDA approved for: 
Newly diagnosed Ph+ CP-CML 
Ph+ CML in CP, AP, or BP, with resistance 
or intolerance to prior therapy, including 
imatinib 
CP: 100 mg once daily 
AP or BP: 140 mg once daily 
Tasigna (nilotinib)7 FDA approved for:  
Newly diagnosed Ph+ CP-CML 
Ph+ CML in CP or AP, resistant or intolerant 
to prior therapy that included imatinib 
CP: 300 mg twice daily 
Resistant CP or BP: 400 mg twice 
daily 
AP=accelerated phase; BC=blast crisis; BP=blast phase; CP=chronic phase; Ph+=Philadelphia chromosome-
positive 
Sources: FDA prescribing information 
 
2.2.1.2 Imatinib, dasatinib, and nilotinib: pivotal trials 
International Randomized Study of Interferon and STI571 (IRIS) trial 
Imatinib has been the recommended first-line treatment for newly diagnosed chronic phase 
CML patients following FDA approval in 2002.  Results from the multicenter, phase III study 
International Randomized Study of Interferon and STI571 (IRIS) trial established imatinib as the 
standard of care.57  Patients were randomized to receive imatinb (400 mg daily) (n=553) or the 
previous standard of care, interferon-alfa plus low-dose cytarabine (control) (n=553).  Crossover to 
alternative group was allowed for treatment failure or intolerance.  The rates of major cytogenetic 
response (MCyR) at 18 months were 87.1% in the imatinib group compared to 34.7% in the control 
(p<0.001).  The rates of CCyR were 76.2% in the imatinib group compared to 14.5% in the control.  
Imatinib was better tolerated compared to interferon-alpha plus cytarabine.  Longer-term follow-up 
data is available from the IRIS trial.17,22  At 5 year follow-up for patients receiving imatinib, Kaplan-
Meier estimates of best rates of CCyR were 69% by 12 months and 87% by 60 months.22  The 5 year 
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overall survival (OS) for patients receiving imatinib was 89%.  Patients who reached CCyR or MMR 
had a significantly lower risk of disease progression compared to patients not achieving CCyR.   
Dasatinib versus imatinib study in treatment-naïve CML (DASISION) trial   
 The safety and efficacy of dasatinib (100 mg daily) and imatinib (400 mg daily) in patients 
newly diagnosed with CP-CML were compared in a multinational study.9  There were 259 patients 
randomized to the dasatinib arm and 260 patients in the imatinib arm.  By 12 months of follow-up, 
the rates of confirmed CCyR and MMR were higher in the dasatinib arm compared to the imatinib 
arm (CCyR: 77% vs. 66%, p=0.007; MMR: 46% vs. 28%, p<0.0001), respectively.  In addition, 
responses were achieved in a shorter time in patients receiving dasatinib compared to imatinib.  The 
rate of CCyR at 3, 6, and 9 months were 54%, 73%, and 78%, respectively for the dasatinib group 
and 31%, 59%, and 67%, respectively for the imatinib group.  The 2 year follow-up data from 
DASISION confirms faster and deeper responses with dasatinib compared to imatinib.10  The median 
time to achieve CCyR and MMR were shorter for dasatinib than for imatinib (CCyR: 3 months vs. 6 
months; MMR: 15 vs. 36 months), respectively.   
Evaluating nilotinib efficacy and safety in clinical trials-newly diagnosed patients (ENESTnd) trial  
 In the phase III multicenter trial, patients newly diagnosed with CP-CML were randomized to 
receive nilotinib (300 mg or 400 mg twice daily) or imatinib (400 mg daily).11-13 The primary 
endpoint was rate of MMR and the secondary endpoint was CCyR at 12 months.11  The MMR and 
CCyR rates were significantly higher in nilotinib groups compared to imatinib at both 12 and 24 
months.11,12  
   
 
 
Table 2.5. Comparison of pivotal trials for first-line TKI therapy in patients newly diagnosed with CP-CML  
 IRIS57 DASISION9,10 ENESTnd11,12 
Intervention Imatinib 400 mg daily or interferon-alfa 
plus low-dose cytarabine 
Dasatinib 100 mg daily or imatinib 400 
mg daily 
Nilotinib 300 mg or 400 mg twice daily or 
imatinib 400 mg daily 
Study Design Multicenter, open-label, randomized, 
controlled phase 3 study 
Multicenter, international, open-label, 
randomized phase 3 study 
Multicenter, open-label, randomized phase 3 
study 
Patient Population N=1,106 patients newly diagnosed with CP-
CML (imatinib, n=553; combination 
therapy, n=553) 
N=519 patients newly diagnosed with 
CP-CML (dasatinib, n=259; imatinib, 
n=260) 
N=846 patients newly diagnosed with CP-
CML (nilotinib 300 mg, n=282; nilotinib 400 
mg, n=281; imatinib, n=283) 
Primary End Point  Progression defined as death from any 
cause during treatment, development of AP-
CML or BP-CML, loss of CHR, loss of 
MCyR, or increasing white counts 
Confirmed CCyR by 12 months after 
initiation of therapy 
MMR at 12 months 
Secondary End 
Point 
x CHR 
x MCyR 
x Partial CyR 
x MMR at any time 
x Time to CCyR and MMR 
x Duration of PFS and OS 
x MMR by 24 months 
x CCyR 
x Time to MMR and CCyR 
Follow-up data 
available to date 
8 years17 24-months10 3 years13 
 Results 
Primary End Point At 12 months, PFS was higher with 
imatinib than combined therapy (96.6% vs. 
79.9, p<0.001), respectively  
Confirmed CCyR was higher with 
dasatinib than imatinib (77% vs. 66%, 
p=0.007, respectively) 
MMR was higher in patients receiving 
nilotinib 300 mg (44%) or 400 mg (43%) 
compared to those receiving  imatinib (22%) 
(p<0.001 for both comparisons) 
Sustained 
Response 
18 Months 24 months 24 months 
 Imatinib Interferon-alfa Dasatinib Imatinib Nilotinib 300 mg 
and 400 mg 
Imatinib 
CCyR, % 76.2 14.5 86 82 87, 85 77 
MMR, % NR NR 64 46 71, 67 44 
PFS, % 92.1 73.5 93.7 92.1 98, 97.7 95.2 
Transformation to 
AP or BP, % 
NR NR 2.3 5.0 0.7, 1.1 4.2 
AP=accelerated phase; BC=blast crisis; BP=blast phase; CHR=complete hematologic response; CP=chronic phase; CyR=cytogenetic response MCyR=major 
cytogenetic response; MMR=major molecular response; OS=overall survival; PFS=progression-free survival; NR, not reported 
Clinical trial acronyms: IRIS, International Randomized Study of Interferon and STI571 (IRIS) trial; DASISION, Dasatinib versus imatinib study in treatment-
naïve CML; ENESTnd, Evaluating nilotinib efficacy and safety in clinical trials-newly diagnosed patient 
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2.2.2 Second-line therapy 
2.2.2.1 Overview 
 Approximately 50% of patients who develop resistance to imatinib will respond to a second-
generation TKI.58  Both dasatinib and nilotinib are approved as second-line therapies to treat CML 
patients who are resistant or intolerant to imatinib.  Additionally, bosutinib was FDA approved in 
September 2012 for adult patients with CP, AP, or BP CML with resistance or intolerance to prior 
therapy.59 Table 6 summarizes design, endpoints, and results for the pivotal second-line studies.  
Studies of nilotinib and bosutinib in the second-line setting used single-arm designs.  The dasatinib 
study was a phase 3 dose-optimization and schedule-optimization study that investigated the effect of 
changing the recommended dose for chronic phase CML patients from 70 mg twice daily to 100 mg 
once daily.60 
2.2.2.2 Dasatinib 
Dasatinib has shown efficacy in patients with CML who are resistant or intolerant of imatinib 
in a series of phase II studies [SRC/ABL tyrosine kinase inhibition activity: research trials of 
dasatinib (START)].  In a dose optimizing study, imatinib-resistant and imatinib-intolerant patients 
achieved similar MCyR across all treatment arms.60  Additionally, dasatinib produced similar CHR, 
MCyR, and CCyR rates across all treatment arms.  Only the efficacy results for 100 mg once daily are 
provided in Table 2.6 as that is the recommended starting dose. 
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Table 2.6. Studies for second-line TKI therapy for the treatment of CML 
 Dasatinib60,61 Nilotinib58,62 Bosutinib63 
Intervention Dasatinib 100 mg daily, 50 
mg twice daily, 140 mg 
daily, or 70 mg daily 
(efficacy provided for 100 
mg group only)  
Nilotinib 400 mg twice 
daily 
Bosutinib 500 mg daily 
Study Design Randomized, international, 
multicenter, open-label 
phase 3 dose-optimization 
and schedule-optimization 
study  
Single-arm, open-label 
phase 2 study 
Single-arm, open-label, 
phase 1/2  study 
Patient 
Population 
N=670 patients with CP-
CML with resistance, 
intolerance, or suboptimal 
response to imatinib (100 
mg daily, n=167; 70 mg 
twice daily, n=168; 140 mg 
daily, n=167; 50 mg twice 
daily, n=168) 
N=321 patients with 
imatinib-resistant (n=226) 
or imatinib-intolerant 
(n=95) CP-CML 
N=266 patients evaluated 
for efficacy with imatinib-
resistant (n=186) or 
imatinib-intolerant (n=80) 
Primary End 
Point  
MCyR at 24 weeks in 
patients with imatinib-
resistance 
MCyR MCyR at 24 weeks in 
patients with imatinib-
resistance  
Secondary End 
Point 
x MCyR in patients 
with imatinib 
intolerance 
x CHR 
x Time and duration 
of MCyR and CHR  
x PFS and OS 
x Time and duration 
of MCyR 
x Time and duration 
of CHR 
x PFS and OS 
x Time and duration 
of MCyR  
x Time and duration 
of CHR 
x PFS and OS 
Follow-up data 
available to date 
2 year61  24-month minimum 
follow-up62 
24-month follow-up 
 Results  
Primary End 
Point 
59% of patients achieved 
MCyR at 24 weeks 
48% of patients achieved 
MCyR at 24 weeks 
31% of patients achieved 
MCyR at 24 weeks 
Sustained 
Response 
24 months 24 months 24.2 months 
MCyR (CCyR) 63% (50%) 59% (44%) 53% (41%) 
Transformation 
to AP or BP 
3% 3.1% 3.8% 
OS 91% 87% 92% 
CHR=complete hematologic response; CP=chronic phase; MCyR=major cytogenetic response; OS=overall 
survival; PFS=progression-free survival; Note: Cross trial comparisons pose challenges due to differences in 
study population and study design.
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2.2.2.3 Nilotinib 
The safety and efficacy of nilotinib was evaluated in a Phase II trial in imatinib resistant or 
intolerant CP and AP-CML patients.58,62  Nilotinib was administered to 321 patients who were 
imatinib resistant (70%) or intolerant (30%) with a primary endpoint of rate of MCyR.58  Overall, 
59% of patients achieved MCyR at 24 months follow-up.  Additionally, 44% achieved CCyR and the 
OS was 87%. 
2.2.2.4 Bosutinib 
   The safety and efficacy of bosutinib used as a second-line therapy was evaluated in 288 
patients with CP imatinib-resistant (69%) or imatinib-intolerant (31%) CML.64  At 24 weeks, the 
primary end point of MCyR was achieved by 31%.  After a median of 24.2 months of follow-up, 86% 
of patients achieved CHR, 53% had a MCyR, and 64% of those achieving CCyR had a MMR. 
Additionally, at 2 years, PFS was 70% and overall survival was 92%.  Bosutinib had an overall 
acceptable safety profile with a notable increased incidence of diarrhea with 82% of patients 
experiencing any grade and 8% grade 3/4 diarrhea.  Approximately, 21% of patients discontinued 
treatment due to adverse events.      
2.2.3 Safety 
2.2.3.1 Overview 
 The choice of first-line therapy depends on disease risk score, physician’s experience, patient 
age, ability to tolerate therapy, and the presence of comorbid conditions.46  The information presented 
below includes a high level overview of agent specific toxicities.  The specific toxicities mentioned 
are included as they may be a factor influencing treatment decision.  For example, if a physician is 
choosing to initiate a second-generation TKI therapy, nilotinib may be preferred over dasatinib for 
patients at risk of developing pleural effusions based on toxicity profile.46   
2.2.3.2 Imatinib 
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Imatinib is generally well tolerated.  The most often reported adverse reactions include 
gastrointestinal toxicity such as mild nausea and diarrhea, edema, rash, and musculoskeletal 
complaints.  Frequently reported grade 3 or 4 toxicities include neutropenia and thrombocytopenia.46  
Erythropoietin and filgrastim have been used and shown effective in patients with imatinib-induced 
anemia and neutropenia65,66 but are not supported by guidelines from the FDA and Centers for 
Medicare and Medicaid Services (CMS).46  A recent study reported cardiotoxicity and congestive 
heart failure (CHF) among 10 patients with longer-term use of imatinib.  Another study found that of 
1,276 patients treated with imatinib, 22 patients (1.7%) developed CHF during treatment.67,68 
2.2.3.3 Dasatinib 
 The most common reported adverse reactions reported in at least 10% of patients newly 
diagnosed with chronic phase CML include myelosuppression, fluid retention, diarrhea, headache, 
musculoskeletal pain, and rash.  These adverse reactions as well as dyspnea and hemorrhage occur in 
greater frequency (≥20%) in patients with resistance or intolerance to prior imatinib therapy.6  
Quintas-Cardama et al. studied risk factors associated with dasatinib therapy after failure of 
imatinib.69  Among 138 patients treated with dasatinib, 35% developed pleural effusion. Patients with 
a cardiac history, hypertension, receiving twice daily dosing with 70 mg are at increased risk of 
developing pleural effusion.  Pleural effusion led to dose interruption in 83% of patients and dose 
reduction in 71% of patients.  Management of pleural effusion includes treatment with diuretics, dose 
interruption, and a short course of steroids (3 days) for patients with significant symptoms.46  After 
symptoms resolve, guidelines recommend that the dose should be reduced. 
2.2.3.4 Nilotinib 
 The most commonly reported non-hematologic adverse reactions (≥10%) were rash, pruritus, 
headache, nausea, fatigue, myalgia, arthralgia, pyrexia, nasopharyngitis,upper respiratory tract 
infection, back pain, cough, asthenia, and gastrointestinal (constipation, diarrhea, abdominal pain, 
vomiting).  Nilotinib has a black box warning for QT prolongation and sudden deaths.7  Nilotinib 
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prolongs the QT interval and electrocardiograms (ECGs) should be obtained at baseline, seven days 
after initiation, and periodically thereafter.  In clinical trials, the maximum mean QTcF change from 
baseline at steady state was 10 msec.  Increase in QTcF > 60 msec from baseline was observed in 
4.1% of the patients and QTcF of >500 msec was observed in 4 patients (<1%).7  Nilotinib doses 
should be held in cases where ECGs have a QTc > 480 msec.  Nilotinib should not be used in patients 
with hypokalemia, hypomagnesemia, or long QT syndrome.  Drugs known to prolong the QT interval 
and strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, ritonavir) should be 
avoided.   
2.3 Treatment Guidelines 
2.3.1 First-line treatment for patients newly diagnosed with CP-CML 
The National Comprehensive Cancer Network (NCCN) is a not-for-profit alliance of 21 U.S. 
National Cancer Institute-designated cancer centers working together to improve the quality, 
effectiveness, and efficiency of cancer care.  NCCN guidelines are the most comprehensive and 
widely used oncology clinical practice guidelines in the world.  NCCN guideline recommendations 
are accepted by the CMS and most private insurance companies.   
The NCCN Guidelines for Chronic Myelogenous Leukemia version 4.2013 recommends 
treatment with a tyrosine kinase inhibitor (TKI) for newly diagnosed patients with CP-CML.56  
Imatinib (400 mg once daily), nilotinib (300 mg twice daily), and dasatinib (100 mg once daily) have 
a category 1 recommendation for initial treatment of CML.56  Category 1 evidence is based upon 
high-level evidence with uniform NCCN consensus that the intervention is appropriate.  High dose 
imatinib (800 mg) is not currently recommended for patients newly diagnosed with CP-CML.  
According to the guidelines, data from DASISION9,10 and ENESTed11-13 suggest intermediate- and 
high-risk patients (based on Sokal or Hasford score) may benefit from a second-generation TKI but 
acknowledge longer-term follow-up is needed to determine whether second-generation TKIs should 
be used as standard first-line therapy.  
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2.3.2 Monitoring response to first-line therapy and indications of treatment change 
Table 2.7 describes the NCCN’s recommendations for monitoring response to first-line TKI 
therapy with imatinib, dasatinib, or nilotinib and indications of treatment change.56  Patients not 
responding to first-line therapy with imatinib should be treated with dasatinib, nilotinib, bosutinib or 
ponatinib in the second-line setting.56  Patients not responding to first-line therapy with a second-
generation TKI could be treated with an alternate second-generation TKI for second-line therapy.  
Patients taking second-line TKI therapy with no cytogenetic response at 3 or 6 months should be 
considered for alternate therapies.70 
Table 2.7 Recommendations for Follow-up Therapy 
Follow-up Response Recommendation 
3 Months BCR-ABL transcript level ≤10% 
or PCyR 
x Continue same dose of imatinib, 
dasatinib, or nilotinib 
BCR-ABL transcript level > 
10% or less than PCyR 
x Switch to alternate 2G-TKI 
x Evaluate for allogeneic HSCT 
depending on response to TKI 
12 Months CCyR x Continue same dose of imatinib, 
dasatinib, nilotinib, or bosutinib 
PCyR x Switch to alternate 2G-TKI 
(preferred) 
x Continue same dose of dasatinib, 
nilotinib, or bosutinib 
x Dose escalation of imatinib to a 
maximum of 800 mg, as tolerated (if 
not a candidate for dasatinib, 
nilotinib, bosutinib, ponatinib, or 
omacetaxine) 
Minor or no cytogenetic 
response 
x Switch to alternate 2G-TKI 
(preferred) 
x Evaluate for allogeneic HSCT 
depending on response to TKI 
Cytogenetic relapse x Switch to alternate 2G-TKI 
(preferred) 
x Dose escalation of imatinib to a 
maximum of 800 mg, as tolerated (if 
not a candidate for dasatinib, 
nilotinib, bosutinib, ponatinib, or 
omacetaxine) 
x Evaluate for allogeneic HSCT 
depending on response to TKI 
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18 Months CCyR x Continue same dose of TKI  
PCyR or cytogenetic relapse x Switch to alternate TKI  
x Evaluate for allogeneic HSCT 
depending on response to TKI 
therapy 
2G-TKI=second-generation TKI; CCyR=complete cytogenetic response; HSCT=hematopoietic stem 
cell transplantations; PCyR=partial cytogenetic response 
Source: NCCN Guidelines v4.2013 
 
2.3.3 Resistance to treatment 
 Patients can develop resistance to imatinib, dasatinib, and nilotinib.  The mechanisms 
associated with treatment resistance are complex and will not be discussed in detail.  Primary 
hematologic resistance, defined as a failure to achieve hematologic remission within 3-6 months of 
initiation, is rare in patients newly diagnosed with CP-CML.  However, primary cytogenetic 
resistance, defined as failure to achieve any level of cytogenetic response at 6 months, MCyR at 12 
months or CCyR at 18 months, occurs in 15-25% of patients newly diagnosed with CP-CML.46  
Secondary resistance occurs in patients who have lost a hematologic or cytogenetic response.  In the 
case of secondary resistance, Cortes et al. recommend initiating patients on a different therapy 
immediately.42  Delaying a treatment change in patients with secondary resistance causes a decreased 
probability of PFS.71   
 Although second-generation TKI therapies are associated with significantly lower rates of 
progression to accelerated phase/blast crisis, patients developing primary or secondary resistance to 
these agents historically did not have any therapeutic options.  A major mechanism of resistance is 
mutation of the BCR-ABL kinase domain.  One of the most common mutations in up to 20% of 
patients with TKI resistance is T315I.  Ponatinib became commercially available at the beginning of 
2013.  It is the only oral TKI therapy with efficacy against the T315I mutation.  Reports suggest that 
T315I mutation is associated with disease progression and poor survival.72,73    
2.4 Medication Adherence 
2.4.1 Overview 
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Long-term continuous exposure to TKI therapy is required to achieve and maintain favorable 
treatment outcomes.17  Therefore, patient adherence, defined as the extent to which a person’s 
lifestyle and/or medication-taking behavior corresponds with agreed upon recommendations from a 
health care provider,74 is crucial.  Clinical responses to therapy are measured in terms of cytogenetic 
(presence of Philadelphia chromosome containing cells) and molecular (presence of abnormal BCR-
ABL genes) response.  Evidence suggests adherence can promote major and complete cytogenetic 
response.20,75  Similarly, adherence to TKI therapy is a critical factor for achieving major and 
complete molecular response.20,75  These clinical parameters have been associated with prolonged 
overall and progression-free survival in patients with CML.17,21,22 
There is a wealth of evidence supporting the benefits of adherence to TKI therapy.  The 
following sections describe reported rates of adherence to TKI therapies, factors associated with TKI 
adherence, and the association of adherence with clinical responses and economic outcomes.  To date, 
most of the literature focuses on imatinib as this was the only TKI therapy indicated for first-line 
treatment until recently.  Since dasatinib and nilotinib received first-line indication for the treatment 
of patients newly diagnosed with CP-CML, no study has directly compared the three TKI therapies 
using clinical trial or real world data. 
2.4.2 Measurement of adherence to TKI therapy in CML 
2.4.2.1 Methods for measuring adherence 
Varying rates of adherence to TKI therapy for the treatment of CML have been reported in 
the literature.  Variations in reported rates may be due to variations in the methods used to assess 
adherence and the operational definitions.  The three common methods to measure adherence include: 
patient self-report, pharmacy refill records, and use of electronic lids.  There are limitations to each 
type of measurement.   
Patient self-report relies on the patient’s perception of medication-taking behavior and is 
subject to recall and reporting bias.76  Pharmacy refill records are based on medication claims which 
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may not be a true reflection of medication utilization.  Additional challenges of using claims data 
include how to best estimate adherence and determining the most appropriate threshold to define 
adherence.77,78  In the CML literature using administrative healthcare databases to assess adherence to 
TKI therapy, a cut point of 85% is used to define adherence.79-82  This threshold has been used 
because it is the midpoint of previous adherence thresholds in cancer research ranging from 80%83 to 
90%.84  Electronic lids to capture dose and time are considered the gold standard for measuring 
adherence but electronic devices may not accurately capture when or how much medication was 
utilized.85   
2.4.2.2 Adherence reported in prospective studies 
 The ADAGIO study (adherence assessment with Glivec: indicators and outcomes) examined 
adherence to imatinib prospectively over a 90-day period in “real practice” among 169 patients.75  
Adherence to imatinib was measured through physician-rated, patient-rated, and pill count.  
Physicians believed on average 92.8% of patients were adherent to imatinib during the first month 
after diagnosis and 87.4% remained adherent after 1 year of treatment.  Based on a visual analog scale 
(VAS), patients reported their baseline and 90-day follow-up adherence as 95.3% and 95.7%, 
respectively.  The percentage of imatinib taken compared to imatinib prescribed was 90.9% (range 
29%-202%) during the 90-day period.  Only 14.2% of patients according to pill count results were 
perfectly adherent to the prescribed regimen. 
 Marin et al. prospectively monitored adherence during long-term imatinib treatment among 
87 patients using microelectronic monitoring systems (MEMS).20  Patients were eligible for the study 
if they had been treated with imatinib for 2 years or longer, were able to tolerate therapy, and were in 
CCyR at time of enrollment.  Median adherence was 97.6% over the 3-month period evaluated, 
26.4% of patients had adherence ≤ 90%, and 14% of patients had adherence ≤ 80%.    
2.4.2.3 Adherence reported in retrospective studies 
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Darkow et al. evaluated medication adherence and treatment interruptions using claims data 
for commercial, Medicare and Medicaid patients taking imatinib.84  Treatment interruption was 
defined as failure to refill imatinib within 30 days from the run-out date of the prior prescription and 
adherence was measured using  a medication possession ratio (MPR), calculated as total days' supply 
of imatinib divided by 365.  Among the 267 patients included, the average MPR was 77.7% over the 
12 month follow-up with 31% of patients having a treatment interruption.  All patients restarted 
imatinib within the study period.  Wu et al. and St. Charles et al. evaluated adherence to imatinib over 
a 12 month period using MarketScan Commercial Claims and Encounters database.79,81  Of the 592 
patients included, 59.1% were considered to have a high MPR using a cut point of ≥85% and the 
mean MPR was 0.79.79   
Wu et al. evaluated adherence to dasatinib or nilotinib as second-line therapy using two large 
administrative claims databases, Ingenix and  MarketScan Commercial Claims and Encounters 
Database, with a maximum follow-up of six months.80  Patients in the dasatinib cohort were less 
adherent than the nilotinib cohort.  The average adherence to dasatinib (n=452) and nilotinib (n=69) 
was 0.69 and 0.79 (p=0.007), respectively.  In another retrospective claims analysis using i3’s Rx Lab 
database, adherence to first-line imatinib and second-line dasatinib and nilotinb was evaluated over a 
six month period.  Average adherence measured using MPR to dasatinib (n=81), nilotinib (n=15) and 
imatinib (n=449) was 0.75, 0.69, and 0.86, respectively.82 
2.4.3 Factors Associated with Adherence 
Several factors have been identified that are associated with poor adherence to TKI therapy 
for the treatment of CML.  St. Charles et al. identified the following predictors of non-adherence to 
imatinib: younger age, shorter exposure to imatinib, starting imatinib dose ≤400 mg, longer lag 
between CML diagnosis to imatinib prescription fill, more concomitant prescriptions, and higher 
percentage of copayment.81   Marin et al. identified lower imatinib adherence rates among younger 
patients, patients with common adverse events (i.e. asthenia, nausea, muscle cramps, and bone or 
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joint pains), patients taking imatinib independently of meals (a contributor to gastrointestinal tract 
upset), and unexplained five-fold increases in BCR-ABL  transcript levels at any time during follow-
up.20   
2.4.4 Adherence and clinical response 
The ADIAGO study examined whether treatment response is associated with adherence 
levels.75  Pill counts were used to measure adherence, expressed as the percentage of imatinib taken to 
imatinib prescribed, over a 3-month period.75  Patients treated with imatinib who had an incomplete 
cytogenetic response (n=15) had taken on average fewer prescribed doses compared to patients with 
complete cytogenetic response (n=109) (76% vs. 91%, p=0.004), respectively. 
Marin et al. evaluated whether imatinib adherence correlates with degree of molecular 
response using MEMS.20  Adherent patients (defined as patients who took >90% of medication as 
prescribe) had a significantly higher 6-year probability of achieving MMR (95% vs. 28%, 
respectively; p<0.001) and CMR (44% vs. 0%; p=0.002) compared to non-adherent patients (patients 
who took ≤90% of medication as prescribed).  The probability of achieving these clinical endpoints 
(i.e. MMR and CMR) is associated with prolonged survival.17,21,22   
2.4.5 Adherence and Economic Outcomes 
Darkow et al. estimated the association between treatment interruptions and non-adherence 
among patients who newly initiated imatinib and healthcare costs over a 12 month period.84  MPR 
was categorized as low (<50%), intermediate (50-89%), high (90-95%) and very high (>95%).  
Average number of outpatient physician visits ranged from 25.6 visits among patients with very high 
adherence to 39.1 visits among patients with low adherence.  Only a small proportion of patients in 
the high and very high MPR groups were hospitalized during the year (8% and 7%, respectively), 
20% of intermediate MPR patients, and more than half of the patients with low MPR (51%) were 
hospitalized during follow-up.  There was an inverse relationship for total medication costs, with 
higher costs among patients with lower MPR.  The lowest total healthcare costs were reported among 
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patients with high and very high adherence ($39,236 and $42,250, respectively), followed by patients 
with intermediate MPR ($54,770), and total healthcare costs were highest among patients with low 
MPR ($131,357).  Wu et al. examined the associated between adherence to imatinib, defined as an 
MPR ≥ 85%, and direct healthcare costs and resource utilization over a 12 month period.79  Patients 
who were more adherent to imatinib therapy had lower resource utilization and overall costs 
compared to those patients with lower adherence.  Regression models indicated a difference of 
$56,324 in total non-imatinib costs (i.e medical costs plus pharmacy costs with imatinib costs 
excluded) between the low and high-MPR cohorts (p<0.001).   
2.5 Summary 
Although there is a wealth of evidence supporting the benefits of adherence to imatinib from 
a clinical, patient, and economic perspective, varying rates of adherence have been reported in the 
literature.  For example, median adherence rates to imatinib, measured over a 3-month period using 
MEMS, were 97.6% (range 22.6-103.8%),86 whereas reports of average adherence measured over a 
one year period using medication possession ratio were 77.7%.84  Because outcomes associated with 
these therapies have focused on imatinib,87  we know relatively little about these issues in relation to 
dasatinib and nilotinib.  Also, in the absence of RCT data, comparative effectiveness data related to 
the first-line use of imatinib, dasatinib, and nilotinib in patients newly treated with CML will help 
inform clinicians who now have more treatment options to consider. 
The proposed study is a first step in evaluating treatment patterns and comparing adherence 
and outcomes among patients newly initiating first and second-generation TKI therapies for the 
treatment of CML.  The specific aims of the study are to:  
Aim 1: Identify factors associated with newly initiating therapy for CML with a second-generation 
versus a first-generation TKI. 
Aim 2: Examine differences in treatment interruption and regimen change between patients newly 
initiating a second-generation versus a first-generation TKI. 
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Aim 3: Determine if adherence is higher among patients newly initiating a second-generation versus a 
first-generation TKI. 
Aim 4: Determine if rates of health services utilization (i.e. number of outpatient physician visits, 
number of inpatient hospital admissions, length of inpatient hospital stays, and number of 
emergency room visits) and healthcare costs differ between patients initiating a second-
generation versus a first-generation TKI. 
Aim 5: Perform exploratory analyses to determine if adherence, health services utilization, and 
healthcare costs differ between patients newly initiating dasatinib versus nilotinib. 
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CHAPTER III: CONCEPTUAL FRAMEWORK 
 This section describes the conceptual framework used to guide the proposed study by 
discussing the factors that may influence treatment selection, and ultimately impact medication use 
patterns and healthcare resource utilization and costs.  The proposed framework is based on Carpenter 
and colleagues’ conceptual model for examining data for nonexperimental cancer comparative 
effectiveness research.88 
3.1 Carpenter and colleagues’ conceptual model for examining non-experimental cancer 
comparative effectiveness research 
Randomized controlled trials (RCTs) remain the gold standard in determining the efficacy of 
new interventions.  However, RCTs are not always feasible and often do not adequately reflect patient 
heterogeneity due to selective inclusion criteria and therefore fall short of informing “real-world” 
clinical practice.  Growing repositories of secondary data collected through registries, electronic 
health records, and administrative claims databases are being leveraged to fill gaps in knowledge 
through nonexperimental cancer comparative effectiveness research.  Carpenter and colleagues’ 
developed a conceptual model to better inform an evolving framework articulating cancer 
comparative effectiveness research data needs to be used for clinical and policy decision making 
(Figure 3.1).88  This conceptual model was developed by incorporating feedback from over 70 cancer 
comparative effectiveness researchers.  Additionally, the model reflects contemporary cancer care by 
characterizing cancer as a longitudinal, chronic condition rather than a single acute-care episode.  
This model also moves beyond the intention-to-treat principle by recognizing the potential for 
multiples lines of therapy, their interaction, and reciprocal feedback.  Although the proposed model 
was developed to inform future data collection, it was also designed to serve as a template for current 
researchers.   
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Figure 3.1 Carpenter and colleagues’ conceptual model for examining data for nonexperimental 
cancer comparative effectiveness research 
Carpenter WR, Meyer AM, Abernethy AP, Sturmer T, Kosork MR. A framework for understanding cancer 
comparative effectiveness research data needs, J Clin Epid. 2012;65:1150-1158.88 
 
3.2 Proposed Conceptual Framework 
Relevant factors influencing TKI use, balanced with information available in the dataset were 
used to develop a conceptual framework.  The conceptual framework for the proposed study is 
depicted in Figure 3.2.  The components from Carpenter and colleagues’ conceptual model that guide 
the conceptual framework in the proposed study include: patient demographic, patient clinical 
characteristics, provider characteristics, TKI treatment choice, health behaviors, and health outcomes.  
The model emphasizes the direct associations between factors that predict TKI use and medication 
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patterns, health services utilization, and costs.  Because we do not have detailed information on the 
interaction of patient and provider characteristics, the relationship is depicted by a dotted line with a 
double arrowhead rather than a solid line.  Although Carpenter and colleagues included reciprocal 
feedback loops in their model recognizing the potential for multiples lines of therapy in cancer 
treatment, this study focuses on evaluating first-line treatment for CML.  Therefore, reciprocal 
feedback loops were not included in the conceptual model for this dissertation.   
There were six demographic characteristics included in the proposed framework.  They 
include: age, gender, geographic region, type of insurance coverage, low income subsidy, and dual 
eligibility status.  As expected, there were no differences in age between patients randomized to 
second versus first-generation TKI therapy in the pivotal RCTs for first-line use of nilotinib and 
dasatinib. 11,22  Currently, it is unknown if differences exist in age between patients who are newly 
initiated on second compared to first-generation TKI therapy.  There is some evidence suggesting 
CML occurs with greater frequency in men.31  The majority of patients included in the pivotal trials 
for imatinib, nilotinib, and dasatinib were male.9,11,57  Geographic region has become a covariate often 
included in studies using administrative data in part because of the ability to measure it.  Geographic 
region has not been reported in the CML literature, but geographic variation in prescribing TKI 
therapies likely exists.  Although all the patients in the study are insured, differences in patient 
demographic characteristics, insurance benefits, and treatment patterns have been reported between 
Humana patients enrolled in a commercial versus a Medicare plan.  For example, a study evaluating 
patterns of osteoporosis treatment demonstrated that commercial patients tended to be younger and 
have fewer comorbidities, and higher out-of-pocket expenses for medications.89  The final 
demographic characteristics included, LIS status and dual eligibility, are only applicable to Medicare 
patients.   To date, these characteristics have not been reported in the CML literature.  However, they 
are included in the conceptual framework because CML is a disease that affects older adults and 
therefore the majority of the population was Medicare patients. Patients who have LIS status are 
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Medicare beneficiaries with income below 150% of poverty and are eligible for cost-share assistance 
for prescription medications under the Medicare Part D program.90  LIS beneficiaries tend to have 
multiple chronic conditions that are controlled by adherence to many medications.91  Dual eligibility 
indicates Medicare patients are also covered under Medicaid which covers ancillary services not 
covered under the Medicare plan.  Often these patients have increased disease burden and have 
different healthcare utilization patterns compared to other Medicare patients.91 
The four clinical characteristics included in the framework were: phase of disease, 
comorbidity, medication count, and vaccine use.  Patients’ starting dose of TKI therapy was assessed 
and used as a proxy for CML phase at the time of initiation.  Long-term comorbidities have been 
associated with reduced adherence.92,93  Patient’s number of prescribed medications is an indicator of 
concomitant disease.  The association reported in the literature between adherence to TKI therapy and 
number of medications taken is mixed.  Darkow et al. reported lower adherence among patients 
taking more medications84 while Noens et al. reported higher adherence among patients taking more 
concomitant medications.75  Flu or pneumonia vaccine use was included because patients who are 
adherent may have a health-seeking tendency and may be more likely to use preventative services.94 
Four physician characteristics were included: provider age, gender, specialty, and practice 
type.  Provider specialty was included and classified as an oncologist or other.  Practice type was 
classified as academic, private, and other (i.e. community hospitals, clinics, or outpatient cancer care 
facilities neither owned by the practicing physicians nor considered academic or university-based).95 
The conceptual framework posits that patient demographic characteristics, patient clinical 
characteristics, and provider characteristics influence treatment selection.  Treatment characteristics, 
in turn, influence medication use patterns (i.e. adherence, treatment interruption, regimen change).87  
Higher rates of adherence have been reported among patients taking imatinib 400 mg compared to 
doses of 600 mg and above.20,75,84  Additionally, studies show adherence to TKI therapy decreases 
over time which may influence subsequent health outcomes.81,96  There is evidence to suggest that 
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adherence to second-generation TKIs is higher compared to imatinib.96  
Finally, the model suggests that the type of TKI therapy influence patients’ use of health care 
services and the costs associated with these services.  In the next section, I describe the methods that 
were used to examine the relationships hypothesized in this conceptual framework.
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Figure 3.2 Proposed Conceptual Framework 
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CHAPTER IV: METHODS 
4.1 Overview 
The aims of this retrospective cohort study are to (1) identify factors associated with newly 
initiating therapy for CML with a second-generation versus a first-generation TKI; (2) examine 
differences in treatment interruption and regimen change between patients newly initiating a second-
generation versus a first-generation; (3) determine if adherence is higher among patients newly 
initiating a second-generation versus a first-generation TKI; (4) determine if rates of health services 
utilization (i.e. number of outpatient physician visits, number of inpatient hospital admissions, length 
of inpatient hospital stays, and number of emergency room visits) and healthcare costs differ between 
patients initiating a second-generation versus first-generation TKI; and (5) perform exploratory 
analysis if adherence, health services utilization, and healthcare costs differ between newly initiating 
dasatinib versus nilotinib. This section provides a detailed description of the data sources, study 
design, measurements, and statistical analyses that were used to accomplish each of the specific aims.  
The University of North Carolina Institutional Review Board determined that the proposed study was 
exempt from review (Appendix 1). 
4.2 Data Source  
4.2.1 Overview 
Data from a large health benefits carrier (Humana), representing over 6 million covered lives 
with wide geographic distribution covering all 50 states, was used to conduct a retrospective cohort 
study.  The database used for the study included beneficiaries who were enrolled in a commercial 
fully-insured plan, a Medicare Advantage Prescription Drug (MAPD) plan, or a Medicare Part D 
Prescription Drug Plan (PDP).  Commercial fully-insured and MAPD members have both medical 
and outpatient pharmacy coverage through Humana.  Medicare PDP members have only Part D 
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(outpatient pharmacy) coverage and no medical coverage (Medicare Part A, B, or C coverage) 
through Humana. Table 4.1 summarizes plans offered through Humana and respective coverage. 
4.2.2 Commercial fully-insured 
 Humana provides medical and pharmacy coverage for commercial fully-insured individuals 
and both large (100+ lives) and small employer groups (2 to 99 lives).  The following medical 
services are covered for commercial fully-insured members: outpatient services (e.g. primary care, 
preventative care, specialist office visits, urgent care visits, and ER visits if not admitted) and 
inpatient hospital care (e.g. admitted hospital stay, home health care, skilled nursing facility care, 
inpatient mental health services or substance abuse services).  Prescription drugs are covered under 
one of six Humana formularies.  The majority of commercial members have a drug formulary with a 
3 or 4 tier benefit design where patient cost-share for medications increase with increasing tier status.   
4.2.3 Medicare 
 Medicare is a federally funded program that provides health insurance for individuals age 65 
and over as well as those under 65 with end-stage renal disease (ESRD) or certain disabilities.  
Almost all Medicare beneficiaries receive Medicare Part A and Part B benefits.  Medicare Part A 
provides coverage for inpatient care in hospitals and use of skilled nursing facilities, hospice, and 
some home health care services.  Part B benefits provide coverage for outpatient care services 
including doctor visits, hospital outpatient care, durable medical equipment (e.g., oxygen), home 
health care, and some preventive services (e.g., flu shots).  Part C benefits or Medicare Advantage 
plans are managed care plans administered by private insurance companies approved by Medicare 
that provide coverage for all Part A and Part B eligible services and in many cases Part D or 
prescription drug plan (PDP) coverage.   
 Before January 1, 2006, Medicare did not offer outpatient prescription drug benefits and 
Medicare members had to rely on other sources such as Medicaid or employer-sponsored health plans 
to assist in paying for outpatient medications, or pay out-of-pocket if assistance was not available.  
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The Medicare Prescription Drug, Improvement, and Modernization Act (MMA) was signed into 
federal law in 2003, establishing the voluntary Medicare outpatient prescription benefit, known as 
Medicare Part D, that became effective January 1, 2006 to help subsidize the costs of prescription 
medications for Medicare members.  Additionally, Medicare has replaced Medicaid as the prime 
source of drug coverage for “dual eligible” members who receive both Medicare and Medicaid 
benefits and some low-income members who may also qualify for additional assistance with Part D 
plan premiums and cost-sharing responsibilities.   
With the establishment of Part D, all Medicare beneficiaries are eligible to access the 
prescription drug benefit through enrollment into one of the private plans approved by the federal 
government, either as a stand-alone PDP or as part of their Medicare Advantage Prescription Drug 
(MAPD) plan.  Plans available to beneficiaries vary in benefit design including monthly premiums 
and copayment structure, formulary restrictions on medications covered, cost-containment or 
utilization management strategies, and coverage through the coverage gap.   
Table 4.1 Type of plans 
Types of plans offered by 
Humana 
Covered Lives  Coverage 
Commercial fully-insured 1.5 million Medical outpatient services, inpatient 
hospitalization stays, ER visits, and 
prescription drug plan coverage 
MAPD 1.9 million Medicare Part A, B, C, and D coverage 
PDP 2.4 million Medicare Part D (prescription drug plan) 
coverage only 
 
4.2.4 Summary of data files 
In the proposed study, three distinct files were merged: membership files containing 
demographic information (age, sex, plan enrollment information); a pharmacy claims file containing 
data on dispensed medications (name, dosage, quantity, day supply, cost); and a medical claims file 
containing up to nine International Classification of Diseases Ninth Revision, Clinical Modification 
(ICD-9-CM) codes per encounter.  Medical claims data are only available for fully-insured 
commercial and MAPD plan members.  A prior comparison of these data to nationally representative 
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samples from the Medical Expenditures Panel Survey and the Medicare 5% sample showed that the 
age adjusted prevalence of diseases was similar in this commercial insurance database to those in 
these nationally representative samples.97 
4.3 Study Design and Selection of Participants 
4.3.1 Study Design Overview 
The proposed study used a retrospective cohort design involving fully-insured commercial 
and Medicare adult patients who newly initiated a TKI as first-line therapy for CML between June 1, 
2010 and December 31, 2011 (intake period).  The intake period was determined based on the FDA 
approval of first-line use for second-generation TKIs for the treatment of CML, allowing for at least a 
1-year follow-up after TKI initiation (maximum follow-up period is December 31, 2012).  Patients 
were identified from outpatient pharmacy claims for the initiation of therapy with the following 
medications, imatinib, nilotinib, or dasatinib. The date of the first pharmacy claim for the TKI therapy 
during the intake period was defined as the index date.  An incident or new user design is preferred 
over prevalent user designs in comparative effectiveness research because it can reduce under 
ascertainment of early events and avoids the potential error of adjusting for covariates on the causal 
pathway or potentially introducing confounding.98,99  No consensus exists for defining an incident 
user of a medication when using a secondary database.99  Among studies utilizing a secondary 
database to evaluate utilization of TKI therapy for the treatment of CML, a baseline period ranging 
from one month to six months during which no prescriptions for TKI therapy are filled has been used 
to define newly treated patients.80,82  For this study, a 4 month period prior to the index date was used 
to define an incident user of a TKI.  This allows for a 30 day refill gap for patients who may have 
filled a prescription for a 90 day supply.  Patients were followed for up to 12 months following the 
index date which was defined as the follow-up period.  Figure 4.1 shows the time period that was 
applied for the study.   
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Study Intake Period 
 
 
 
 
 
 
 
 
 
Figure 4.1 Study Time Period  
4.3.2 Selection Criteria 
Patients were included in the study sample if they (1) had at least one claim for a TKI therapy 
(i.e. imatinib, nilotinib, or dasatinib) during the intake period of June 1, 2010 to December 31, 2011; 
(2) were new users to TKI therapy defined as having no claim for a TKI therapy during the baseline 
period; (3) were continuously enrolled in a Humana commercial fully-insured or Medicare plan for 4 
months during the baseline period; (4) were between the ages of 18 and 89 years old at the index date; 
and (5) had a diagnosis for CML at the time the TKI therapy was initiated.  Patients who met the 
study criteria were categorized into two mutually exclusive medication cohorts using an ‘as treated’ 
design based on whether they received a first or second-generation TKI as their index medication: 
imatinib (first-generation TKI) and nilotinib or dasatinib (second-generation TKIs).  An ‘as treated’ 
analysis classifies patients according to the treatment they took and may restrict analyses to adherent 
patients.   
 
4 Months Pre-Index 
(Baseline period) 
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2/1/2010                                  Maximum study period                              12/31/2012 
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 40 
 
 
4.3.3 Subset of Patients Meeting Selection Criteria  
To assess rates of health services utilization (i.e. number of outpatient physician visits, 
number of inpatient hospital admissions, length of inpatient hospital stays, and number of emergency 
room visits) and healthcare costs, it is necessary to access patients’ medical data.  Therefore, the 
subset of patients enrolled in a Humana plan that provides both pharmacy and medical coverage was 
further identified to compare differences in healthcare utilization and costs between patients initiating 
a second-generation versus first-generation TKI (Aim 4).  Only those patients with at least 12 months 
of follow-up were evaluated for this aim.  The purpose of Aim 5 is to perform exploratory analyses to 
determine if adherence, healthcare utilization, and healthcare costs differ between patients newly 
initiating a specific second-generation TKI (i.e. either nilotinib or dasatinib).  Therefore, only patients 
in the second-generation TKI therapy cohort were included for the exploratory analyses (Aim 5).  
4.4 Measures 
4.4.1 Overview 
This section describes how the patient demographic characteristics, patient clinical 
characteristics, and provider characteristics were measured.  A detailed description of the independent 
variables, dependent variables, and the statistical analyses employed for each aim is described in 
Section 4.6. 
4.4.2 Primary Study Measures 
Type of TKI.  A dichotomous variable was created to indicate whether the prescription filled at the 
index date was for a first-generation TKI (imatinib) or second-generation TKI (nilotinib or dasatinib).  
Use of a first-generation TKI was the referent. 
Treatment interruption.  Treatment interruption was defined as a gap in any TKI pharmacy claim 
that is longer than an allowable refill gap plus days’ supply from the previous TKI medication claim.  
Baladi et al. evaluated treatment interruption on imatinib based on a 30 day refill gap.84  For this 
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study, an allowable refill gap of 30 days was used. Time in days from the index date to date of 
treatment interruption was assessed. 
TKI regimen change.  Regimen change was defined as 1) a prescription claim for a different TKI 
therapy; or 2) an increase in dose for the same medication during the follow-up period.   
Adherence.  Adherence to TKI therapy was calculated as proportion of days covered (PDC).  PDC is 
a newer measure for calculating adherence using administrative claims data than the medication 
possession ratio (MPR).  Unlike MPR, PDC is not a simple summation of days’ supply of medication 
over an interval.100  PDC assesses days with or without medication, and has been described as the 
proportion of days a patient has a medication available in a study period.101  The PDC relies on 
pharmacy data to determine the date of each TKI therapy prescription, the number of tablets 
dispensed, and days’ supply for the prescription.  It was assumed that a patient had the medication 
available for the day of the prescription and for the remaining days’ supply of that prescription.  The 
PDC method evaluates each day during the designated study time period to determine whether a 
patient has the TKI therapy they initiated for each day using a binary measure indicating presence or 
absence of a TKI therapy.  For the primary analysis, patients were censored if they changed to a 
different TKI therapy, end of enrollment, or the end of the study period, whichever came first.  The 
number of possession days for each patient was divided by the total days of follow-up for each patient 
to determine a continuous measure of PDC which ranges from 0 to 1.  Each patient had a different 
denominator based on date of censoring.    If a claim has a days’ supply exceeding the end of the 
study period, days’ supply was truncated to the end of the measurement period.  PDC was 
dichotomized at 0.85.79  Scores ≥0.85 were classified as adherent and scores <0.85 were classified as 
non-adherent. 
Health services utilization.  All-cause healthcare utilization was assessed during the follow-up period 
using the medical claims file.  Four distinct utilization measures were assessed: (1) number of 
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outpatient physician visits; (2) number of inpatient hospitalization admissions; (3) number of 
inpatient hospital days; and (4) ER visits. 
Healthcare costs. The total direct all-cause healthcare costs were calculated from medical and 
pharmacy claims data for each patient during the follow-up period.  Covered services under the 
medical and pharmacy benefit are described in more detail under Section 4.2 Data Source.  The cost 
calculation included both plan paid and member out-of-pocket costs (i.e. patient copayments and co-
insurance).  Three distinct variables were calculated: (1) medical costs; (2) pharmacy costs; and (3) 
total healthcare costs calculated as the sum of medical and pharmacy costs.   
 
Table 4.2 Summary of primary study measures 
Variable Type Source Data File Definition 
Type of TKI at 
index date 
Dichotomous Pharmacy claims file Use of a second-generation TKI 
therapy (nilotinib or dasatinib) at 
index date with first-generation TKI 
therapy (imatinib) serving as 
referent 
Treatment 
interruption 
Continuous Pharmacy claims file Time in days from date of first TKI 
prescription claim to date of 
treatment interruption 
TKI regimen 
change 
Dichotomous Pharmacy claims file Regimen change, measured as a 
dichotomous variable indicating 
whether a patient changed to any 
different TKI therapy or increased 
dose for the same medication 
during the follow-up period 
Adherence Dichotomous Pharmacy claims file Adherence to TKI therapy during 
the follow-up period, measured by 
PDC. Patients with a PDC≥0.85 
were classified as adherent and 
those with PDC <0.85 were 
classified as non-adherent. 
Health services 
utilization 
Count Medical claims file Four distinct variables were created 
and assessed during the follow-up 
period for 1) outpatient physician 
visits; 2) inpatient hospitalization 
stays; 3) inpatient hospital days; 
and 4) ER visits. 
Healthcare costs Continuous Medical claims file Three distinct variables were 
calculated for healthcare costs 
during the follow-up period for 1) 
pharmacy costs; 2) medical costs; 
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and 3) total all-cause costs 
(pharmacy plus medical). 
 
4.4.3 Covariates 
The covariates included in this study are informed by Carpenter and colleagues’ conceptual 
model for examining nonexperimental cancer comparative effectiveness research.88  Covariates are 
divided into three categories: patient demographic characteristics, patient clinical characteristics, and 
provider characteristics.  Operationalization of the covariates within each category is described below 
and summarized in Table 4.6. 
Patient demographic characteristics 
Age. Patient age was calculated in years as of the index date. Age was calculated as the number of 
days between the index date and the patient’s date of birth divided by 12 months. 
Gender. Patient gender was measured as a dichotomous variable. 
Geographic region. Geographic region was based on the patient’s state of residence on the index 
date.  Refer to Table 4.3 for the regional assignment (Northeast, Midwest, South, West) which is 
based on the U.S. Census Bureau assignment of states to geographic region. 
Table 4.3 Geographic Region Definitions 
Region  States 
Northeast 
Connecticut, Maine, Massachusetts, New Hampshire, Vermont, Rhode Island, New 
Jersey, New York, and Pennsylvania 
Midwest 
Illinois, Indiana, Michigan, Ohio, Wisconsin, Iowa, Kansas, Minnesota, Missouri, 
Nebraska, North Dakota, and South Dakota 
South  
Delaware, District of Columbia, Florida, Georgia, Maryland, North Carolina, South 
Carolina, Virginia, Alabama, Kentucky, Mississippi, Tennessee, West Virginia, 
Arkansas, Louisiana, Oklahoma, and Texas 
West 
Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, Wyoming, 
Alaska, California, Hawaii, Oregon, and Washington 
Source: http://www.census.gov/geo/www/geo_defn.html#GeographicCode 
Plan. Patients were classified as having a commercial fully-insured or Medicare plan with Humana as 
of the index date.  Differences between patient demographic characteristics, insurance benefits, and 
treatment patterns have been reported among Humana patients enrolled in a commercial versus a 
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Medicare plan.  A study evaluating patterns of osteoporosis treatment demonstrated that commercial 
patients tended to be younger, with fewer comorbidities, and higher out-of-pocket expenses for 
medications.89  Financial product indictor was used to determine whether a patient is enrolled in a 
fully-insured commercial or Medicare plan.  A patient is enrolled in a fully-insured commercial plan 
when the financial product code is one of the following: IHM, IMV, HMOC, PPO, POS, or IND.  A 
patient is enrolled in a Medicare plan when the financial code is one of the following: MEDR, 
MEDR-HMO, MEDR-PFFS, MEDR-POS, or MEDR-PPO. 
Low Income Subsidy (LIS) nondual eligible status. Medicare beneficiaries with income below 150% 
of poverty and limited resources are eligible for additional premium and cost-share assistance for 
prescription drugs under the Medicare Part D program.  These patients are flagged as LIS patients in 
Humana’s claims database. This variable was measured at the index date for Medicare patients only.  
LIS nondual eligible patients are distinguished from dual eligible patients because LIS nonduals have 
higher incomes, proactively apply for LIS whereas duals are auto enrolled, and almost all duals had 
coverage under Medicaid before Part D.91 
Dual eligibility. Dual eligibility indicates that Medicare patients are also covered under Medicaid 
which covers ancillary services not covered under the Medicare plan.  Often these patients have 
increased disease burden and have different healthcare utilization patterns compared to other 
Medicare patients.91  These patients are flagged as having Medicaid dual eligibility in Humana’s 
claims database.  Dual eligibility status was evaluated at the index date. 
Patient clinical characteristics 
TKI dose schedule.  Treatment dose schedule for TKI therapy was assessed based on which TKI 
therapy was initiated at the index date.  The treatment schedule of the index TKI therapy was 
classified as daily or twice daily based on the daily average consumption (DACON) for the index 
prescription. DACON is used to describe the average number of dosage units dispensed per day.  A 
DACON of 1 represents once daily dosing and a DACON of 2 represents twice daily dosing. 
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Proxy for CML phase.  Patients’ starting dose of TKI therapy was assessed and used as a proxy for 
CML phase at the time of initiation.  The dose was calculated as the strength of the TKI therapy 
dispensed, multiplied by the quantity filled, divided by the days’ supply.  Each TKI therapy has a 
dose that suggests suboptimal or accelerated phase (see Table 2.4).  A dichotomous variable was 
created based on starting dose to distinguish 1) chronic phase initiation dosing; and 2) suboptimal or 
accelerated phase dosing.   
Channel of drug distribution. The channel of drug distribution through which the index prescription 
was obtained was categorized as specialty, retail, managed care organization pharmacy, or long term 
care pharmacy.  
Patient cost-share for TKI therapy. Patient cost-share was measured using cost per 30 day supply of 
TKI therapy for the index prescription.  If the patient received a 30 day supply of medication for the 
index medication, the cost the patient paid for that prescription was reported.  For patients receiving 
less than or greater than a 30 day supply for the index medication, the cost for the prescription was 
divided by the days’ supply and then multiplied by 30.  
Coverage gap.  A dichotomous variable was created for Medicare beneficiaries to indicate whether a 
patient reached the coverage gap at any time during the follow-up period.  The standard Medicare 
Part D prescription drug benefit has three phases of coverage during a plan year: initial, coverage gap, 
and catastrophic coverage.  Until 2011, patients were responsible for the entire cost of medications 
during the coverage gap phase.  Entry into the coverage gap was determined based upon the total 
amount spent on medications (that occurs through the Part D benefit) during each plan year.  Each 
year, CMS establishes a new deductible, initial coverage period, coverage gap period, and 
catastrophic coverage period.  The coverage gap period for each year and catastrophic phase are 
defined in Table 4.4.  The standard Medicare Part D Prescription Drug Plan (PDP) varies by plan 
offering; however, the criterion for entry into the coverage gap does not vary.   
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Table 4.4 Standard Medicare Part D Prescription Drug Benefit 
Plan Year Initial Deductible Total Drug Cost for 
Coverage Gap Entry 
True Out of Pocket Cost 
(TrOOP) for Catastrophic 
Coverage Entry 
2010 $310 $2,830 $4,550 
2011 $310 $2,840 $4,550 
2012 $320 $2,930 $4,700 
 
RxRisk Score.  The RxRisk-V is a prescription claims-based comorbidity index originally developed 
as an enhancement of the RxRisk risk assessment instrument for use in the Veterans Health 
Administration (VHA) population.102-104  The RxRisk-V score is determined based on the 
identification of 45 distinct comorbid conditions via their associated medication treatments (Table 
4.5). In order to calculate the RxRisk-V score, comorbid conditions are mapped to drug classes and 
individual drugs via Medi-Span generic product identifier (GPI) codes.  The GPI is a therapeutic 
classification system that is useful for aggregating similar drug products at a drug class level. The GPI 
is a 14-digit code that contains 7 pairs of digits and uses a hierarchical therapeutic classification 
scheme. The first pair of digits represents the drug group and subsequent paired digits represent the 
drug class, drug subclass, drug name, drug name extension, dosage form, and strength.  Three 
comorbid conditions that are defined based on claims for durable medical equipment (neurogenic 
bladder, ostomy, and urinary incontinence) were not included in the RxRisk-V score calculation since 
these claims are not captured in the pharmacy claims file.  
Because the RxRisk-V score is derived from pharmacy claims data, it may provide a more 
complete and accurate comorbidity picture when data from a narrow window of claims are used, or in 
cases where diagnosis codes are not routinely recorded.  The RxRisk-V has been rigorously tested 
and has demonstrated concordance with the Deyo-Charlson score. Although the RxRisk-V was 
originally developed for use in the Veterans Health Administration (VHA) population, the measure 
has been found to perform well in other populations.  A recent evaluation of Rx Risk-V by Farley and 
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colleagues found that the RxRisk-V outperforms both the Deyo-Charlson and the Elixhauser 
comorbidity measures in predicting healthcare expenditures among managed care plan members.105  
In addition, Farley et al. found that the unweighted version of the RxRisk-V has better predictive 
validity for costs than does the weighted version. The unweighted RxRisk-V score was calculated for 
each patient during the baseline period.  
Table 4.5 RxRisk-V comorbidity categories and associated drug classes/drugs* 
RxRisk-V Categories Drugs classes/drugs 
Alcohol dependence disulfiram, naltrexone 
Allergies 
antihistamines (except hydroxyzine and diphenhhydramine), nasal 
anti-inflammatories 
Anticoagulation anticoagulants 
Antiplatelet agents antiplatelet agents 
Anxiety and tension  anxiolytics (benzodiazepine and barbiturate)   
Arrhythmias antiarrhythmics, digoxin 
Benign prostatic hypertrophy alpha blockers 
Bipolar disorder lithium 
CHF/hypertension loop diuretics, ACE, and angiotensin II inhibitors   
Dementia   donepezil, tacrine 
Depression   antidepressants 
Diabetes insulins, oral hypoglycemics 
End stage renal disease  alpha erythopoetin, calcifediol, calcitriol, sevelamer   
Epilepsy   anticonvulsants 
Gastric acid disorder H2 blockers, proton pump inhibitors 
Glaucoma   topical (ophthalmic) antiglaucoma agents 
Gout antigout agents 
Hepatitis C interferon/ribavirin combinations 
HIV anti-HIV antivirals 
Hyperkalemia sodium polystyrene sulfonate  
Hyperlipidemia antilipemic agents 
Hypertension 
thiazides, potassium-sparing agents, combination antihypertensives, 
other antihypertensives (eg, clonidine, hydralazine)   
Hypothyroidism thyroid replacements   
IHD/angina nitrates 
IHD/hypertension beta blockers, calcium channel blockers  
Inflammatory bowel syndrome IBS-specific drugs, rectal anti-inflammatories   
Liver failure lactulose   
Malignancies 
antineoplastic agents (all oral and systemic agents but excluding 
topicals) 
Malnutrition enteral nutritional supplements  
Migraine antimigraine medications (ergots, triptans, methysergide)   
Neurogenic bladder urinary catheters (supplies) 
Osteoporosis/Pagets alendronate, etidronate 
Ostomy colostomy and urostomy supplies   
Pain opiate-containing pain medications 
Pain/Inflammation nonsteroidal anti-inflammatory drugs 
Pancreatic insufficiency pancreatic exocrine enzyme replacements  
Parkinson disease  antiparkinsonian agents 
Psoriasis  systemic and topical antipsoriatics 
Psychotic illness antipsychotics 
Reactive airway disease   inhaled bronchodilators, leukotriene inhibitors  
Smoking cessation nicotine, Zyban 
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Steroid-responsive conditions glucocorticoids (steroids)   
Transplant immune suppressants 
Tuberculosis anti-tubercular agents 
Urinary incontinence diapers and pad (supplies) 
*Adapted from Sloan et al., 2003 
Deyo Charlson Comorbidity Index.  The Deyo Charlson Comorbidity Index (DCI) uses 17 categories 
of comorbidity to calculate a score that reflects cumulative increased likelihood of one-year 
mortality.106  It is based on ICD-9 diagnoses and procedure codes, and their associated weights.  
Table 4.6 lists the comorbidities and their weightings used in the calculation of the DCI.  The DCI 
score can range from 0 to 33.  Claims with the specified codes are used in the calculation of the DCI 
if they meet the following criteria: (1) used on an inpatient hospitalization; or (2) used on two or more 
outpatient claims, separated by a period of 30 days or more.107 
Table 4.6 Deyo Charlson Comorbidity Index 
Comorbidity Codes Weight 
Myocardial Infarction 410.xx, 412.xx 1 
Congestive Heart Failure 428.xx 1 
Peripheral Vascular Disease 441.xx, 443.9, 785.4, V43.4, 38.48* 1 
Cerebrovascular Disease 430.xx-437.xx, 438.xx 1 
Dementia 290.xx 1 
Chronic Pulmonary Disease 490.xx-496.xx, 500.xx-505.xx, 506.4 1 
Connective Tissue Disease 710.xx, 714.xx, 725.xx 1 
Peptic Ulcer Disease 531.4x-531.7x, 532.4x-532.7x, 533.4x-
533.7x, 534.4x-534.7x, 531.0x-531.3x, 
532.0x-532.3x, 533.0x-533.3x, 534.0x-
534.3x, 531.9x, 532.9x, 533.9x, 534.9x 
1 
Mild Liver Disease 571.2, 571.4, 571.5, 571.6 1 
Diabetes without Complications 250.0x-250.3x, 250.7x 1 
Diabetes with Complications 250.4x-250.6x 2 
Paraplegia and Hemiplegia 342.x, 344.1 2 
Renal Disease 582.x, 583.0-583.7, 585.xx, 586.xx, 588.xx 2 
Cancer (Including Leukemia and Lymphoma) 140.xx-172.xx, 174.xx-195.xx, 200.xx-208.xx 2 
Moderate or Severe Liver Disease 572.2-572.8 3 
Metastatic Carcinoma 196.x-199.x 6 
Acquired Immunodeficiency Syndrome (AIDS) 042.xx-044.x 6 
*ICD-9-CM Procedural Code 
Number of unique concurrent medications. Total number of unique concurrent medications was 
defined using pharmacy claims data where the service date occurred during the baseline period.  The 
total number of unique concurrent medications was a count of all medications with the exception of 
TKI therapies based on the GPI. GPI-8 identifies a product at the chemical or drug name level and 
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was used to identify unique medications where the patient was required to receive 2 or more claims.  
Two or more claims were required to eliminate including medications for short term use.   
Vaccine use.  Flu or pneumonia vaccine use was assessed during the baseline period.  This covariate 
was included because patients who are adherent may have a health-seeking tendency and may be 
more likely to use preventative services.94 
Provider characteristics 
Gender. Provider gender was available through the Humana provider file and measured as a 
dichotomous variable. 
Age.  Provider age was calculated in years as of the index date.  Age was calculated as the number of 
days between the index date and the provider’s date of birth, which was available in the Humana 
provider file, divided by 12 months. 
Provider specialty.  National Provider Identifier (NPI) was available in the Humana provider file.  
NPI was used to identify provider specialty through the Centers for Medicare and Medicaid Services 
NPI registry.108  Provider specialty was categorized as oncologist or other. 
Practice type.  Provider practice type was investigator coded and categorized as academic, private, 
and other.  Other practice setting was defined as community hospitals, clinics, or outpatient cancer 
care facilities neither owned by the practicing physicians nor considered academic or university-
based.95  Provider name, practice name, and address were available in the Humana provider file.  
First, providers practicing in an academic setting were identified based on practice name and address 
available in the Humana provider file. Next, additional research was conducted for the remaining 
providers to determine whether a provider practiced in a private setting or other.  Practice name and 
address were used to locate the practice’s website.  The information needed to determine if a practice 
was private or other was available in the “About us” or “history” sections of the websites. 
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Table 4.7 Summary of Covariates 
Variable Type Data Source Time Assessed  Definition 
Demographic characteristics 
Age Categorical 
Pharmacy 
claims file 
Index date 1=<55; 2=55-64; 
3=65-74; 4=>75 
Gender Dichotomous Membership file Index date 0=female; 1=male 
Geographic 
region 
Categorical Membership file Index date 1=South; 
2=Northeast; 
3=Midwest; 
4=West 
Plan Categorical Membership file Index date 0=Commercial 
fully-insured; 
1=Medicare 
LIS  Dichotomous Membership file Index date 0=no; 1=yes 
Dual eligibility Dichotomous Membership file Index date 0=no; 1=yes 
Clinical characteristics 
TKI dose 
schedule 
Categorical Pharmacy 
claims file 
Index date 0=once daily 
dosing; 1=twice 
daily dosing 
Proxy for CML 
phase  
Dichotomous Pharmacy 
claims file 
Index date  0=chronic phase 
dosing; 
1=suboptimal or 
accelerated phase 
dosing 
Channel of drug 
distribution 
Categorical Pharmacy 
claims file 
Index date 1=specialty; 
2=retail; 
3=managed care 
organization 
(MCO); 4=long 
term care 
pharmacy 
Member out-of-
pocket cost for 
month supply of 
index TKI 
Continuous Pharmacy 
claims file 
Index date 1=$0-$1000; 
2=$1,001-$2,000; 
3=$2001-$3,000; 
4=$3,001-$4,000; 
5=>$4,000 
Coverage gap 
calculated 
separately for 
2010, 2011, 2012 
Dichotomous Pharmacy 
claims file 
Follow-up 0=no; 1=yes 
RxRisk-V Score Categorical  Pharmacy 
claims file 
Baseline period 0=RxRisk-V score 
between 0-2; 
1=RxRisk-V score 
>2 
Deyo Charlson 
Comorbidity 
Index 
Categorical Medical claims 
file 
Baseline period 0=DCI 0,1 
1=DCI greater than 
1 
Number of unique 
concurrent 
medications 
Count Pharmacy 
claims file 
Baseline period 0=medication 
count between 0-2; 
1=medication 
count >2  
Vaccine use Dichotomous Pharmacy 
claims file 
Baseline period 0=no; 1=yes 
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Provider Characteristics 
Gender Dichotomous Provider file Index date 0=female; 1=male 
Provider age Categorical Provider file Index date 0=<35; 1=35-44; 
2=45-54; 3=55-64; 
4=≥65 
Provider specialty Categorical  Provider 
file/NPI registry 
Index date 0=other; 
1=oncologist 
Practice type Categorical Provider 
file/Investigator 
coded 
June, 2013 1=academic; 
2=private;  
3=other 
 
4.5 Power Analyses 
Based on the data available for this study, 239 patients initiated therapy with a first-
generation TKI (imatinib) and 132 patients initiated therapy with a second-generation TKI (nilotinib 
or dasatinib). Adherence (Aim 3) drives the power calculation. Adherence rates for imatinib, 
nilotinib, and dasatinib have been similar in clinical trials. Wu et al. evaluated adherence to imatinib 
therapy using claims data where adherence was defined as a MPR ≥85%.79  Approximately, 60% of 
patients were adherent over a 12-month period.  To test the hypothesis that adherence to second-
generation TKI therapies (i.e. nilotinib and dasatinib) is higher compared to imatinib, adherence must 
be substantially higher.  Using Proc Power®, a 2x2 proportion test with unequal sample sizes 
estimated that 371 patients provide approximately 97.7% power to detect a 20% difference in the 
proportion of adherent patients (i.e. 60% versus 80%) between imatinib and a second-generation TKI 
therapy using a two-tailed alpha=0.05. There is 81.4% power to detect a 15% difference (i.e. 60% 
versus 75%), 44.5% power to detect a 10% difference (i.e. 60% versus 70%), and 13.4% power to 
detect a 5% difference (i.e. 60% versus 65%) in adherence.  
To test the hypothesis for Aim 4 that patients initiating a second versus first-generation TKI 
have lower total all-cause healthcare costs over a 12-month period, a power calculation using a two 
sample t-test with unequal sample sizes assuming unequal variances was completed.  Cost data from 
Hirji  et al. was used for the assumptions for the power calculations.82  The mean 6-month all-cause 
healthcare costs for imatinib and dasatinib patients were $46,342 and $54,808, respectively.  These 
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costs were multiplied by two to predict 12-month all-cause costs.  It is estimated using an unequal 
group weight of 1.5:1, 133 patients provide >99% power to detect a $45,000 difference in 12 month 
all-cause healthcare costs between patients initiating a second versus first-generation TKI, >99% 
power to detect a $35,000 difference, 99.7% power to detect a $25,000 difference, and 80% power to 
detect a $15,000 difference. 
4.6 Methodological Issues 
Because there are no available RCTs with direct comparisons of the effectiveness for all three 
TKI therapies and there is limited ability to generalize RCT evidence to clinical practice, it is critical 
to use observational data to evaluate the effectiveness of a first-generation TKI (imatinib) to second-
generation TKIs (nilotinib and dasatinib) in patients newly initiating TKI therapy for the treatment of 
CML.  Observational data are used to compare outcomes of different therapies to inform clinical 
guidelines and practice.  Although observational data can be used to supplement RCT data, it is often 
biased due to unmeasured confounders.  Confounding in pharmacoepidemiology studies is 
multifaceted as treatment exposure is not randomized.  The most cause for concern when comparing 
outcomes between first versus second-generation TKI therapy is that treatment decisions can be 
influenced by severity of disease, frailty and other prognostic factors (confounding by indication).109  
Second-generation TKIs were originally only indicated for second-line use in imatinib resistant or 
intolerant patients.  Although the NCCN guidelines recommend a prognostic assessment at baseline 
to help guide the choice of primary treatment,46 there is no current evidence suggesting physicians are 
prescribing second-generation TKIs in patients with more severe disease.  Furthermore, it is unlikely 
that treatment decisions are currently influenced by severity of disease but by efficacy, dose schedule, 
and provider preferences.  Second-generation TKIs have shown to be more efficacious compared to 
imatinib in patients newly diagnosed with CML and provide a faster and deeper response.9,11  
Recently, Cortes et al. published a paper describing how they treat newly diagnosed CP-CML patients 
and recommend all new patients be treated with second-generation TKI therapy as they believe in the 
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long run patients will do better with this strategy.42  Additionally, physician’s preference likely 
influences initial TKI therapy which may be guided by clinical experience as well as the dose 
schedule. Both imatinib and dasatinib are available as once daily dosing which may improve 
adherence whereas nilotinib is taken twice daily. 
Although confounding by disease severity may not pose a threat to internal validity of the two 
cohorts, cancer severity is a factor that may confound the relationship between patients’ adherence 
and healthcare costs and utilization.  It is likely that patients in more advanced stages of CML have 
higher healthcare costs and different rates of adherence than patients in less advanced stages.  The 
dataset being used in this study does not provide information to identify and adjust for the phase of 
CML (chronic phase, accelerated phase, or blast crisis).  However, TKI starting dose was used as a 
proxy for chronic phase versus a more advanced stage.   
Survival analysis was used to evaluate time to treatment interruption and time to regimen 
change because patients in the study had different lengths of follow-up.  Time to event was defined as 
time elapsed between first TKI therapy fill (i.e. index date) and treatment interruption or switch.  
Poisson regression models were used to compare health servicesutilization between patients initiating 
a second versus first-generation TKI.  To estimate the association between initiating a second versus 
first-generation TKI and healthcare costs while controlling for baseline differences, multivariate 
regression analyses were conducted.  Because healthcare costs data are known to have a highly 
skewed distribution with non-constant variances, generalized linear models (GLM) were fitted to 
estimate mean healthcare costs.110  Risk adjustment methods were used to address confounding in the 
analyses described above.  Risk adjustment methods result in unbiased estimates by adjusting for 
measured confounders with the assumption that all confounders are either measured or that 
unmeasured are “ignorable”.111  If unmeasured confounders cannot be ignored, the estimates from 
risk adjustment are biased.   
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4.7 Statistical analyses  
All analyses were conducted using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).   
Baseline Characteristics 
 Descriptive statistics were used to summarize demographics, other baseline characteristics, 
and TKI use.  Baseline characteristics were evaluated for the baseline time period or at the time of the 
index date.  The following information was presented: 
Baseline Characteristics 
Age (at index date) Number of unique concurrent medications 
Gender  Chanel of distribution 
Plan (commercial vs. Medicare) Patient cost-share of index TKI therapy 
Geographic region  Coverage gap 
Dual eligibility status* RxRisk-V  
LIS status* Charlson Comorbidity Index 
Index TKI (1st vs. 2nd generation TKI) Provider age 
TKI starting dose Provider gender 
TKI dose schedule Provider specialty 
Proxy for CML phase Provider practice setting 
Vaccine use  
*For Medicare members only 
Information listed above was compared between the two cohorts (first-generation and second-
generation TKI).  In general, continuous variables were compared using t-tests or Wilcoxon rank sum 
test while categorical variable were summarized using chi-square or Fisher's exact tests. 
Propensity Score (PS) Estimation 
Propensity score estimation is a technique used to control for naturally occurring differences 
between treatment groups in observational studies.112  Propensity score methods include matching, 
stratification on the propensity score, inverse probability weighting using the propensity score, and 
regression adjustment.113  Because patients were not randomly assigned their TKI therapy, a 
propensity score quintile was used as a covariate in the regression adjustment.   
The methodology used for the estimation of a propensity score requires two groups at a time.  
The steps for estimating the propensity score for each subject are as follows114: 
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1. Use a logistic regression model to estimate the propensity score.  Treatment assignment is 
the binary response (dependent variable) and the covariates are the explanatory 
(independent) variables.   
2. Stratify observations by quintiles of the distribution of the estimated propensity scores.115 
3. Check the balance achieved by comparing the covariate values across treatment groups 
for each quintile and covariate.  A significant test result implies that the covariate is not 
balanced for the two treatments within the subclass. 
4. If balance is not achieved, the model used to estimate the propensity score needs to be 
refined.   
5. A histogram should be used to evaluate the PS range.  Analyses should first be conducted 
without any restriction of the PS range.  Then, if needed additional analyses should be 
restricted to observations within a PS range that is common to patients initiating a first 
versus second-generation TKI, thereby excluding all patients in the nonoverlapping parts 
of the PS distribution.116     
The propensity score approach requires two assumptions.  First, the propensity score only 
controls for observed characteristics.  If there is an unobserved variable that significantly affects the 
outcome, it will not be controlled.  Second, treatment assignment must be strongly ignorable.  The 
treatment assignment is considered strongly ignorable if the treatment assignment (whether or not the 
patient received a particular medication) and the response (the outcome) is conditionally independent 
given the observed characteristics (e.g. age, gender).    
4.7.1 Aim 1: Identify factors associated with newly initiating therapy for CML with a second-
generation versus a first-generation TKI 
4.7.1.1 Logistic Regression 
A multivariable logistic regression analysis was performed to assess factors associated with 
newly initiating a second-generation TKI therapy compared to a first-generation TKI for the treatment 
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of CML (Model 1).  Statistical significance was assessed at alpha=0.05 for this purpose.  Model fit 
and predictability statistics were reported (e.g. Hosmer and Lemeshow Goodness-of-Fit Test, c 
statistics).   
 Model 1: 
ۺܗ܏ܑܜሺ࢙ࢋࢉ࢕࢔ࢊ െ ࢍࢋ࢔ࢋ࢘ࢇ࢚࢏࢕࢔ࢀࡷࡵ࢛࢙ࢋሻ ൌ ઺૙ ൅ ઺૚ሺࢇࢍࢋሻ ൅ ઺૛ሺࢍࢋ࢔ࢊࢋ࢘ሻ ൅ ઺ ሺ࢘ࢋࢍ࢏࢕࢔ሻ
൅ ઺૝ሺ࢖࢒ࢇ࢔ሻ ൅ ઺૞ሺࡸࡵࡿሻ ൅ ઺૟ሺࢊ࢛ࢇ࢒ࢋ࢒࢏ࢍ࢏࢈࢏࢒࢏࢚࢟ሻ ൅ ઺ૠሺࢉ࢕࢓࢕࢘࢈࢏ࢊ࢏࢚࢏ࢋ࢙ሻ
൅ ઺ૡሺ࢜ࢇࢉࢉ࢏࢔ࢋ࢛࢙ࢋሻ ൅ ઺ૢሺ࢓ࢋࢊ࢏ࢉࢇ࢚࢏࢕࢔ࢉ࢕࢛࢔࢚ሻ
൅ ࢼ૚૙ሺ࢖࢘࢕࢜࢏ࢊࢋ࢘ࢉࢎࢇ࢘ࢇࢉ࢚ࢋ࢘࢏࢙࢚࢏ࢉ࢙ሻ ൅ ઽ 
Age: a vector of age at index date 
Gender: a vector of male and female gender 
Geographic region: a vector of region indicators (NE, MW, S, W) 
Plan: a vector of patients enrolled in a commercial or Medicare plan 
LIS: a vector of LIS vs. non-LIS (Medicare patients only) 
Dual eligibility: a vector of dual eligibility vs. non-dual eligibility (Medicare patients 
only)  
Comorbidities: a vector of RxRisk score >2 compared to ≤2 
Vaccine use: a vector of vaccine vs. non-vaccine use 
Medication count: a vector of medication count >2 compared to ≤2 
Provider characteristics: a vector of age, gender, provider type, and practice type 
 
4.7.1.2 Sensitivity Analysis 
Two sensitivity analyses were performed.  The first sensitivity analysis was limited to 
patients enrolled in a MAPD plan or fully-insured commercial plan.  These patients have medical data 
available.  The logistic regression model used the Deyo Charlson Comorbidity Index as a measure of 
comorbidity instead of the RxRisk score.  Patients may have comorbidities not treated by medication 
which are not captured using RxRisk score.  The second sensitivity analysis included only patients 
who initiated on chronic phase dosing; therefore, patients with accelerated disease were removed and 
this covariate was not included in the model. 
4.7.2 Aim 2: Examine differences in treatment interruption and regimen change comparing patients 
newly initiating a second-generation versus a first-generation TKI  
4.7.2.1 Overview 
 57 
 
 
The null-hypothesis for Aim #2 is that there are no significant differences in medication use 
patterns between patients who newly initiate a second-generation compared to a first-generation TKI 
therapy for the treatment of CML.  The alternative hypothesis for Aim #2 is that patients initiating a 
second-generation TKI therapy stay on therapy longer and are less likely to have a regimen change.   
The percentage of patients that had a treatment interruption and a TKI regimen change during 
the follow-up period was reported for each cohort. Additionally, risk adjustment analyses and 
multivariable logistic regression were used to evaluate differences in medication use patterns between 
patients initiating first versus second-generation TKI therapy.  Cox proportional hazard models were 
used to evaluate the time to treatment interruption and regimen change which was interpreted as the 
duration of TKI therapy, for patients initiating first versus second-generation TKI therapy. 
4.7.2.2 Treatment Interruption 
4.7.2.2.1 Main Analyses 
Risk Adjustment Analyses 
Survival analysis was used to evaluate time to treatment interruption because patients in the 
study have different lengths of follow-up.  Time to event was defined as time elapsed between first 
TKI therapy fill (i.e. index date) and date of treatment interruption, end of enrollment, or the end of 
the study period, whichever came first.  Risk adjustment methods were used to address confounding.  
Risk adjustment methods result in unbiased estimates by adjusting for measured confounders with the 
assumption that all confounders are either measured or that unmeasured confounders are 
“ignorable”.111  If unmeasured confounders cannot be ignored, the estimates from risk adjustment will 
be biased. 
 Cox proportional hazard (CPH) regression models were used as the regression model for the 
risk adjustment analysis.  CPH is a robust model and is preferred over other survival approaches when 
there are several explanatory variables.117  An unadjusted CPH model was used to estimate the non-
adjusted time to treatment interruption for the first-generation and second-generation TKI groups.  
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Additionally, a multivariable CPH model was used to control for differences in the distribution of 
covariates across the two cohorts and evaluate the potential confounding effects of the covariates 
(Model 2).  Model 2 adjusts for all time-independent baseline demographic and clinical 
characteristics.  The Cox model formula states that the hazard at time t is the product of two factors: 
(1) h0(t) is the baseline hazard function that is left unspecified, and is non-negative and (2) an 
exponentiated linear function of a set of X fixed variables.   Finally, a CPH model that included PS 
quintile as a covariate in the regression adjustment was used (Model 3). There are three statistical 
objectives for the CPH model: (1) to test for the significance of the treatment status variable, adjusted 
for possible confounding; (2) to obtain a point estimate of the effects (ßs) of the explanatory 
variables; and (3) to obtain a confidence interval for this effect.118  The measure of effect, the hazard 
ratio, can be calculated from these estimates. 
Model 2: 
hi(t,xi) = h0(t) * exp(βtTi + βxXi)  
 t: the time (days) from the index prescription to event or censoring 
T: treatment (1 second-generation TKI and 0 for first-generation TKI) 
X: the vector for all baseline characteristics 
βt: coefficient of T, the difference in survival time 
βx:  a vector of coefficients for the X 
i: individual patient 
 
Model 3: 
hi(t,xi) = h0(t) * exp(βtTi + βpsPSi) 
 t: the time (days) from the index prescription to event or censoring 
T: treatment (1 second-generation TKI and 0 for first-generation TKI) 
βt: coefficient of T, the difference in survival time 
βps: a vector of coefficients for the PS 
PS: the propensity score quintile 
i:  individual patient 
 
Post-hoc Treatment Patterns Analysis for Patients with a Treatment Interruption 
For those patients identified as having a treatment interruption during the follow-up period, a 
post-hoc analysis was included to evaluate behavior change following treatment interruption.  TKI 
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treatment patterns were then followed for patients with a treatment interruption from the date of 
interruption until there was another change.  Patients were classified has having a medication change, 
reinitiating the index medication, discontinuing therapy, or disenrolling from a Humana plan. 
4.7.2.2.2 Sensitivity analysis 
 Two sensitivity analyses were completed.  The first sensitivity analysis was conducted and 
limited to patients who were initiated on a starting dose that indicated chronic phase disease.  Three 
CPH models were included: unadjusted, multivariable, and PS quintile.  The second sensitivity 
analysis was completed to censor for death.  Therefore, in this sensitivity analysis, time to event was 
defined as time elapsed between first TKI therapy fill (i.e. index date) and date of treatment 
interruption, end of enrollment, date of death, or the end of the study period, whichever came first. 
3.7.2.3 TKI Regimen Change 
3.7.2.3.1 Main Analyses 
Risk Adjustment Analyses 
 Similar risk adjustment analyses were conducted for time to regimen change as were used for 
treatment interruption.  Time to event was defined as time elapsed between first TKI therapy fill (i.e. 
index date) and regimen change, end of enrollment, or the end of the study period, whichever came 
first. 
4.7.2.2.2 Sensitivity Analyses 
Two sensitivity analyses were completed.  The first sensitivity analysis was conducted and 
limited to patients who were initiated on a starting dose that indicated chronic phase disease.  Three 
CPH models were included: unadjusted, multivariable, and PS quintile.  The second sensitivity 
analysis used logistic regression models to assess the association between initiating a first versus 
second-generation TKI therapy and regimen change.   
4.7.3 Aim 3: Determine if adherence is higher among patients newly initiating a second-generation 
versus a first-generation TKI 
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4.7.3.1 Overview 
The null-hypothesis for Aim 3 is that there is no significant difference in medication 
adherence among patients who newly initiate a second-generation compared to a first-generation TKI 
therapy for the treatment of CML.  The alternative hypothesis for Aim 3 is that patients taking a 
second-generation TKI therapy are more adherent compared to patients taking a first-generation TKI 
therapy.   
Unadjusted mean adherence, measured using PDC, was compared between the cohorts using 
a t test.  Additionally, each patient was categorized into one of three adherence categories based on 
PDC values: high (PDC ≥0.85); intermediate (PDC 0.40-0.84); and low (PDC <0.4). The percentage 
of adherent patients was compared between the cohorts using chi-square test.  
Differences in adherence between patients initiating first versus second-generation TKI 
therapy was assessed using logistic regression.  Adherence, measured using PDC, was dichotomized 
at 0.85. Scores ≥0.85 were considered adherent and scores <0.85 were considered non-adherent.   
4.7.3.2 Logistic Regression and Propensity Score Adjustment 
Three logistic regression models were included (i.e. unadjusted, multivariable, and PS 
quintile) to examine differences in adherence between patients initiating a first compared to a second-
generation TKI therapy.  The dependent variable was adherence to TKI therapy, defined as PDC 
≥0.85.  The primary independent variable was initiation of therapy with a first-generation versus 
second-generation TKI therapy.   
4.7.3.3 Sensitivity Analyses 
Three different types of sensitivity analyses were performed.  First, sensitivity analyses were 
conducted to include modifications of the logistic regression model.  Dose schedule and duration of 
therapy (i.e. days on therapy) were included and added separately to the initial model.  A sensitivity 
analysis was conducted and limited to patients who were initiated on a starting dose that indicated 
chronic phase disease. 
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Second, sensitivity analyses were conducted with adherence dichotomized at 0.80.  Scores 
≥0.80 were considered adherent and scores <0.80 were considered non-adherent.  Although an a 
priori sensitivity analysis to evaluate high, intermediate, and low adherence was planned, the analysis 
was limited by a small sample size for the low adherence category (n=4).  
Third, adherence was assessed using an ITT approach.  For this analysis, patients were 
assigned to either the first-generation or second-generation TKI cohort, regardless of whether the 
patient subsequently had a treatment interruption or changed therapy.  Patients were censored by the 
end of the study period or end of enrollment, whichever occurred first.  
4.7.4 Aim 4: Determine if rates of health services utilization (i.e. outpatient physician visits, inpatient 
hospital admissions, inpatient hospital days, and ER visits) and healthcare costs differ between 
patients initiating a second-generation versus a first-generation TKI 
Overview 
The null-hypothesis for Aim 4 is that there are no significant differences in health services 
utilization or healthcare costs between patients who initiate a second-generation versus a first-
generation TKI.   
The association between TKI therapy and health services utilization and healthcare costs 
while controlling for other baseline confounders was assessed.  Usual linear regression models are 
inappropriate in this context, primarily because healthcare costs and utilization are non-negative and 
their distributions right skewed.  Ordinary least squares linear models assuming a normal distribution 
may yield badly biased and/or less precise estimates of means.119,120  Therefore, generalized linear 
models (GLMs), a class of estimators that allow for a non-normal distribution as well as non-constant 
variance were used.  The GLM framework is flexible enough to accommodate different types of 
dependent variables.  For health services utilization, GLM with Poisson distribution and log link has 
been widely used in the literature.110,121  For healthcare costs, GLM with gamma distribution and log 
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link function was utilized.  Health services utilization and healthcare costs were evaluated over a 
fixed 12 month period following the index date.  
4.7.4.2 Health Services Utilization 
Separate models were estimated for each outcome, including number of outpatient physician 
office visits, number of inpatient hospital admissions, number of inpatient hospital days, and number 
of ER visits.  If the majority of patients never used a particular service, a logistic regression model 
was used to compare healthcare resource utilization between the two cohorts.  If the majority of 
patients had more than one type of visit during the follow-up period, Poisson regression models were 
used to compare healthcare utilization between the two cohorts (Model 4), where the ßs are the log 
relative risk parameters.  Unadjusted and adjusted means were reported.   
Model 4: 
ܔܗ܏ ቀܖܜቁ ൌ ઺૙ ൅ ઺૚ሺࢀ࢟࢖ࢋ࢕ࢌࢀࡷࡵ࢚ࢎࢋ࢘ࢇ࢖࢟ሻ ൅ ࢼ૛ሺ۾܁ሻ ൅ ઽ  
n: count of events for a given individual 
t: is time for follow-up 
Type of TKI therapy: an indicator of first or second-generation TKI therapy use 
PSi: the propensity score quintile 
 
4.7.4.3 Healthcare costs 
Medical, pharmacy, and total cost categories (i.e. pharmacy plus medical costs) were 
analyzed separately.  To estimate the association between TKI therapy and healthcare costs, GLMs 
were fitted to estimate mean healthcare costs (Model 5).  The usefulness of the GLM model for 
modeling healthcare costs is its ability to handle non-constant variance (heteroscedasticity) and 
avoids having to retransform log-transformed costs, which is a common strategy for handling highly 
skewed healthcare cost data.110  The ßs are the regression coefficients, which are the log relative risk 
parameters.  The fitted GLM was used to produce adjusted mean cost estimates for patients initiating 
therapy on first versus second-generation TKI therapy and tested whether the differences between 
adjusted means was statistically significant.  Unadjusted and adjusted means were reported.   
 63 
 
 
Model 5: 
 
 
μit: represents mean costs for patient i at time t 
Pi: indicates whether a patient initiated therapy with a second-generation versus a 
first-generation TKI  
Xii: a vector of coefficients for control variables 
 
4.7.5 Aim 5: Perform exploratory analyses to determine if adherence, healthcare utilization, and 
healthcare costs differ between patients newly initiating nilotinib versus dasatinib.  
4.7.5.1 Overview 
The null hypothesis for Aim #5 is that no significant differences exist between nilotinib and 
dasatinib for adherence, healthcare utilization, and healthcare costs.  
 To date, there have been no direct comparisons of nilotinib and dasatinab as first-line therapy 
for CML patients.  Additionally, there are no observational studies available comparing adherence, 
healthcare utilization, and healthcare costs among patients newly initiating nilotinib and dasatinib.  
The analytical approaches for comparing nilotinib and dasatinib were the same as those comparing 
first and second-generation TKI therapies.   
4.8 Missing Data 
The pharmacy claims data were explored to determine the amount of missing data and 
patterns of missing data for claims for TKI therapy.  There were no missing data for any of the claims 
for TKI therapy.  Additionally, there were few missing data in the medical data.  Multiple imputation 
would have been used for handling missing data for independent variables with missing data on less 
than 5% of a variable.122 This approach was not used as there were no missing data for the 
independent variables. 
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CHAPTER V: RESULTS 
5.1 Study Population 
A flowchart of the sample selection process and construction of the study cohorts is 
illustrated in Figure 5.1.  There were 2,369 patients with a pharmacy claim for a TKI therapy between 
June 1, 2010 and December 31, 2011.  After applying the inclusion and exclusion criteria, 368 
patients remained for analysis for Aims 1, 2, and 3. This included 237 patients who initiated therapy 
on a first generation TKI (i.e. imatinib) and 131 patients who initiated therapy on a second-generation 
TKI (i.e. 68 dasatinib, 63 nilotinib).  A subset of 133 patients was identified who (1) were enrolled in 
a Humana plan that provides both pharmacy and medical coverage and (2) had at least 12 months of 
follow-up data available.  Data from these patients were used to compare differences in healthcare 
utilization and costs between patients who initiated a first versus second-generation TKI therapy (Aim 
4).  Finally, within the subset of 133 patients, 23 were taking dasatinib and 19 were taking nilotinib.  
These two groups were used for the exploratory analyses that comprise Aim 5.  
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Figure 5.1 Selection Criteria 
Number of patients with at least one TKI 
therapy pharmacy claim between June 1, 2010 
and December 31, 2011 
n=2,369 
Patients without 4 months baseline 
continuous eligibility 
n=496 
Patients with TKI therapy in the previous 4 
months 
n=1,211 
Number of patients meeting selection criteria 
n= 368 
Patients not between 18 and 89 years of 
age 
n=10 
Excluded patients enrolled in a Medicare 
PDP and without 12 months continuous 
eligibility during follow-up period 
n=235 
Patients with no CML diagnosis at index 
date 
n=284 
n=1,873 
n=662 
n=652 
Second-generation TKI cohort 
n=131 
First-generation TKI cohort 
n=237 
First-generation TKI cohort 
n=91 
Second-generation TKI cohort  
n=42 
Subset included in healthcare utilization and 
cost analyses 
n=133 
Dasatinib 
n=23 
Nilotinib 
n=19 
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5.2 Baseline Characteristics 
The characteristics of patients newly initiating a TKI therapy for the treatment of CML are 
presented in Table 5.1.  Of the 368 patients included in the full sample, 64.4% (n=237) were started 
on a first-generation TKI.  The two cohorts differed on the following five characteristics: age; plan 
type; dose schedule of the TKI therapy; CML phase, as measured by the starting dose proxy measure; 
and patient out-of-pocket costs for the index TKI prescription.  Patients included in the second-
generation TKI cohort were younger compared to those in the first-generation TKI cohort (p=0.04).  
Additionally, a higher proportion of patients in the second-generation TKI cohort were enrolled in a 
commercial plan compared to those in the first-generation TKI cohort (p=0.04).  Although the 
RxRisk-V and Charlson Comorbidity scores were similar between cohorts, there was a difference on 
the proxy measure of CML phase, as measured by the starting dose proxy measure.  Specifically, 
patients who were initiated on a second-generation TKI were more likely to start on a dose that 
indicates accelerated disease than patients initiated on a first-generation TKI (p<0.0001).  As 
expected, patients included in the first-generation TKI cohort were more likely to initiate TKI therapy 
with once daily dosing rather than twice daily compared to the second-generation TKI cohort 
(p<0.001).  Although there were no differences between patient out-of-pocket costs for the index TKI 
prescription when cost was tested as a continuous variable, differences emerged when it was 
categorized as an ordinal variable.  Patients initiating therapy on a second-generation TKI compared 
to a first-generation TKI had higher out-of-pocket costs for the index TKI prescription (p<0.001).  
Finally, patients initiated on therapy with a first-generation TKI were on average enrolled in a 
Humana plan for 335 days compared to 325 days for patients initiated on a second-generation TKI.   
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Table 5.1 Baseline Characteristics 
 First-Generation TKI 
Cohort 
n=237 
Second-Generation TKI 
Cohort 
n=131 
p value 
Demographic Characteristics 
Age (years), mean (SD), 
[range] 
69.9 (11.4) [32-89] 67.2 (13.5) [24-88] 0.04 
Age (years), n (%)    
<55 26 (11.0) 22 (16.8) 0.28 
55-64 24 (10.1) 17 (13.0)  
65-74 102 (43.0) 53 (40.4)  
≥75 85 (35.9) 39 (29.8)  
Female, n (%) 125 (52.7) 74 (56.5) 0.49 
Plan, n (%)    
Commercial 14 (5.9) 17 (13.0) 0.04 
MAPD 94 (39.7) 37 (28.2)  
PDP 129 (54.4) 77 (58.8)  
Geographic region, n (%)    
Northeast 15 (6.3) 13 (9.9) 0.56 
Midwest 50 (21.1) 29 (22.1)  
South 134 (56.5) 72 (55.0)  
West 38 (16.1) 17 (13.0)  
LIS status, n (%)* 54 (22.8) 36 (27.5) 0.32 
Dual eligibility, n (%)* 26 (11.0) 22 (16.8) 0.11 
Clinical Characteristics 
Index medication 
starting dose in mg, mean 
(SD), [range] 
   
Imatinib 378 (97) [100-800] N/A  
Dasatinib N/A 100 (22) [40-150]  
Nilotinib N/A 606 (157) [150-800]  
Dose schedule, n (%)    
Once daily 234 (98.7) 73 (55.7) <0.001 
Twice daily 3 (1.3) 58 (44.3)  
Proxy for CML phase, n (%)†    
Chronic 230 (97.0) 108 (82.4) <0.0001 
Accelerated or blast crisis 7 (3.0) 23 (17.6)  
Vaccine use, n (%) 30 (12.7) 19 (14.5) 0.62 
Number of unique concurrent 
medication, n (%) 
   
0-2 104 (43.9) 59 (45.0) 0.83 
>2 133 (56.1) 72 (55.0)  
Channel, n (%)    
Specialty 125 (52.7) 81 (61.8) 0.22 
Retail 105 (44.3) 49 (37.4)  
MCO 3 (1.3) 0 (0)  
Long term care 4 (1.7) 1 (0.8)  
Member out-of-pocket cost for 
index medication, mean (SD), 
[range]  
$1,566 ($1,204) 
[$0-$4,742] 
$1,844 ($1,586) 
[$0-$7,685] 
0.12 
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Member out-of-pocket cost for 
index TKI prescription, n (%) 
   
$0-$1,000 89 (37.6) 51 (38.9) 0.001 
$1,001-$2,000 45 (19.0) 14 (10.7) 
$2,001-$3,000 75 (31.6) 43 (32.8) 
$3,001-$4,000 23 (9.7) 8 (6.1) 
>$4,000 5 (2.1) 15 (11.5) 
Coverage Gap, n (%)    
2010 141 (59.5) 66 (50.4) 0.09 
2011 225 (94.9) 123 (93.9) 0.67 
2012 188 (79.3) 93 (71.0) 0.07 
RxRisk-V Score, mean (SD), 
[range] 
5.1 (3.3) [0-16] 5.0 (3.1) [0-14] 0.69 
Charlson Comorbidity Index, 
mean (SD), [range]‡ 
2.5 (2.7) [0-14] 2.3 (3.1) [0-13] 0.81 
Provider Characteristics 
Male, n (%) 194 (81.9) 104 (80.6) 0.65 
Age (years), mean (SD), range 50.6 (9.5) [27-73] 49.8 (10.3) [31-74] 0.42 
Age (years), n (%)    
≤44 68 (28.7) 46 (35.1) 0.53 
45-54 85 (35.9) 39 (29.8)  
55-64 65 (27.4) 37 (28.2)  
≥65 19 (8.0) 9 (6.9)  
Specialty, n (%)    
Oncologist 221 (93.3) 122 (93.1) 0.97 
Non-oncologist 16 (6.7) 9 (6.9)  
Practice Setting, n (%)    
Academic 30 (12.7) 18 (13.7) 0.87 
Private 108 (45.6) 56 (42.7)  
Other¶  99 (41.8) 57 (43.5)  
LIS=low income subsidy; MAPD=Medicare Advantage Prescription Drug plan; PDP=prescription drug plan; 
MCO=managed care organization 
*LIS and dual eligibility are only assessed for Medicare patients  
†Patients’ starting dose of TKI therapy was assessed and used as a proxy for CML phase at the time of initiation 
 ‡Calculated only for patients with medical data available; 76 patients started on imatinib and 46 patients started 
on a 2G-TKI had medical data available 
¶Other practice setting was defined as community hospitals, clinics, or outpatient cancer care facilities neither 
owned by the practicing physicians nor considered academic or university-based 
 
 
5.3 Propensity Score (PS) Estimation 
5.3.1 PS Generation 
Because patients were not randomly assigned their TKI therapy, a propensity score was 
estimated and used as a covariate in the models to control for differences between first and second-
generation TKI cohorts.  A propensity score is the predicted probability of treatment conditional on 
selected covariates.  Logistic regression was used to estimate propensity scores.  The following 
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covariates were used to estimate the probability of initiating a second-generation TKI: patient 
demographic (i.e., age, gender, plan type, region, LIS, dual eligibility status), clinical (i.e., proxy for 
CML phase, RxRisk-V score, medication count, flu or pneumonia vaccination), and provider 
characteristics (i.e., age, gender, specialty, practice setting).  Dose schedule, member out-of-pocket 
costs, and channel of distribution were not included in the propensity score because they were 
assessed at the index date and are correlated with the type of TKI or how the patient may obtain the 
TKI (i.e. channel of distribution). 
5.3.2 Fit   
The c, or concordance, statistic is often cited as a measure of the fit of the propensity score.  
It can take on values between 0.5 (classification no better than flipping a coin) and 1.0 (perfect 
classification).  The c-statistic measures the ability of a model to predict treatment status using the 
observed covariates.  Several reviews have reported a c-statistic greater than 0.90 indicates very good 
ability of the propensity score model to predict treatment status.123  The c-statistic for this study was 
0.70.  Although a c-statistic is often reported, it provides no certainty that all measured confounders 
have been balanced between treatment groups.  Therefore rather than letting the c-statistic guide 
selection of covariates into the propensity score model selection was informed by the conceptual  
model used to identify potentially important predictors of treatment selection (Figure 3.2).123  
After model fit was evaluated, the distribution of the propensity scores for patients initiating 
first versus second-generation TKI therapy was evaluated.  A histogram is commonly used to 
compare the distributions of the propensity scores for treatment groups.  Figure 5.2 shows that PS 
significantly overlapped between patients who initiated therapy on first versus second-generation TKI 
therapy.  Therefore, PS trimming was not needed.   
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Figure 5.2 Distribution of propensity scores 
 
5.3.3 Balance by quintiles 
Table 5.2 shows the balance of covariates used to estimate the probability of initiating a 
second-generation TKI.  Although in theory one must be able to achieve balance on all the covariates 
of interest to obtain an unbiased estimate, this did not occur.  There are two covariates that were 
significantly different within the quintiles including patients with low income subsidy (quintile 1) and 
vaccine use (quintile 2) suggesting these covariates were not balanced for the two treatments within 
these subclasses.  It was determined that these variables were not of clinical significance and 
therefore bias adjustment or adding interaction terms was not warranted. 
  
 
First-generation TKI 
Second-generation TKI 
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Table 5.2 Balance of covariates by quintile 
 Quintile 1 
n=73 
(61 1G; 12 
2G) 
Quintile 2 
n=74 
(52 1G; 22 2G) 
Quintile 3 
n=74 
(50 1G; 24 2G) 
Quintile 4 
n=73 
(50 1G; 23 
2G) 
Quintile 5 
n=73 
(24 1G; 50 
2G) 
Demographic 
characteristics  
p-value p-value p-value p-value p-value 
Age  0.25 0.80 0.13 0.60 0.21 
Sex 0.48 0.52 0.24 0.89 0.42 
Plan 0.20 0.11 0.78 0.18 0.34 
Region 0.99 0.77 0.80 0.18 0.60 
LIS 0.01 0.21 0.95 0.66 0.25 
Duals 1.0 0.10 0.44 0.22 0.31 
Clinical 
characteristics 
     
Proxy for CML 
phase 
1.0 1.0 1.00 1.00 0.17 
RxRisk-V score 0.30 0.57 0.51 0.60 0.77 
Medication count 0.88 0.22 0.83 0.07 0.10 
Vaccine use 0.19 0.05 0.50 0.41 0.95 
Provider 
characteristics 
     
Age 0.55 0.71 0.82 0.91 0.99 
Sex 0.34 0.94 0.48 0.61 0.20 
Specialty 0.58 0.25 0.59 0.07 0.17 
Practice type 0.36 0.95 0.93 0.90 0.95 
1G=first-generation TKI; 2G=second-generation TKI 
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5.4 Aim 1: Identify factors associated with newly initiating therapy for CML with a second 
generation versus a first-generation TKI.  
5.4.1 Main analyses 
5.4.1.1 Summary of analyses 
 Logistic regression was used to identify factors associated with newly initiating a second-
generation TKI therapy.  Patient demographic (i.e., age, gender, plan type, region, LIS, dual eligibility 
status), clinical (i.e., RxRisk-V score, CML phase of disease, flu or pneumonia vaccination, 
medication count), and provider characteristics (i.e., age, gender, specialty, practice setting) were 
included as covariates for adjustment.  Model fit was assessed through the Hosmer and Lemeshow 
goodness-of-fit test (p=0.61).   
5.4.1.2 Results 
CML disease phase and enrollment in a MAPD plan were the only factors associated with 
initiating a second-generation versus first-generation TKI.  Patients with a starting dose that reflected 
accelerated disease (OR=8.06, 95% CI: 3.22-20.18) were more likely to initiate therapy with a 
second-generation TKI.  Patients enrolled in a MAPD plan (commercial plan was referent) were less 
likely to initiate a second-generation TKI (OR: 0.27, 95% CI: 0.09-0.79). 
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Table 5.3 Factors associated with initiating a second-generation TKI 
 Odds Ratio 95% CI p-value 
Demographic Characteristics    
Age (referent age<55)    
55-64 1.23 0.46-3.29 0.67 
65-74 0.85 0.34-2.08 0.72 
>75 0.90 0.36-2.27 0.82 
Gender, male vs. female 0.71 0.44-1.14 0.16 
Plan (referent commercial)    
MAPD 0.27 0.09-0.79 0.02 
PDP 0.53 0.19-1.50 0.23 
Region (referent south)    
Midwest 1.15 0.63-2.10 0.66 
Northeast 1.38 0.57-3.35 0.48 
West 0.82 0.42-1.65 0.58 
LIS, yes vs. no 0.98 0.46-2.06 0.95 
Duals, yes vs. no 1.78 0.72-4.38 0.21 
Clinical Characteristics    
Proxy for CML phase, accelerated 
vs. chronic 
8.06 3.22-20.18 <.0001 
RxRisk-V score, >2 vs ≤2 1.13 0.57-2.24 0.74 
Medication count, >2 vs ≤2 0.88 0.49-1.60 0.69 
Vaccine, yes vs no 2.16 0.96-4.85 0.06 
Provider Characteristics    
Age (referent <45)    
45-54 0.72 0.40-1.29 0.27 
55-64 0.86 0.46-1.62 0.64 
>65 0.81 0.31-2.10 0.67 
Gender, female vs. male 1.01 0.52-1.93 0.99 
Specialty, oncologist vs. non-
oncologist 
0.83 0.33-2.10 0.70 
Practice setting (referent other)    
Academic 0.71 0.33-1.52 0.38 
Private 0.93 0.56-1.54 0.78 
 
5.4.2 Sensitivity Analyses 
A sensitivity analysis was conducted for patients with medical data available (n=162).  Model 
fit was assessed through the Hosmer and Lemeshow goodness-of-fit test (p=0.88).  The Charlson 
comorbidity index replaced the RxRisk-V score as a measure of comorbidity in the sensitivity 
analysis.  Similar to the main analyses, patient comorbidity was not a significant factor associated 
with initiating a second-generation versus a first-generation TKI therapy.  In the sensitivity analysis, 
CML disease severity was associated with initiating a second-generation TKI which was consistent 
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with the main analyses.   Additionally, increased patient age (reference age was <55 years) was 
associated with lower odds of initiating a second versus first-generation TKI therapy and vaccine use 
was associated with a higher odds of initiating a second-generation TKI therapy (Table 5.4). 
Table 5.4 Factors associated with initiating a second versus first-generation TKI in sensitivity 
analysis limited to patients with medical data available (n=162)* 
Covariates Odds Ratio 95% CI 
Accelerated phase vs. chronic phase† 22.50 4.36-116.07 
Patient age  
(reference age<55) 
  
55-64 0.97 0.30-3.12 
65-74 0.18 0.06-0.53 
>75 0.19 0.06-0.62 
Vaccine use (Yes vs. No) 3.01 1.23-7.35 
*The following covariates were included in the full model: demographic characteristics (i.e. age, gender, plan 
type, region, LIS, dual eligibility status), clinical characteristics (i.e. Charlson comorbidity index, CML phase of 
disease, flu or pneumonia vaccination, medication count), and provider characteristics (i.e., age, gender, 
specialty, practice setting) 
 †Patients’ starting dose of TKI therapy was assessed and used as a proxy for CML phase at the time of 
initiation 
 
 A second sensitivity analysis was conducted limited to patients who were initiated on a 
starting dose that indicated chronic phase disease (n=338).  Therefore, patients’ who initiated therapy 
on a dose that indicates accelerated disease were excluded.  Patients with chronic phase disease who 
were enrolled in a Medicare plan (commercial plan was the referent) were less likely to initiate a 
second-generation TKI compared to a first-generation TKI.  Vaccine use was associated with higher 
odds of initiating a second-generation TKI (Table 5.5). 
Table 5.5 Factors associated with initiating a second versus first-generation TKI in sensitivity 
analysis limited to patients with chronic phase CML (n=338)* 
Covariates Odds Ratio 95% CI 
Plan type (referent commercial)   
MAPD 0.21 0.08-0.53 
PDP 0.52 0.23-1.18 
Vaccine use (Yes vs. No) 2.34 1.04-5.28 
*The following covariates were included in the full model: demographic characteristics (i.e. age, gender, plan 
type, region, LIS, dual eligibility status), clinical characteristics (i.e. Charlson comorbidity index, flu or 
pneumonia vaccination, medication count), and provider characteristics (i.e., age, gender, specialty, practice 
setting) 
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5.5 Aim 2: Examine differences in treatment interruption and regimen change comparing 
patients newly initiating a second-generation versus a first-generation TKI 
5.5.1 Treatment interruption 
5.5.1.1 Main analyses 
5.5.1.1.1 Summary of analyses 
Treatment interruption was defined as a gap in the index TKI therapy of greater than 30 days.  
Patients were followed from the first TKI therapy fill (i.e. index date) to the date of treatment 
interruption, end of enrollment or end of study period, whichever came first.  Unadjusted outcomes 
are provided for treatment interruption.  Additionally, three cox proportional-hazard (CPH) models 
were used to compare rates of treatment interruption between second-generation and first-generation 
TKI therapy.  The three CPH models were an unadjusted, multivariable, and propensity score (PS) 
quintile.  Finally, because half of the patients within the study had a treatment interruption, a post-hoc 
analysis was included to evaluate behavior change following treatment interruption.   
5.5.1.1.2 Results 
  In the unadjusted analyses, patients in the first-generation TKI therapy cohort were less likely 
to have a treatment interruption compared to those in the second-generation TKI cohort (x2=6.27, 
p=0.01) (Table 5.6).  In addition, patients initiated on a first-generation TKI stayed on therapy longer 
compared to patients initiating a second-generation TKI therapy (233 days vs. 186 days, respectively, 
t=3.18, p=0.002).   
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Table 5.6 Unadjusted outcomes for treatment interruption by TKI therapy 
 First-generation TKI 
cohort 
n=237 
Second-generation TKI 
cohort 
n=131 
p-value 
Treatment interruption, n (%) 107 (45.1) 77 (58.8) 0.01 
Time period treatment 
interruption occurred post index 
date, n (%) 
   
0-50 days 27 (90.0) 24 (92.3) 0.76 
51-100 days 30 (76.9) 22 (73.3) 0.73 
101-150 days 13 (68.4) 14 (93.3) 0.07 
151-200 days 11 (100) 4 (66.7) 0.04 
201-250 days 11 (84.6) 3 (100.0) 0.47 
251-300 days 7 (87.5) 7 (100.0) 0.33 
301-365 days 8 (6.8) 3 (6.8) 0.99 
Number of days on therapy, mean 
(SD)  
233.4 (138.1) 185.5 (139.4) 0.002 
 
 
All three Cox proportional hazard models (i.e. unadjusted, multivariable, and PS quintile) 
demonstrated consistent results (Table 5.7).  Patients initiating a second-generation TKI were at 
greater risk of experiencing a treatment interruption compared to those initiating therapy with a first-
generation TKI (HR: 1.59 unadjusted, 95% CI: 1.18-2.12; HR: 1.48 multivariable, 95% CI: 1.08-
2.02; HR: 1.50 PS quintiles, 95% CI: 1.10-2.04).  Results from the unadjusted Cox proportional 
hazard model are shown in Figure 5.3.   Table 5.8 shows the results from the multivariable CPH 
model.  In addition to patients initiating a second versus a first-generation TKI being at increased risk 
for a treatment interruption, accelerated phase CML versus chronic phase CML was also associated 
with increased risk of treatment interruption (HR: 1.97, p<.01),   
Table 5.7 Association between initiating a second-generation TKI and treatment interruption  
Model Hazard Ratio 95% CI 
Unadjusted 1.59 1.18-2.12 
Multivariable* 1.48 1.08-2.02 
PS quintiles*† 1.50 1.10-2.04 
*Multivariable and PS quintiles model included the following covariates for adjustment: primary independent 
variable was type of TKI, demographic characteristics (i.e. age, gender, plan type, region, LIS, dual eligibility 
status), clinical characteristics (i.e. RxRisk-V score, CML phase of disease, flu or pneumonia vaccination, 
medication count), and provider characteristics (i.e., age, gender, specialty, practice setting) 
†PS quintiles was not associated with treatment interruption 
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Figure 5.3 Time to treatment interruption, stratified by initiation with first versus second-
generation TKI therapy 
 
1G-TKI=first-generation TKI; 2G-TKI=second-generation TKI 
Model fit: likelihood ratio p=0.0025. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time (days) 
1G-TKI     210           180               167              156               145             138       130 
2G-TKI     107              85                  71                67                 64               57         54 
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Table 5.8 Multivariable analysis of initiation of TKI therapy with second versus first-generation 
TKI and treatment interruption 
 Hazard Ratio 95% CI p-value 
Initiating a second-generation 
TKI versus first-generation 
TKI 
1.48 1.08-2.02 0.01 
Demographic Characteristics    
Age (referent age<55)    
55-64 0.95 0.52-1.76 0.87 
65-74 0.72 0.42-1.31 0.27 
>75 0.90 0.52-1.63 0.72 
Gender, male vs. female 0.86 0.63-1.16 0.32 
Plan (referent commercial)    
MAPD 0.97 0.48-2.02 0.93 
PDP 0.94 0.48-1.93 0.86 
Region (referent south)    
Midwest 0.87 0.58-1.27 0.48 
Northeast 1.27 0.72, 2.3 0.39 
West 1.28 0.81-1.95 0.27 
LIS, yes vs. no 1.19 0.73-1.88 0.47 
Duals, yes vs. no 0.77 0.43-1.38 0.38 
Clinical Characteristics    
Proxy for CML phase, accelerated 
vs. chronic 
1.97 1.16-3.20 <.01 
RxRisk, >2 vs ≤2 1.12 0.71, 1.77 0.64 
Medication count, >2 vs ≤2 1.15 0.79-1.70 0.49 
Vaccine, yes vs no 0.76 0.44-1.27 0.31 
Provider Characteristics    
Age (referent <45)    
45-54 1.64 1.10-2.46 0.02 
55-64 1.48 0.96-2.29 0.08 
>65 2.16 1.17-3.87 0.01 
Gender, female vs. male 1.42 0.94-2.11 0.08 
Specialty, oncologist vs. non-
oncologist 
1.01 0.55-2.05 0.98 
Practice setting (referent other)    
Academic 1.17 0.71-1.85 0.53 
Private 1.03 0.74-1.43 0.87 
 
 
For those patients with a treatment interruption (n=184), medication change, re-initiation of 
the index medication, treatment discontinuation, or disenrollment from a Humana plan were 
evaluated.  Approximately, 58% of patients who initiated therapy with a first-generation TKI re-
initiated the index medication following a treatment interruption compared to 38% of patients who 
initiated therapy with a second-generation TKI (Figure 5.4).  Medication change was the next most 
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common treatment pattern with almost one-fourth of patients changing medications in each cohort.  A 
higher proportion of patients in the second-generation TKI cohort discontinued therapy compared to 
the first-generation TKI cohort by the end of the 1-year follow-up (30% vs. 15%, respectively).  Few 
members with a treatment interruption disenrolled from a Humana plan. 
 
Figure 5.4 Treatment patterns following treatment interruption 
Treatment patterns were followed for one change following treatment interruption.  There were a total of 184 
patients with a treatment interruption (107 from the first-generation TKI cohort and 77 from the second-
generation TKI cohort)   
 
5.5.1.2 Sensitivity Analyses  
 A sensitivity analysis was conducted and limited to patients who were initiated on a starting 
dose that indicated chronic phase disease (n=338).  The results for the sensitivity analysis were 
consistent with those for the main analyses.  Patients initiating a second-generation TKI were at 
greater risk of experiencing a treatment interruption compared to those initiating therapy with a first-
generation TKI (Table 5.9).  
58%22%
15%
5%
First-generation TKI
n =107
Re-initiation Medication Change
Discontinuation Disenrollment
37%
25%
30%
8%
Second-generation TKI
n=77
Re-inititation Medication Change
Discontinuation Disenrollment
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 A second sensitivity analysis was conducted to censor for death as a competing risk (Table 
5.10).  For this analysis patients were followed from the first TKI therapy fill (i.e. index date) to the 
date of treatment interruption, end of enrollment, date of death, or end of study period, whichever 
came first.  The results were consistent with the main models.  Patients initiating a second-generation 
TKI were at greater risk of experiencing a treatment interruption compared to those initiating therapy 
with a first-generation TKI. 
Table 5.9 Association between initiating a second-generation TKI and treatment interruption in 
sensitivity analysis limited to patients with chronic phase CML (n=338)  
Model Hazard Ratio 95% CI 
Unadjusted 1.44 1.05-1.98 
Multivariable* 1.44 1.03-2.00 
PS quintiles* 1.45 1.04-2.00 
 
*Multivariable and PS quintiles model included the following covariates for adjustment: primary independent 
variable was type of TKI, demographic characteristics (i.e. age, gender, plan type, region, LIS, dual eligibility 
status), clinical characteristics (i.e. RxRisk-V score, CML phase of disease, flu or pneumonia vaccination, 
medication count), and provider characteristics (i.e., age, gender, specialty, practice setting) 
 
Table 5.10 Association between initiating a second-generation TKI and treatment interruption 
in sensitivity analysis that includes censoring based on date of death (n=368)*  
Model Hazard Ratio 95% CI 
Unadjusted 1.58 1.17-2.11 
Multivariable† 1.46 1.07-1.99 
PS quintiles† 1.50 1.10-2.04 
*Patients were censored based on date of treatment interruption, death, disenrollment, or end of study period, 
whichever came first 
†Multivariable and PS quintiles model included the following covariates for adjustment: primary independent 
variable was type of TKI, demographic characteristics (i.e. age, gender, plan type, region, LIS, dual eligibility 
status), clinical characteristics (i.e. RxRisk-V score, CML phase of disease, flu or pneumonia vaccination, 
medication count), and provider characteristics (i.e., age, gender, specialty, practice setting) 
 
5.5.2 Regimen change 
5.2.2.1 Main Analyses 
5.2.2.1.1 Summary of analyses 
Regimen change was defined as initiation of a different TKI therapy for CML (i.e. imatinib, 
dasatinib, nilotinib, and bosutinib) or a dose increase of the index TKI therapy during the follow-up 
period.  Patients were followed from the first TKI therapy fill (i.e. index date) to the date of 
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medication change, end of enrollment or end of study period, whichever came first.  Unadjusted 
outcomes were provided for regimen change.   Additionally, three cox proportional-hazard models 
were used to compare regimen change rates between second-generation and first-generation TKI 
therapy.   
5.2.2.1.2 Results 
Approximately 19% of patients in each cohort had a regimen change during the follow-up 
period (Table 5.11).  The majority of patients with a regimen change had a medication change (e.g. 
patients who initiated imatinib and changed to dasatinib) rather than a dose increase (e.g. patients who 
initiated imatinib 400 mg daily increasing their dose to 800 mg daily).  There were no differences in 
regimen change between patients who initiated a first compared to a second-generation TKI based on 
bivariate results (x2=0.06, p=0.88).  
Results from the three Cox proportional hazard models (i.e. unadjusted, multivariable, and PS 
quintile) showed consistent results (Tables 5.12 and 5.13).  There were no differences in TKI regimen 
change between patients initiating a first compared to a second-generation TKI.  Table 5.13 shows the 
results from the multivariable CPH model.  Older provider age (i.e. 45-64 years) versus younger 
provider age (i.e. <45 years) was associated with patients having a TKI regimen change.   
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Table 5.11 Unadjusted outcomes for regimen change by TKI therapy * 
 First-generation TKI 
cohort 
Second-generation TKI 
cohort 
p-value 
TKI regimen change, n (%) 45 (19.0) 24 (18.3) 0.79  
Medication change, n (%)  32 (13.5) 19 (14.5) 0.88  
Dose increase, n (%) 15 (6.3 ) 5 (3.8) 0.31 
Time period regimen change 
occurred post index date, n (%) 
   
0-50 days 6 (60.0) 6 (75.0) 0.50 
51-100 days 10 (50.0) 5 (35.7) 0.41 
101-150 days 6 (46.1) 4 (80.0) 0.20 
151-200 days 3 (60.0) 2 (40.0) 0.53 
201-250 days 8 (72.7) 2 (50.0) 0.41 
251-300 days 6 (75.0) 4 (66.7) 0.73 
301-365 days 6 (3.5) 1 (1.1) 0.25 
*Regimen change was defined as initiation of a different TKI therapy for CML (i.e. imatinib, dasatinib, 
nilotinib, and bosutinib) or a dose increase of the index TKI therapy during the follow-up period 
 
 
 
 
 
 
 
 
 
 
Table 5.12 Association between initiating a second-generation TKI and regimen change 
 Analysis Hazard Ratio 95% CI 
TKI regimen change Unadjusted 1.01 0.60-1.63 
Multivariable*† 1.16 0.68-1.93 
PS quintiles* 1.13 0.66-1.87 
Medication change Unadjusted 1.13 0.63-1.97 
Multivariable*† 1.29 0.70-2.33 
PS quintiles* 1.23 0.67-2.20 
Dose increase Unadjusted 0.61 0.20-1.59 
Multivariable*† 0.70 0.21-2.00 
PS quintiles* 0.70 0.22-1.88 
*Multivariable and PS quintiles model included the following covariates for adjustment: primary independent 
variable was type of TKI, demographic characteristics (i.e. age, gender, plan type, region, LIS, dual eligibility 
status), clinical characteristics (i.e. RxRisk-V score, CML phase of disease, flu or pneumonia vaccination, 
medication count), and provider characteristics (i.e., age, gender, specialty, practice setting) 
† PS quintiles was not associated with TKI regimen change, medication change or dose increase 
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Table 5.13 Multivariable analysis of initiation of TKI therapy with second versus first-
generation TKI and regimen change 
 Hazard Ratio 95% CI p-value 
TKI (2nd versus 1st-generation) 1.16 0.68, 1.93 0.59 
Demographic    
Age (referent age <55)    
55-64 1.33 0.50, 3.68 0.58 
65-74 0.60 0.23, 1.70 0.31 
>75 1.38 0.57, 3.74 0.50 
Sex, male vs. female 0.78 0.78, 2.08 0.33 
Plan (referent Commercial)    
MAPD 0.95 0.27, 3.92 0.94 
PDP 1.40 0.43, 5.53 0.60 
Region (referent south)    
Midwest 0.53 0.25, 1.05 0.08 
Northeast 1.65 0.70, 3.61 0.23 
West 0.72 0.32, 1.46 0.39 
LIS*, yes vs. no 1.51 0.73, 2.89 0.24 
Dual eligibility*, yes vs. no 0.61 0.25, 1.46 0.27 
Clinical characteristics    
Proxy for CML phase†, 
 accelerated vs. chronic 
 0.16 0.01, 0.73 0.07  
RxRisk, >2 vs ≤2 0.94 0.44, 2.05 0.88 
Medication count, >2 vs ≤2 1.14 0.62, 2.22 0.68 
Vaccine 1.92 0.89, 4.49 0.14 
Provider characteristics    
Age (referent <45)    
45-54 2.32 1.15, 4.95 0.03 
55-64 2.74 1.35, 5.91 <0.01 
>65 1.62 0.48, 4.78 0.40 
Sex, female vs. male 0.90 0.40, 1.83 0.78 
Specialty, oncologist vs. non-
oncologist 
0.85 0.34, 2.56 0.75 
Practice type‡ (referent other)    
Academic 1.48 0.66, 3.06 0.31 
Private 0.89 0.51, 1.53 0.66 
*LIS and dual eligibility are only assessed for Medicare patients  
†Patients’ starting dose of TKI therapy was assessed and used as a proxy for CML disease severity at the time 
of initiation 
‡Other practice setting was defined as community hospitals, clinics, or outpatient cancer care facilities neither 
owned by the practicing physicians nor considered academic or university-base 
 
5.2.2.2 Sensitivity Analyses 
A sensitivity analysis was conducted and limited to patients who were initiated on a starting 
dose that indicated chronic phase disease (n=338).  The results for the sensitivity analysis were 
consistent with those for the main analyses.  There was no difference in TKI regimen change for 
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patients initiating a second-generation TKI compared to those initiating therapy with a first-
generation TKI (Table 5.14). 
Table 5.14 Association between initiating a second-generation TKI and regimen change 
(n=338)* 
Model Hazard Ratio 95% CI 
Unadjusted 1.13 0.67-1.85 
Multivariable† 1.13 0.66-1.90 
PS quintiles† 1.14 0.67-1.89 
*Only patients with a starting dose indicating chronic phase disease were included 
†Multivariable and PS quintiles model included the following covariates for adjustment: primary independent 
variable was type of TKI, demographic characteristics (i.e. age, gender, plan type, region, LIS, dual eligibility 
status), clinical characteristics (i.e. RxRisk-V score, CML phase of disease, flu or pneumonia vaccination, 
medication count), and provider characteristics (i.e., age, gender, specialty, practice setting) 
 
A second sensitivity analysis used a logistic regression model to assess the association 
between initiating a first versus second-generation TKI therapy and changing TKI regimens (i.e. a 
dose increase or medication change) during the follow up period for those patients with 12 months 
continuous enrollment (n=311).  The sensitivity analyses demonstrated consistent results with the 
main analyses.  There was no association between initiating a first compared to a second-generation 
TKI and regimen change (Unadjusted: OR: 0.90, 95% CI 0.50-1.61; Multivariable: 0.95, 95% CI 
0.52-1.87; PS quintile OR: 0.92, 95% CI 0.50-1.68).  
5.6 Aim 3: Determine if adherence is higher among patients newly initiating a second-
generation versus a first-generation TKI 
5.6.1 Main Analyses 
5.6.1.1 Summary of analyses 
Adherence was calculated using proportion of days covered (PDC) for patients while they 
were on the initial TKI therapy only.  Patients were censored if they changed to a different TKI 
therapy, end of enrollment, or the end of the study period, whichever came first.  Three logistic 
regression models were used to evaluate the association between initiating a second-generation versus 
first-generation TKI therapy and adherence.  The three logistic regression models were an unadjusted, 
multivariable, and PS quintile.   
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5.6.1.2 Results 
 Patients initiating a first-generation TKI had a higher mean adherence than patients initiating 
a second-generation TKI.  The mean adherence was 0.77 and 0.68 for the first and second-generation 
TKI cohort, respectively (t=2.70, p=0.007) (Table 5.15).  The proportion of adherent patients, defined 
as PDC ≥0.85, was similar between cohorts (x2=0.84, p=0.36).  Patients with high adherence (PDC 
≥0.85) made up the largest group for both cohorts, followed by partial adherence (PDC, 0.4-0.85) and 
low adherence (PDC <0.4) (x2=7.03, p=0.03).   
Logistic regression was used to assess the association between initiating a second-generation 
versus first-generation TKI and adherence.  Results from the logistic regression models shown in 
Tables 5.16 and 5.17 (i.e. unadjusted, multivariable, and PS quintile) were consistent with the 
unadjusted results (Table 5.15, x2=0.84, p=0.36).  There were no differences in adherence between 
patients initiating a second-generation compared to a first-generation TKI.  Table 5.17 shows the 
results from the multivariable logistic regression model.  Patients with accelerated phase CML versus 
chronic phase CML were less likely to be adherent (OR: 0.42, p=0.04) 
Table 5.15 Unadjusted outcomes for adherence by TKI therapy 
 First-generation TKI 
n=237 
Second-generation TKI 
n=131 
p-value 
PDC, mean (SD), [range] 0.77 (0.24) [0.04-1.00] 0.68 (0.31) [0.06-1.00] 0.007 
Adherent (PDC ≥0.85), n (%) 124 (52.3) 62 (47.3) 0.36 
PDC, mean (SD), range by 
adherence category 
   
High, (PDC≥0.85) 0.94 (0.04) [0.85-1.0] 0.95 (0.04) [0.85-1.0] 0.32 
Intermediate, (PDC, 0.4-0.85) 0.69 (0.11) [0.42-0.84] 0.63 (0.14) [0.41-0.84] 0.02 
Low (PDC<0.4) 0.24 (0.10) [0.04-0.38] 0.19 (0.10) [0.01-0.36] 0.06 
Adherence by category, n 
(%) 
   
High, (PDC≥0.85) 124 (52.3) 62 (47.3) 0.03 
Intermediate, (PDC, 0.4-0.85) 85 (35.9) 40 (30.5) 
Low (PDC<0.4) 28 (11.8) 29 (22.0) 
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Table 5.16 Association between initiating a first- versus second-generation TKI and adherence 
 Model Odds Ratio 95% CI 
Adherence, defined as 
PDC ≥0.85 
Unadjusted 0.82 0.53-1.26 
Multivariable*† 0.88 0.55-1.40 
PS quintiles*‡ 0.88 0.56-1.38 
* Multivariable and PS quintiles model included the following covariates for adjustment: primary independent 
variable was type of TKI, demographic characteristics (i.e. age, gender, plan type, region, LIS, dual eligibility 
status), clinical characteristics (i.e. RxRisk-V score, CML phase of disease, flu or pneumonia vaccination, 
medication count), and provider characteristics (i.e., age, gender, specialty, practice setting) 
†See Table 5.17 for specific information related to covariates 
‡PS quintiles was not associated with being adherent (OR: 0.93, 95% CI 0.80-1.08) 
 
Table 5.17 Multivariable analysis evaluating the association between initiating a first versus 
second-generation TKI and adherence 
 Odds Ratio 95% CI p-value 
Initiating a second-generation TKI 
versus first-generation TKI 
0.88 0.55, 1.41 0.61 
Demographic Characteristics    
Age (referent age<55)    
55-64 1.30 0.51, 3.29 0.58 
65-74 1.88 0.56, 2.99 0.56 
>75 0.93 0.42, 2.11 0.99 
Gender, male vs. female 1.36 0.88, 2.11 0.17 
Plan (referent commercial)    
MAPD 1.06 0.38, 2.97 0.91 
PDP 1.26 0.48, 3.55 0.65 
Region (referent south)    
Midwest 1.58 0.89, 2.81 0.12 
Northeast 0.97 0.41, 2.27 0.94 
West 0.87 0.47, 1.63 0.67 
LIS, yes vs. no 0.87 0.44, 1.73 0.69 
Duals, yes vs. no 1.20 0.51, 2.84 0.67 
Clinical Characteristics    
Proxy for CML phase, accelerated vs. 
chronic 
0.42 0.18, 0.99 0.04 
RxRisk, >2 vs ≤2 1.02 0.54, 1.95 0.94 
Medication count, >2 vs ≤2 0.66 0.38, 1.13 0.13 
Vaccine, yes vs no 1.72 0.81, 3.62 0.15 
Provider Characteristics    
Age (referent <45)    
45-54 0.82 0.47, 1.41 0.47 
55-64 1.25 0.69, 2.25 0.47 
>65 0.61 0.25, 1.49 0.28 
Gender, female vs. male 0.60 0.33, 1.13 0.10 
Specialty, oncologist vs. non-
oncologist 
0.85 0.34, 2.0  
Practice setting* (referent other)    
Academic 0.97 0.48, 1.96 0.93 
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Private 0.85 0.53, 1.36 0.49 
*Other practice setting was defined as community hospitals, clinics, or outpatient cancer care facilities neither 
owned by the practicing physicians nor considered academic or university-based 
 
5.6.2 Sensitivity Analyses 
 Additional covariates were added to the multivariable logistic regression model in the 
sensitivity analyses.  First, twice daily dose schedule (referent once daily dosing) was added to the 
initial model.  In this analysis, schedule was not associated with adherence (OR: 0.86, 95% CI: 0.42- 
1.85).   Second, duration of therapy based on days on therapy days was added to the initial model as a 
categorical variable (i.e. 0-100 days, 101-200 days, 201-300 days, and 301-365 days).  Longer 
duration of therapy was associated with higher odds of being adherent (OR: 54.20, 95% CI 21.08-
139.68 for duration of therapy between 301-365 days compared to 0-100 days).  An additional 
sensitivity analysis was completed to exclude patients with accelerated disease, leaving 338 for 
analysis.  In this model, no covariates were associated with adherence.   
It is generally agreed that a cut point of 0.8 provides meaningful information to distinguish 
between adherent and non-adherent patients.  Therefore, a sensitivity analysis was conducted with 
adherence dichotomized at 0.80.  Scores ≥0.80 were considered adherent and scores <0.80 were 
considered non-adherent.  The logistic regression analyses are shown Table 5.18.  Initiating a second 
versus a first-generation TKI was not associated with being more adherent when adherence was 
defined as ≥0.80.  These results are consistent with the results from the primary analysis which 
defined adherence as a PDC ≥0.85. 
Table 5.18 Association between initiating a second-generation TKI and medication adherence 
(defined as PDC ≥0.80) 
 Analysis Odds Ratio 95% CI 
Adherence, defined as 
PDC ≥.80 
Unadjusted 0.70 0.46-1.08 
Multivariable*† 0.76 0.47-1.23 
PS quintiles*‡ 0.76 0.48-1.20 
* Multivariable and PS quintiles model included the following covariates for adjustment: primary independent 
variable was type of TKI, demographic characteristics (i.e. age, gender, plan type, region, LIS, dual eligibility 
status), clinical characteristics (i.e. RxRisk-V score, CML phase of disease, flu or pneumonia vaccination, 
medication count), and provider characteristics (i.e., age, gender, specialty, practice setting) 
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†Vaccine use was associated with a higher odds of being adherent (OR: 2.22, 95% CI: 1.01, 4.84). Advanced 
phase CML was associated with lower odds of being adherent (OR: 0.37, 95% CI: 0.16, 0.87). 
‡PS quintile was not associated with being adherent (OR: 0.91, 95% CI: 0.78-1.07). 
 
Additionally, adherence was evaluated using an ITT approach.  Patients were assigned to 
either the first-generation or second-generation TKI cohort, regardless of whether the patient 
subsequently had a treatment interruption or changed therapy.  Patients were censored by the end of 
the study period or end of enrollment, whichever occurred first. Using this approach (data not shown), 
patients initiating a first-generation TKI therapy were more adherent compared to those initiating 
therapy with a second-generation TKI (PDC 0.77 and 0.68, respectively, t=2.94, p=0.003).  
Consistent with the main analysis, the proportion of adherent patients, defined as PDC ≥0.85, was 
similar between cohorts (54.8% vs. 45.0% for first-generation and second-generation TKI cohort, 
respectively; x2=3.52, p=0.07).  
5.7 Aim 4: Determine if rates of health services utilization (i.e. number of outpatient physician 
visits, number of inpatient hospital admissions, length of inpatient hospital stays, and number 
of emergency room visits) and healthcare costs differ between patients initiating a second-
generation versus a first-generation TKI. 
5.7.1 Health services utilization 
5.7.1.1 Summary of analyses 
Health services utilization were captured over the 12 months following initiation of therapy 
for a subset of patients with pharmacy and medical data available and compared between patients 
initiating a second-generation TKI versus a first-generation TKI.  Unadjusted results were reported 
for each type of health service.  Additionally, two generalized linear models (GLMs) were used to 
estimate outpatient visits and inpatient hospital days.  Duration of the initial treatment, measured in 
days, was included in both adjusted models.  Inpatient visits and ER visits were not widely used 
services.  Therefore, a logistic regression model was used to compare inpatient visits between the two 
cohorts.  Due to few patients having ER visits, only descriptive information is provided. 
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5.7.1.2 Results 
 Table 5.19 shows the unadjusted results for outpatient physician visits, inpatient 
hospitalization admissions, inpatient hospital days, and ER visits for patients initiating a first 
compared to a second-generation TKI therapy.  Outpatient visits were the most used service. The 
mean number of outpatient visits during the 12-month period following initiation of TKI therapy was 
37.8 and 42.4 for patients initiating a first compared to a second-generation TKI (p=0.33).  
Approximately, 20.4% (n=19) of patients initiating a first-generation TKI and 31.8% (n=14) of 
patients initiating a second-generation TKI had an inpatient visit during the follow-up period.  There 
were only three patients with an inpatient visit who were classified as having accelerated phase 
disease.  Patients initiating a first-generation TKI had, on average, lower inpatient admissions 
compared to those initiating therapy on a second-generation TKI (0.31 and 0.66 inpatient admissions, 
respectively, p=0.10).  ER visits were the least used service for patients included in this study.  Only 6 
patients from each cohort had an ER visit during the follow-up period and all patients were classified 
as having chronic phase disease.  Patients initiating a first-generation TKI had, on average a lower 
number of ER visits compared to those initiating therapy on a second-generation TKI (0.10 and 0.52 
ER visits, respectively, p=0.10).   
Results of the GLM examining the association between initiation of a second versus first-
generation-TKI and (1) outpatient visits and (2) inpatient days are shown in Tables 5.20 and 5.21, 
respectively.  Initiating a second-generation TKI was associated with increased outpatient visits and 
inpatient days. The estimates from the GLM were then exponentiated and can be interpreted as 
incidence rate ratios which are shown in Table 5.21.   
A logistic regression model was used to evaluate the association between initiation of a 
second versus first-generation TKI and having an inpatient visit during the follow-up period (Table 
5.22).  As shown in Table 5.22, this association was not significant.  However, patients with an 
increased baseline medication count (i.e. >2 medications versus ≤2) and those with LIS status had a 
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higher odds of having an inpatient visit.  The following provider characteristics were associated with 
having a lower odds of having an inpatient visit: academic practice type versus other practice type 
and an oncologist versus non-oncologist. 
Table 5.19 Health services utilization during the 12 month period post index date 
 First-generation TKI 
Unadjusted mean (SD) 
range 
n=93 
Second-generation TKI 
Unadjusted mean  (SD) 
range 
n=44 
p-value 
Outpatient visits 37.83 (25.66) 
[0-149] 
42.39 (25.42) 
[6-134] 
0.33 
Inpatient visits 0.31 (0.71) 
[0-4] 
0.66 (1.29) 
[0-6] 
0.10 
Inpatient hospital 
days 
1.30 (3.91) 
[0-28] 
3.98 (8.54) 
[0-34] 
0.05 
ER visits 0.10 (0.39) 
[0-2] 
0.52 (1.64) 
[0-7] 
0.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 91 
 
 
5.20 Association between initiating a second-generation versus first-generation TKI and 
outpatient visits and inpatient hospital days* 
 Outpatient Visits Inpatient Hospital Days 
Model Estimate 95% CI p-value Estimate 95% CI p-value 
Multivariable†       
TKI (2nd versus 1st-
generation) 
0.12 0.06, 0.18 <.001 1.18 0.89-1.47 <.0001 
Demographic       
Age 0.04 -0.0002, 0.07 0.05 0.10 -0.08, 0.29 0.28 
Sex -0.17 -0.23, -0.11 <.0001 0.63 0.37, 0.89 <.0001 
Plan 0.09 0.05, 0.12 <.0001 0.26 0.09, 0.42 <.01 
Region -0.12 -0.15, -0.08 <.0001 0.06 -0.11, 0.24 0.48 
LIS 0.13 0.05, 0.21 0.001 0.82 0.51, 1.13 <.0001 
Dual 0.03 -0.07, 0.14 0.55 0.07 -0.35, 0.49 0.75 
Clinical 
characteristics 
      
Duration of therapy -0.0005 -0.0008, -
0.0002 
<.001 -0.0003 -0.0015, 
0.0009 
0.62 
Proxy for CML 
phase 
0.54 0.41, 0.66 <.0001 -0.19 0.58, 0.21 0.36 
RxRisk 0.43 0.34, 0.52 <.0001 1.55 0.88, 2.18 <.0001 
Medication count 0.07 -0.004, 0.14 0.06 0.95 0.59, 1.31 <.0001 
Vaccine 0.25 0.19, 0.32 <.0001 0.32 0.01, 0.62 0.04 
Provider 
characteristics 
      
Age 0.06 0.03, 0.09 <.001 0.13 -0.01, 0.28 0.07 
Sex -0.13 -0.23, -0.11 <.0001 -1.03 -1.35, 0.72 <.0001 
Specialty -0.18 -0.29, 0.07 <.01 0.42 0.24, 1.08 0.21 
Practice type -.011 -0.15, -0.07 <.0001 0.39 0.21, 0.58 <.0001 
PS quintile†       
TKI (2nd versus 1st-
generation) 
0.12 0.05-0.19 <.0001 1.03 0.75, 1.30 <.0001 
Quintile -0.02 -0.04-0.00 0.06 0.09 0.008, 0.18 0.03 
Duration of therapy -0.0004 -0.0006—
0.0001 
<.01 0.0009 -0.0002, 
0.002 
0.11 
* Mean health services utilization was evaluated using GLM with Poisson distribution and log link 
NA, not applicable 
†Multivariable and PS quintiles model included the following covariates for adjustment: primary independent 
variable was initiating a first versus second-generation TKI, demographic characteristics (i.e. age, gender, plan 
type, region, LIS, dual eligibility status), clinical characteristics (i.e. duration of treatment (days), RxRisk-V 
score, CML phase of disease, flu or pneumonia vaccination, medication count), and provider characteristics 
(i.e., age, gender, specialty, practice setting) 
 
  
 92 
 
 
Table 5.21 Incidence rate ratio for outpatient visits and inpatient hospital days comparing 
initiation of a second versus first-generation TKI  
TKI (2nd versus 1st-
generation) 
IRR 95% CI 
Outpatient visits   
Multivariable analysis* 1.12 1.06, 1.20 
PS quintile analysis 1.12 1.01, 1.21 
Inpatient hospital days   
Multivariable analysis* 3.25 2.43, 4.35 
PS quintile analysis 2.80 2.12, 3.67 
IRR=incidence rate ratio 
*Multivariable and PS quintiles model included the following covariates for adjustment: primary independent 
variable was initiating a first versus second-generation TKI, demographic characteristics (i.e. age, gender, plan 
type, region, LIS, dual eligibility status), clinical characteristics (i.e. duration of treatment (days), RxRisk-V 
score, CML phase of disease, flu or pneumonia vaccination, medication count), and provider characteristics 
(i.e., age, gender, specialty, practice setting) 
 
 
5.22 Association between initiating a second-generation versus first-generation TKI and 
inpatient visits* 
 Odds Ratio 95% CI p-value 
Inpatient visits    
Multivariable*† 3.91 0.91, 16.76 0.07 
PS quintiles*‡ 1.68 0.62, 4.60 0.31 
* Multivariable and PS quintiles model included the following covariates for adjustment: primary independent 
variable was type of TKI, demographic characteristics (i.e. age, gender, plan type, region, LIS, dual eligibility 
status), clinical characteristics (i.e. duration of treatment (days), RxRisk-V score, CML phase of disease, flu or 
pneumonia vaccination, medication count), and provider characteristics (i.e., age, gender, specialty, practice 
setting) 
†Covariates associated with increased risk of inpatient visits: increased medication count, low income subsidy; 
Covariates associated with decreased risk of inpatient visits: academic practice, oncologist  
‡Quintile and duration of therapy were not significant in the model 
 
5.7.2 Healthcare costs 
5.7.2.1 Main Analyses 
5.7.2.1.1 Summary of analyses 
Medical, TKI-related pharmacy, non TKI-related pharmacy, and total costs (i.e. pharmacy 
plus medical costs) during the 12 months following TKI initiation were compared between patients 
who initiated therapy with a second versus first-generation TKI therapy. Unadjusted and adjusted 
healthcare costs are presented.  For healthcare costs, GLM with gamma distribution and log link 
function was utilized.  The two adjusted models were multivariable and PS quintile.  Duration of the 
initial treatment, measured in days, was included in both adjusted models.   
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5.7.2.1.2 Results 
The unadjusted mean total costs 12 months following initiation of a second-generation TKI 
($88,804) were significantly higher compared to those patients who initiated a first-generation TKI 
therapy ($68,068, p<.01) (Table 5.23).  The total costs for both cohorts were driven by TKI related 
costs ($54,284 and $66,954 for the first and second-generation TKI cohorts, respectively, p<.01).   
Results of the GLM examining the association between initiation of a first versus second-
generation-TKI and healthcare costs are shown in Tables 5.24 and 5.25.  The βs presented in Table 
5.24 are regression coefficients, which are the log relative risk parameters.  Positive estimates are 
associated with higher costs and negative estimates are associated with lower costs.  The results 
indicate that initiating a second-generation TKI compared to a first-generation TKI was associated 
with higher total healthcare costs (multivariable: estimate=0.26, p=0.01; PS quintile: estimate=0.30, 
p=<.001).  Therefore, total healthcare costs for patients initiating a second-generation were 1.30 
[exp(0.26)] times the total healthcare costs for patients initiating therapy on a first-generation TKI.  
This was also the case for TKI-related costs (multivariable: estimate=0.24, p<.01; PS quintile 
estimate=0.29, p<.01).  However, the estimate was not significant for non TKI-related costs and 
medical costs.  Finally, the predicted, adjusted total and TKI-related costs were greater among the 
second-generation TKI cohort compared to the first-generation TKI cohort, $86,509 versus $66,443 
(p<.001) and $64,991 versus $55,838 (p<.01), respectively. 
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Table 5.23 Healthcare costs incurred during the 12 month period following initiation of first 
versus second-generation TKI therapy (n=133)* 
 First-generation TKI 
Unadjusted mean costs 
(SD) [range] 
n=91 
Second-generation TKI 
Unadjusted mean costs (SD) 
[range] 
n=42 
p-value 
Total costs (pharmacy 
+ medical) 
$68,068 ($29,207) 
[$7,459-$266,172] 
$88,804 ($44,217) 
[$15,536-$193,950] 
<.01 
Pharmacy costs $56,753 ($18,041) 
[$5368-$116,253] 
$68,955 ($35,472) 
[$8,924-$134,040] 
0.03 
TKI-related $54,284 ($18,691) 
[$3,920-$116,065] 
$66,594 ($35,488)  
[$6,782-$128,791] 
0.03 
Non TKI-related $2,469 ($4,458) 
[$0-$28,564] 
$2,361 ($2,096) 
[$0-$7,360] 
0.10 
Medical costs $11,315 ($22,119) 
[$0-$177,961] 
$19,850 ($33,400) 
[$634-$183,237] 
0.05 
* Cost calculation included both plan paid and member out-of-pocket costs (i.e. patient copayments and co-
insurance).   
  
 
 
Table 5.24 Multivariable analysis of initiation of TKI therapy with second versus first-generation TKI and total, TKI-related costs, non 
TKI-related costs, and medical costs (n=133)*  
Model Total Costs TKI-Related Costs Non TKI-Related Costs Medical Costs 
 Estimate 95% CI p-value Estimate 95% CI p-value Estimate 95% CI p-value Estimate 95% CI p-value 
Multivariable†             
TKI (2nd versus 1st-
generation) 
0.26 0.11-0.42 .001 0.24 0.07, 0.40 <.01 0.50 -0.07, 1.08 0.09 0.30 -0.18, 0.78 0.22 
Demographic             
Age -0.08 -0.17, 0.02 0.10 -0.11 -0.22, -
0.004 
0.04 0.09 -0.20, 0.39 0.53 0.05 -0.20, 0.29 0.71 
Sex 0.08 -0.07, 0.22 0.28 0.06 -0.09, 0.21 0.46 -0.35 -0.78, 0.09 0.12 0.006 -0.40, 0.41 0.98 
Plan 0.05 -0.04, 0.13 0.29 -0.08 -0.17, 0.01 0.09 0.16 -0.09, 0.41 0.22 0.55 0.31, 0.80 <.0001 
Region 0.07 -0.03, 0.16 0.17 0.008 -0.10, 0.11 0.88 0.10 -0.19, 0.38 0.51 0.21 -0.08, 0.50 0.15 
LIS 0.14 -0.05, 0.34 0.16 -0.01 -0.22, 0.20 0.91 0.36 -0.26, 0.99 0.26 0.95 0.37, 1.54 <.01 
Dual -0.21 0.49, 0.07 0.14 0.13 -0.3, 0.17 0.40 -0.23 -1.13, 0.68 0.63 -0.69 -1.51, 0.13 0.10 
Clinical 
characteristics 
            
Duration of therapy 0.002 0.0009, 0.002 <.0001 0.003 0.002, 
0.004 
<.0001 -0.0003 -0.002, 
0.002 
0.81 -0.002 -0.004, -0.0005 0.02 
Proxy for CML phase -0.02 -0.29, 0.25 0.90 0.08 -0.21, 0.37 0.58 -0.72 -1.64, 0.21 0.13 0.10 -0.77, 0.98 0.82 
RxRisk 0.11 -0.09, 0.31 0.29 0.02 -0.20, 0.23 0.87    0.99 0.40, 1.60 0.001 
Medication count 0.10 -0.07, -0.28 0.25 0.07 -0.11, 0.26 0.44 0.92 0.40, 1.43 <.001 0.34 -0.16, 0.83 0.19 
Vaccine 0.07 -0.10, 0.23 0.43 0.08 -0.10, 0.25 0.37 0.27 -0.24, 0.78 0.29 0.15 -0.33, 0.64 0.53 
Provider 
characteristics 
            
Age -0.08 -0.16, -0.004 0.04 -0.03 -0.11, 0.05 0.47    -0.13 -0.35, 0.09 0.25 
Sex 0.09 -0.10, 0.27 0.38 0.08 -0.12, 0.28 0.43 0.17 -0.42, 0.76 0.57 -0.09 -0.61, 0.45 0.76 
Specialty -0.008 -0.29, 0.27 0.96 -0.007 -0.31, 0.30 0.96 0.13 -0.77, 1.03 0.78 --1.10 -1.91, -0.29 <.01 
Practice type -0.02 -0.10, 0.06 0.61 0.002 -0.08, 0.08 0.96 -0.14 -0.38, 0.11 0.28 -0.06 -0.28, 0.17 0.62 
PS quintile‡             
TKI (2nd versus 1st-
generation) 
0.30 0.13, 0.47 <.001 0.29 0.11, 0.46 <.01 -0.17 -0.72, 0.39 0.55 0.38 -0.06, -0.83 0.09 
Quintile 0.003 -0.05, 0.05 0.93 -0.02 -0.07, 0.04 0.60 0.12 -0.07, 0.31 0.22 0.07 -0.08, 0.22 0.35 
Duration of therapy 0.001 0.006, 0.002 <.001 0.003 0.002, 
0.004 
<.0001 -0.0001 -0.003, 
0.002 
0.91 -0.004 -0.006, -0.002 <.001 
* GLM with gamma distribution and log link; Cost calculation included both plan paid and member out-of-pocket costs (i.e. patient copayments and co-insurance).   
†Multivariable model included the following covariates for adjustment: primary independent variable was initiating a first versus second-generation TKI; demographic 
characteristics (i.e. age, gender, plan type, region, LIS, dual eligibility status), clinical characteristics (i.e. duration of treatment (days) on index medication, RxRisk-V score, CML 
phase of disease, flu or pneumonia vaccination, medication count), and provider characteristics (i.e., age, gender, specialty, practice setting) 
‡PS quintile model included the following covariates for adjustment: primary independent variable was initiating a first versus second-generation TKI, covariates (i.e. PS quintile, 
duration of treatment (days) on index medication)
95
 
 96 
 
 
Table 5.25 Predicted, adjusted healthcare costs during the 12 month period following initiation 
of first versus second-generation TKI therapy (n=133)* 
 First-generation TKI 
mean costs (95% CI) 
n=91 
Second-generation TKI 
mean costs (95% CI) 
n=42 
p-value 
Total costs (pharmacy 
+ medical) 
$66,443 ($61,194, $72,143) $86,509 ($76,275, $98,125) 0.001 
 
Pharmacy costs    
TKI-related $51,344 ($47,014, $56,072) $64,991 ($56,818, $74,340) <.01 
Non TKI-related $1,387 ($1,064, $1,807) $2,294 ($1,480, $3,556) 0.09 
Medical costs $9,331 ($7,389, $11,783) $12,633 ($8,691, $18,365) 0.22 
* GLM with gamma distribution and log link; Cost calculation included both plan paid and member out-of-
pocket costs (i.e. patient copayments and co-insurance).   
Multivariable model included the following covariates for adjustment: primary independent variable was 
initiating a first versus second-generation TKI; demographic characteristics (i.e. age, gender, plan type, region, 
LIS, dual eligibility status), clinical characteristics (i.e. duration of treatment (days) on index medication, 
RxRisk-V score, CML phase of disease, flu or pneumonia vaccination, medication count), and provider 
characteristics (i.e., age, gender, specialty, practice setting) 
 
5.7.2.2 Sensitivity Analyses 
 A sensitivity analysis limited to patients who were initiated on a starting dose that indicated 
chronic phase disease (n=123) was completed.  The results were consistent with the main analyses, 
the unadjusted mean total healthcare, pharmacy and medical costs incurred during the 12 months 
following initiation of a second-generation TKI were significantly higher than those incurred by 
patients who initiated a first-generation TKI therapy (Table 5.26).  
 
Table 5.26 Unadjusted healthcare costs incurred during the 12 month period following 
initiation of first versus second-generation TKI therapy (n=123)* 
 First-generation TKI 
Unadjusted mean costs 
(SD) [range] 
n=89 
Second-generation TKI 
Unadjusted mean costs (SD) 
[range] 
n=34 
p-value 
Total costs (pharmacy 
+ medical) 
$67,370 ($29,000) 
[$7,460-$266,172] 
$93,079 ($43,908) 
[$15,536-$193,950] 
<.001 
Pharmacy costs $55,838 ($16,921)  
[$5,368-$88,450] 
$71,386 ($36,063) 
[$8,924-$134,040] 
<.01 
TKI-related $53,315 ($17,499) 
[$3,919-$88,219] 
$68,779 ($36,221) 
[$6,782-$128,791] 
0.01 
Non-TKI related $2,522 ($4,494) 
[$0-$28,564] 
$2,607 ($2,205) 
[$41-$7,360] 
0.06 
Medical costs $11,532 ($22,320) 
[$0-$177,722] 
$21,693 ($35,628) 
[$634-$183,237] 
0.04 
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5.8 Aim 5: Perform exploratory analyses to determine if adherence, healthcare utilization, and 
healthcare costs differ between patients newly initiating dasatinib versus nilotinib. 
 Exploratory analyses were conducted to compare adherence, healthcare utilization, and 
healthcare costs between patients newly initiating dasatinib versus nilotinib.   
5.8.1 Adherence 
The results for adherence are shown in Table 5.27.  There was no difference in mean 
adherence among patients initiating nilotinib compared to dasatinib.  The mean adherence was 0.68 
and 0.69 for patients initiating nilotinib and dasatinib, respectively (t=-0.10, p=0.92).  Additionally, 
the proportion of adherent patients, defined as PDC ≥0.85, was similar between cohorts (x2=0.40, 
p=0.52).  Logistic regression was used to assess the association between initiating dasatinib versus 
nilotinib and adherence (Table 5.28) while controlling for potential confounders.  As in the 
unadjusted analyses, there were no differences in adherence between patients initiating nilotinib 
compared to dasatinib.  Further, none of the covariates in the model were significant. 
Table 5.27 Unadjusted adherence outcomes for patients initiating nilotinib versus dasatnib 
 Nilotinib 
n=63 
Dasatinib 
n=68 
p-value 
PDC, mean (SD), 
[range] 
0.68 (0.31) [0.08-1.0] 0.69 (0.31) [0.01-1.0] 0.92 
Adherent (PDC ≥0.85), 
n (%) 
28 (44.4) 34 (50.0) 0.52 
Adherence by category, 
n (%) 
   
High (PDC, ≥0.85) 28 (44.4) 34 (50.0) 0.99 
Intermediate (PDC, 0.4-
0.85)   
21 (33.3) 19 (27.9) 
Low (PDC, <0.4) 14 (22.2) 15 (22.1) 
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Table 5.28 Multivariable analysis evaluating the association between initiating a second-
generation TKI and adherence 
 Odds Ratio 95% CI p-value 
Initiating nilotinib versus dasatinib 0.98 0.42, 2.32 0.97 
Demographic Characteristics    
Age (referent age<55)    
55-64 1.72 0.32, 9.22 0.53 
65-74 1.43 0.30, 6.94 0.66 
>75 1.52 0.29, 7.96 0.62 
Gender, male vs. female 1.93 0.84, 4.41 0.12 
Plan (referent commercial)    
MAPD 1.32 0.22, 7.61 0.76 
PDP 1.14 0.19, 6.87 0.89 
Region (referent south)    
Midwest 1.47 0.49, 4.41 0.49 
Northeast 1.59 0.39, 6.47 0.52 
West 2.23 0.63, 7.86 0.21 
LIS, yes vs. no 1.49 0.41, 5.45 0.55 
Duals, yes vs. no 0.46 0.11, 2.02 0.30 
Clinical Characteristics    
Proxy for CML phase, accelerated vs. 
chronic 
0.36 0.11, 1.14 0.08 
RxRisk, >2 vs ≤2 1.67 0.50, 5.53 0.40 
Medication count, >2 vs ≤2 0.55 0.19, 1.57 0.26 
Vaccine, yes vs no 2.03 0.44, 9.36 0.36 
Provider Characteristics    
Age (referent <45)    
45-54 1.54 0.55, 4.35 0.41 
55-64 1.11 0.38, 3.28 0.85 
>65 1.48 0.27, 7.81 0.67 
Gender, female vs. male 0.22 0.06, 0.80  0.02 
Specialty, oncologist vs. non-
oncologist 
0.80 0.13, 4.79  
Practice setting* (referent other)    
Academic 1.03 0.27, 3.93 0.97 
Private 0.77 0.32, 1.86 0.57 
 
5.8.2 Health services utilization 
Table 5.29 shows the results for outpatient physician visits, inpatient hospitalization 
admissions, inpatient hospital days, and ER visits during the12 month follow-up period for patients 
initiating nilotinib and dasatinib.  Outpatient visits were the most used service with mean number of 
visits of 39 and 45 for patients initiating nilotinib and dasatinib, respectively (p=0.43).  Inpatient 
visits and ER visits were not widely used services.   Six patients had at least one inpatient visit during 
the follow-up period; whereas, 14 patients had at least one ER visit during this time period.   
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Results of the GLM examining the association between initiating dasatinib versus nilotinib 
and (1) outpatient visits and (2) inpatient days are shown in Tables 5.30 and 5.31.  Unlike the 
bivariate analyses, initiating dasatinib compared to nilotinib was associated with increased outpatient 
visits and inpatient days.  The estimates from the GLM were then exponentiated and can be 
interpreted as incidence rate ratios which are shown in Table 5.31.  The number of outpatient visits 
for patients initiated on dasatinib was 1.14 [exp(0.13)] times the number of outpatient visits for 
patients initiated on nilotinib (Table 5.31).  
A logistic regression model was used to evaluate the association between initiating dasatinib 
versus nilotinib and inpatient visits (data not shown).   This model indicated no association between 
initiating dasatinib compared to nilotinib and having an inpatient visit.  Further, no other covariates 
included in the model were statistically significant. 
Table 5.29 Health services utilization during the 12 month period  following initiation of 
nilotinib versus dasatinib 
 Nilotinib 
Unadjusted mean (SD) 
[range] 
n=20 
Dasatinib 
Unadjusted mean (SD) 
[range] 
n=24 
p-value 
Outpatient visits 39.05 (23.19) 
[9-91] 
45.17 (27.32) 
[6-134] 
0.43 
Inpatient visits 0.50 (1.10) 
[0-4] 
0.79 (1.44) 
[0-6] 
0.46 
Inpatient hospital days 2.70 (6.78) 
[0-29] 
5.4 (9.78) 
[0-34] 
0.37 
ER visits 0.35 (1.35) 
[0-6] 
0.67 (1.86) 
[0-7] 
0.53 
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Table 5.30 Association between initiating dasatinib versus nilotinib and outpatient visits and 
inpatient days* 
 Outpatient Visits Inpatient Hospital Days 
Model Estimate 95% CI p-value Estimate 95% CI p-value 
Multivariable†       
TKI (dasatinib 
versus nilotinib) 
0.13 0.01, 0.25 0.03 1.17 0.55, 1.79 .0002 
Demographic       
Age 0.12 0.05, 0.19 0.001 0.08 -0.20, 0.36 0.59 
Sex 0.006 -0.12, 0.12 0.92 -1.09 -1.79, -0.40 <.01 
Plan 0.006 0.06, 0.17 <.001 0.33 0.07, 0.60 0.01 
Region -0.06 -0.15, 0.02 0.14 0.95 0.49, 1.42 <.0001 
LIS 0.40 0.25, 0.54 <.0001 3.08 2.24, 3.92 <.0001 
Dual -0.45 -0.66, -0.24 <.0001 -0.48 -1.89, 0.92 0.50 
Clinical 
characteristics 
      
Duration of therapy -0.0002 -0.0006, 0.002 0.34 0.005 0.003, 0.008 <.0001 
Proxy for CML 
phase 
0.58 0.42, 0.74 <.0001 1.45 0.55, 2.35 <.01 
RxRisk 0.17 0.06, 0.33 0.03 0.88 -0.52, 2.28 0.22 
Medication count 0.11 -0.05, 0.26 0.16 3.63 2.71, 4.55 <.0001 
Vaccine 0.05 -0.12, 0.23 0.55 -2.51 -3.46, -1.56 <.0001 
Provider 
characteristics 
      
Age 0.009 -0.05, 0.07 0.77 -0.08 -0.39, 0.25 0.65 
Sex 0.04 -0.14, 0.21 0.67 -0.39 -1.60, 0.81 0.52 
Specialty -0.27 -057, 0.03 0.08 -3.99 -6.29, -1.70 <.001 
Practice type 0.08 -0.02, 0.17 0.10 1.28 0.95, 1.62 <.0001 
PS quintile†       
TKI (datastinib 
versus nilotinib) 
0.05 -0.03, 0.16 0.20 0.69 0.36, 1.01 <.0001 
Quintile -0.12 -0.15, -0.09 <.0001 0.07 -0.03, 0.17 0.16 
Duration of therapy -0.0001 -0.0005, 0.0003 0.63 0.004 0.002, 0.005 <.0001 
* Mean health services utilization was evaluated using GLM with Poisson distribution and log link 
†Multivariable and PS quintiles model included the following covariates for adjustment: primary independent 
variable was initiating dasatinib versus nilotinib, demographic characteristics (i.e. age, gender, plan type, 
region, LIS, dual eligibility status), clinical characteristics (i.e. duration of treatment (days), RxRisk-V score, 
CML phase of disease, flu or pneumonia vaccination, medication count), and provider characteristics (i.e., age, 
gender, specialty, practice setting) 
 
Table 5.31 Incidence rate ratios for outpatient visits and inpatient hospital days comparing 
initiation of dasatinib versus nilotinib 
TKI (dasatinib vs. nilotinib) IRR 95% CI 
Outpatient visits   
Multivariable analysis* 1.14 1.01, 1.28 
PS quintile analysis* 1.05 0.97, 1.17 
Inpatient hospital days   
Multivariable analysis* 3.22 1.73, 5.99 
PS quintile analysis* 1.99 1.43, 2.75 
IRR=incidence rate ratio 
*Multivariable and PS quintiles model included the following covariates for adjustment: primary independent 
variable was initiating dasatinib versus nilotinib, demographic characteristics (i.e. age, gender, plan type, 
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region, LIS, dual eligibility status), clinical characteristics (i.e. duration of treatment (days), RxRisk-V score, 
CML phase of disease, flu or pneumonia vaccination, medication count), and provider characteristics (i.e., age, 
gender, specialty, practice setting) 
 
 
5.8.3 Healthcare costs 
5.8.3.1 Main Analyses 
The results for unadjusted and adjusted healthcare costs are presented in Tables 5.32 and 
5.34.  Total costs, TKI-related pharmacy costs, non TKI-related pharmacy costs, and medical costs 
incurred during the 12 month period following the initiation of TKI therapy were not significantly 
different for patients initiating dasatinib versus nilotinib.  The total unadjusted costs for patients 
initiating dasatinib and nilotinib were driven by TKI-related pharmacy costs ($62,140 and $70,273, 
respectively, p=0.44) (Table 5.32). 
Results of the GLM examining the association between initiating nilotinib versus dasatinib 
and healthcare costs are shown in Tables 5.33 and 5.34.  The results are consistent with the 
unadjusted results showing no difference in total, TKI-related costs, non TKI-related costs or medical 
costs during the 12 month period following initiation of therapy.  Increased number of days on 
therapy was associated with higher total healthcare and TKI-related costs; however, there was no 
association between duration of therapy and non TKI-related or medical costs.  
Table 5.32 Healthcare costs incurred during the 12 month period following initiation of 
nilotinib versus dasatinib (n=44)* 
 Nilotinib 
Unadjusted mean costs 
(SD) [range] 
n=20 
Dasatinib 
Unadjusted mean costs (SD) 
[range] 
n=24 
p-value 
Total Costs (pharmacy + 
medical) 
$80,617 ($41,124) [$15,536-
$168,179] 
$95,568 ($46,415) 
[$25986-$193,950] 
0.32 
Pharmacy Costs $64,533 ($34,158) 
[$8,924-$110,178] 
$72,607 ($36,871) 
[$9132-$134,040] 
0.45 
TKI-related $62,140 ($34,308) 
[$7,445-109,290] 
$70,273 ($36,781) 
[$6,782-$128,791] 
0.44 
Non-TKI related $2,394 ($2,049) 
[$236-$7,052) 
$2,335 ($2,179) 
[$0-$7,360] 
0.82 
Medical Costs $16,084 ($22,990) 
[$2,069-$88,085] 
$22,961 ($40,302) 
[$634-$183,237] 
0.32 
*Cost calculation included both plan paid and member out-of-pocket costs (i.e. patient copayments and co-
insurance).   
  
 
 
Table 5.33 Association between initiating nilotinib versus dasatinib and total, TKI-related costs, non TKI-related costs, and medical costs* 
Model Total Costs TKI-Related Costs Non TKI-Related Costs Medical Costs 
 Estimate 95% CI p-value Estimate 95% CI p-value Estimate 95% CI p-value Estimate 95% CI p-value 
Multivariable†             
TKI (nilotinib vs. 
dasatinib) 
0.19 -0.07, 0.45 0.16 0.08 -0.22, 0.39 0.58 -0.10 -0.61, 0.40 0.69 0.17 -0.52, 0.86 0.63 
Demographic             
Age -0.06 .023, 0.11 0.50 -0.11 -0.30, 0.08 0.25 0.34 -0.08, 0.75 0.11 0.18 -0.28, 0.64 0.45 
Sex 0.04 -0.26, 0.34 0.80 0.18 -0.16, 0.52 0.31 -0.16 -0.78, 0.46 0.62 -0.86 -1.57, -0.15 0.02 
Plan -0.01 -0.15, 0.13 0.89 -0.11 -0.26, 0.04 0.15 0.21 -0.07, 0.50 0.14 0.44 0.08, 0.79 0.02 
Region 0.20 0.02, 0.39 0.03 -0.12 -0.35, 0.11 0.31 0.50 0.15, 0.86 <.01 0.54 0.09, 0.99 0.02 
LIS 0.13 -0.22, 0.48 0.47 -0.004 -0.40, 0.40 0.99 1.19 0.43, 1.96 <.01 2.12 1.16, 3.09 <.0001 
Dual -0.22 -0.73, 0.29 0.40 0.24 -0.35, 0.82 0.42 -0.19 -1.32, 0.93 0.74 -1.29 -2.45, -0.14 0.03 
Clinical 
characteristics 
            
Duration of therapy 0.002 0.001, 0.003 <.0001 0.005 0.003, 0.006 <.0001 -0.003 -0.005, 
0.0005 
0.02 -0.002 -0.004, 0.001 0.29 
Proxy for CML phase -0.13 -0.51, 0.24 0.49 0.02 -0.45, 0.48 0.94 -0.34 -1.11, 0.43 0.39 -0.25 -1.11, 0.61 0.56 
RxRisk -0.13 -0.49, 0.23 0.49 0.21 -0.19, 0.60 0.31 1.51 0.83, 2.19 <.0001 0.31 -1.24, 0.62 0.51 
Medication count 0.30 -0.03, 0.63 0.07  -0.06 -0.44, 0.31 0.74 0.45 -0.22, 1.11 0.19 1.55 0.67, 2.4 <.001 
Vaccine -0.20 -0.60, 0.20 0.33 0.08 -0.41, 0.57 0.75 -0.017 -0.81, 0.77 0.97 -0.81 -1.79, 0.18 0.11 
Provider 
characteristics 
            
Age -0.06 -0.21, 0.08 0.39 0.12 -0.04, 0.29 0.14 -0.06 -0.33, 0.21 0.65 -0.11 -0.49, 0.27 0.58 
Sex 0.54 0.17, 0.91 <.01 0.06 -0.38, 0.49 0.80 1.15 0.36, 1.95 <.01 0.27 -0.72, 1.26 0.60 
Specialty -0.82 -1.51, 0.13 0.02 -0.09 -0.87, 0.69 0.82 -1.86 -3.28, 0.45 0.01 -2.73 -4.42, -1.05 <.01 
Practice type 0.03 -0.13, 0.19 0.70 0.05 -0.13, 0.24 0.57 0.19 0.50, 0.13 0.25 0.24 -0.16, 0.65 0.23 
PS quintile‡             
TKI (nilotinib versus 
dasatinib) 
0.20 -0.09, 0.48 0.18 0.19 -0.09, 0.47 0.19 -0.03 -0.65, 0.60 0.93 0.26 -0.46, 0.98 0.48 
Quintile -0.05 -0.16, 0.06 0.38 -0.006 -0.11, 0.10 0.91 -0.005 -0.24, 0.23 0.96 -0.11 -0.39, 0.18 0.46 
Duration of therapy 0.003 0.001, 0.004 <.0001 0.005 0.004, 0.006 <.0001 -0.0001 0.003, 
0.002 
0.93 -0.002 -0.005, 0.001 0.21 
* GLM with gamma distribution and log link; Cost calculation included both plan paid and member out-of-pocket costs (i.e. patient copayments and co-insurance).   
†Multivariable included the following covariates for adjustment: primary independent variable was initiating nilotinib vs. dasatinib, demographic characteristics (i.e. age, gender, 
plan type, region, LIS, dual eligibility status), clinical characteristics (i.e. duration of treatment (days) on index medication, RxRisk-V score, CML phase of disease, flu or 
pneumonia vaccination, medication count), and provider characteristics (i.e., age, gender, specialty, practice setting) 
‡PS quintile included the following covariates for adjustment: primary independent variable was initiating nilotinib vs. dasatinib, covariates (i.e. PS quintile, duration of treatment 
(days) on index medication
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Table 5.34 Predicted, adjusted healthcare costs during the 12 month period following   initiation 
of nilotinib versus dasatinib (n=44)* 
 Nilotinib 
mean costs (95% CI) 
n=20 
Dasatinib 
mean costs (95% CI) 
n=24 
p-value 
Total Costs (pharmacy 
+ medical) 
$72,817 
($61,010, $86,916) 
$87,807  
($74,997, $102,816) 
0.16 
Pharmacy Costs    
TKI-related $53,874 
($43,958, $66,026) 
$58,618 
($48,913, $70,242) 
0.58 
Non-TKI related $1,781 ($1,256, $2,528) $1,606 ($1,175, $2,196) 0.69 
Medical Costs $10,773 ($6,871, $16,892) $12,776 ($8,602, $18,974) 0.63 
* GLM with gamma distribution and log link; Cost calculation included both plan paid and member out-of-
pocket costs (i.e. patient copayments and co-insurance).   
Multivariable model included the following covariates for adjustment: primary independent variable was 
initiating nilotinib vs. dasatinib; demographic characteristics (i.e. age, gender, plan type, region, LIS, dual 
eligibility status), clinical characteristics (i.e. duration of treatment (days) on index medication, RxRisk-V score, 
CML phase of disease, flu or pneumonia vaccination, medication count), and provider characteristics (i.e., age, 
gender, specialty, practice setting) 
 
5.8.3.2 Sensitivity Analysis 
A sensitivity analysis of the unadjusted costs was conducted and limited to patients who were 
initiated on a starting dose that indicated chronic phase disease (n=34) (Table 5.35).  Similar to the 
main analysis, total healthcare, TKI-related pharmacy, non TKI-related pharmacy, and medical costs 
during the 12 month period following the initiation of TKI therapy were not significantly different for 
patients initiating dasatinib versus nilotinib.   
Table 5.35 Healthcare costs incurred during the 12 month period following initiation of 
nilotinib versus dasatinib (n=34)* 
 Nilotinib 
Unadjusted mean costs 
(SD) [range] 
n=14 
Dasatinib 
Unadjusted mean costs (SD) 
[range] 
n=20 
p-value 
Total Costs (pharmacy + 
medical) 
$84,772 ($42,135) 
[$15,536, $168,179) 
$98,894 ($45,247) 
[$25,986, $193,950] 
0.40 
Pharmacy Costs $64,683 ($34,085)  
[$8,924-$110,178) 
$76,078 ($37,518) 
[$9,132-$134,040] 
0.34 
TKI-related $61,934 ($34,377) 
[$7,445, $109,290] 
$73,570 ($37,569) 
[$6,782, $128,791] 
0.33 
Non-TKI related $2,749 ($2,228) 
[$236-$7,052] 
$2,507 ($2,242) 
[$41, $7,360] 
0.74 
Medical Costs $20,089 ($25,737) 
[$2,069-$88,085] 
$22,817 ($41,811) 
[$634, 183,237] 
0.36 
*Only patients with a starting dose indicating chronic phase disease were included
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CHAPTER VI: DISCUSSION 
6.1 Overview 
This study describes factors associated with initiating a second-generation compared to a 
first-generation TKI for the treatment of CML and patterns of TKI treatment interruption and regimen 
change in a large national health plan that included both commercial and Medicare members after 
second-generation TKI therapies were FDA approved as first-line therapy.  In addition, adherence, 
health services utilization and healthcare costs were compared between patients newly initiating a 
second versus first-generation TKI.  During the study period, approximately 64% of patients received 
a first-generation TKI (i.e. imatinib) as the initial therapy.  Patients’ starting dose of TKI therapy was 
used as a proxy for disease phase at the time of initiation.  Of the patients included in the study, 92% 
of patients were initiated on a dose indicating chronic phase disease. The study results support four 
main findings.   
First, within the entire population, 50% of patients had a treatment interruption, defined as a 
gap in therapy of at least 30 days, during the follow-up period.  In this study, patients in the first-
generation TKI cohort were less likely to have treatment interruption compared to those in the 
second-generation TKI cohort.  Additionally, patients initiated on a first-generation TKI stayed on 
therapy longer compared to patients initiating a second-generation TKI therapy.  These findings were 
opposite of what was hypothesized.  Of the patients with treatment interruption, 58% of patients who 
initiated therapy with a first-generation TKI re-initiated the index medication following an 
interruption compared to 38% of patients who initiated therapy with a second-generation TKI.  In 
both cohorts, medication change was the next most common treatment pattern with almost one-fourth 
of patients changing medications in each cohort.  A larger proportion of patients in the second-
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generation TKI cohort discontinued therapy compared to the first-generation TKI cohort by the end of 
a year follow-up (30% vs. 15%, respectively).  
Second, there is evidence that adherence to first-line TKI therapy, regardless of whether 
patients initiated a second versus first-generation TKI, is suboptimal in patients with CML.  
Approximately, half of patients had a PDC lower than 85% during the follow-up period.  Although 
there was no association between initiating a second versus first-generation TKI and adherence when 
PDC was dichotomized at 0.85 when PDC was used as a continuous measure mean adherence was 
higher for patients initiating first compared to second-generation TKI therapy (PDC 0.77 and 0.68, 
respectively, p=0.007).  This finding was opposite of what was hypothesized (i.e. patients taking a 
second-generation TKI therapy are more adherent compared to patients taking a first-generation TKI 
therapy). 
Third, outpatient visits were the most used health service for both cohorts.  Patients initiating 
a first-generation TKI had fewer outpatient visits and hospital days compared to patients initiating a 
second-generation TKI which was opposite of the study hypotheses for these outcomes.  No 
differences were noted between inpatient hospitalizations or ER visits during the 12 month follow-up 
period between the two cohorts which is consistent with the study hypotheses.  Patients initiating a 
first-generation TKI had lower overall healthcare, pharmacy and medical costs during the follow-up 
period.  It is important to note that this analysis used an ITT approach and patients were assigned to 
the first or second-generation TKI cohort based on the initial treatment.  Total healthcare costs for 
both cohorts were driven by TKI-related costs.   
Fourth, the exploratory analysis comparing patients initiating dasatinib and nilotinib showed 
similar results between the two agents for the outcomes studied which was consistent with the study 
hypotheses.  There were no differences in mean adherence for patients initiating dasatinib versus 
nilotinib or health services utilization.  The average total costs for patients initiating nilotinib over the 
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12 month follow-up period were higher compared to patient initiating dasatinib but these results were 
not statistically significant.  
6.2 Interpretation 
The rationale for initiating a second-generation TKI as frontline therapy for patients with 
chronic phase disease is remarkable rates of early responses with almost 90% of patients achieving a 
complete cytogenetic response (CCyR) by 3 months of therapy and excellent event-free survival, 
transformation-free survival, and survival.14-16  The counterargument is that approximately two-thirds 
of patients have an acceptable response to imatinib based on the results of the IRIS study17 and other 
reports.18,19  Although second-generation TKIs achieve quicker and deeper clinical responses, the 
results of this study show that imatinib was more widely prescribed as frontline therapy compared to 
second-generation TKIs in this population between 2010 and 2011.   
This study showed that patients enrolled in a commercial plan and patients with a starting 
dose that reflected accelerated disease were more likely to initiate therapy with a second-generation 
TKI.  Patients enrolled in a commercial plan are on average younger than patients enrolled in a 
Medicare plan.  Providers may prescribe second-generation TKIs to younger patients because they 
perceived these patients were most likely to benefit.109  Better prognosticators are needed to 
determine which patients do better on first versus second-generation TKI therapy frontline.  Other 
analyses have shown that patients with CML who present with features of accelerated disease at the 
time of diagnosis have an excellent outcome with TKIs, particularly second-generation TKI.124  
Consistent with studies showing improved clinical endpoints, patients in this study with accelerated 
phase disease were more likely to initiate a second-generation TKI.   
Although there is not a consensus on whether to initiate patients with chronic phase CML on 
a first versus second-generation TKI, the goal of therapy is to achieve optimal adherence which is a 
critical factor for achieving molecular responses.  Marin and colleagues found a correlation between 
low adherence, defined as ≤90%, and 6-year probability to achieve a major molecular response and 
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complete molecular response.20 The current study found that adherence to TKI therapy was 
suboptimal in patients with CML, regardless of whether patients initiate on a first versus second-
generation TKI.  Approximately half of patients had optimal adherence, defined as ≥85%, during the 
follow-up period.  This rate is slightly lower than what others have shown for patients initiating 
therapy on imatinib with approximately 60% being classified as having optimal adherence.79,125   
When PDC was used as a continuous variable, mean adherence was higher for patients 
initiating first compared to second-generation TKI therapy (PDC 0.77 and 0.68, respectively, 
p=0.007).  The mean adherence rate for patients initiating imatinib was similar to other reports.79,84  
Darkow and colleagues, reported mean adherence of 77.7% over a  12 month follow-up, with 31% of 
patients having a treatment interruption.  All patients restarted imatinib within the study period.   
In the current study, the proportion of patients with a treatment interruption was similar to 
what has been reported within clinical trials. Specifically, 58.8% of patients initiating therapy on a 
second-generation TKI had a treatment interruption during the 12-month follow-up period compared 
to 45.1% of patients initiating a first-generation TKI.  Within the Phase III study, DASISION, 
comparing dasatinib versus imatinib, 59% and 43% had a treatment interruption, respectively.10  
Similar results have been reported in the Phase III study, ENESTnd, comparing nilotinib 600 mg and 
800 mg versus imatinib.  The proportion of patients with an adverse event leading to a dose reduction 
or interruption was 55%, 63%, and 46%, respectively.62  Treatment interruptions and dose reductions 
were allowed to manage adverse events in the clinical trials.  In the current study, the difference 
between treatment interruptions among patients initiating a first versus second-generation TKI is 
likely due to the differences in toxicity profiles of the specific agents resulting in adverse events.  The 
second-generation TKI therapies have unique toxicities which could contribute to extended treatment 
interruptions compared to imatinib.  Specifically, pleural effusion is a unique adverse event related to 
dasatinib treatment and QT prolongation has been reported among patients taking nilotinib.  
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Additionally, the second-generation TKI therapies have deeper cytogenetic and molecular responses, 
which mean longer time to hematologic recovery.   
Of the patients with a treatment interruption in the current study, the majority re-initiated the 
starting therapy or changed medications.  However, 15% of patients in the first-generation TKI cohort 
and 30% of patients in the second-generation TKI cohort who had a treatment interruption 
discontinued therapy for the remainder of the study period.  Within the clinical trials, there were no 
differences in discontinuation between patients randomized to a second-generation TKI versus 
imatinib.  The two-year follow-up DASISION study reported 23% of patients taking dasatinib and 
25% of patients taking imatinib discontinued treatment.10   The ENESTnd study only reported 
discontinuation due to adverse events.  Adverse events leading to discontinuation occurred in 13% of 
patients taking the higher dose of nilotinib versus 11% of patients taking imatinib.62  Other reasons 
for permanent discontinuation reported in real world reports include: progression, intolerance, failure, 
elective allogeneic transplantation, and death from non-CML-related causes.19      
In practice, a therapy change is indicative of treatment failure or intolerance.  For example, a 
patient who has lost a CCyR or a complete hematologic response (i.e. secondary resistance), therapy 
should be changed immediately.42  A delayed treatment change in a patient who has lost cytogenetic 
response can cause a decreased probability of event-free survival.71  Approximately 19% of patients 
in each cohort had a regimen change during the follow-up period which most often involved changing 
to a different TKI.   
CML is a chronic disease requiring routine follow-up.  As expected, outpatient visits were the 
most used service with an average of 37.8 and 42.4 visits for patients initiating a first compared to a 
second-generation TKI over a 12 month period.  This is consistent with what others have reported.79  
The average number of inpatient and ER visits for both cohorts was low.  However, patients initiating 
a first-generation TKI had fewer hospitalizations, hospital days, and ER visits during the 12 month 
follow-up period compared to patients initiating a second-generation TKI.   
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Both the overall pharmacy costs and total healthcare costs for both cohorts were driven by 
TKI-related costs.  Although we found that patients initiating a first-generation TKI had lower overall 
healthcare, pharmacy and medical costs during the follow-up period, these results need to be 
interpreted with caution.  This analysis used an ITT approach and patients were assigned to the first 
or second-generation TKI cohort based on the initial treatment.  Duration of initial therapy was 
controlled for in the GLM models and was associated with greater total healthcare, pharmacy and 
medical costs.   
An exploratory analysis was conducted and limited to patients taking either dasatinib or 
nilotinib.  Similar to indirect comparisons of these agents to each other in the clinical trials (i.e. 
DASISION and ENESTnd), there were no differences in any of the endpoints studied between 
patients initiating dasatinib versus nilotinib. 
6.3 Strengths  
 This study contributes to the literature by being the first to compare second versus first-
generation TKI therapy as frontline treatment for CML using real world data.  Because there is no 
consensus on whether to start patients on a first compared to a second-generation TKI therapy as first-
line therapy, this study helps to fill knowledge gaps using observational data since the second-
generation TKIs received a first-line indication.  Prior studies have evaluated adherence, health 
services utilization, and healthcare costs for patients who initiated imatinib as first-line and second-
generation TKIs in the second-line setting.79,80,84  
 The main strengths of this analysis include a robust database for evaluating outcomes for a 
rare cancer affecting older adults.  This study identified 368 newly treated CML patients over a year 
and a half period which is more than expected based on the incidence rate reported in the literature.  
The literature reports an incidence rate of 1.6 per 100,000 and Humana had approximately 5.8 million 
enrollees during plan years 2010 and 2011.  In addition to the large sample size for CML, this study 
also included both commercial and Medicare plan types.  The diversity of plan type enrollees 
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increases the external validity of the results to a larger cross section of both commercial and Medicare 
populations in the United States. 
6.4 Limitations 
Limitations common to studies using administrative claims data apply in this study. These 
include lack of certain information in the database (e.g., health behavior and health belief 
information), error in claims coding, and the potential influence of unidentified confounding 
variables.  Administrative claims data include paid claims only.  If a patient were given sample 
medications, these would not be reflected in the claims data.  On the other hand, a claim for a TKI 
therapy does not necessarily mean the patient actually took the medication.   
Although having a robust sample of newly treated CML patients is a strength of this study, it 
is important to note a higher incidence of CML in the Humana plan may be due adverse selection.  
The median age at diagnosis is 64.  Humana is second largest Medicare Part D provider, and TKI 
therapy to treat CML is expensive.  Because the current study utilized claims data from a single 
health plan, specifically a large Medicare Part D provider, the results might not be generalized to the 
general population.   
Information regarding the phase of CML and other factors that could lead physicians and 
patients to select a particular TKI therapy was not readily available through medical chart review.  
Although patients’ starting dose of TKI therapy was assessed and used as a proxy for CML phase at 
the time of initiation, this method has not been validated.  Appropriate CML staging is determined 
during the work-up through bone marrow aspiration and cytogenetic analysis.  The nature of this 
study prevents us from making definitive causal association between type of TKI therapy and 
adherence, health services utilization and healthcare costs.  Additionally, TKI utilization is being 
measured over the same time period outcomes are being assessed and therefore no clear temporal 
relationship between exposure and outcome can be established.  We attempted to reduce selection 
bias and strengthen the causal inference by using a new user design with multivariate regression 
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modeling, however, these methods can only reduce bias caused by measured covariates; neither can 
reduce bias caused by unmeasured covariates.  Achieving a complete cytogenetic response is 
considered the gold standard for good response to therapy.  The laboratory results for cytogenetic and 
molecular responses were not available for this study and therefore stage of disease at diagnosis and 
disease progression was not assessed.   
All cost data were based on the actual cost during the plan year they were incurred.  Costs 
were not converted to $US (2013) using the medical component of the Consumer Price Index.  Total 
healthcare costs were driven by the TKI-related costs.  The price of TKI therapy has increased year 
over year.  For example, imatinib and dasatinib have taken a 9.9% and 3.8% price increase, 
respectively during 2012.  This trend is likely to increase as brand name imatinib is ending its life 
cycle.  Therefore, the healthcare cost data presented in this study is likely lower than what would be 
expected in 2013.  
Since this study was initiated, the landscape of available TKIs for treating CML has rapidly 
evolved.  Bosutinib was FDA approved in September 2012 for adult patients with chronic, 
accelerated, or blast crisis CML with resistance or intolerance to prior therapy.  Ponatinib was also 
approved in the second-line setting in December 2012 and is the most potent TKI for the treatment of 
CML.  Ponatinib has subsequently been removed from the market because of the risk of life-
threatening blood clots and severe narrowing of blood vessels.  Although having several treatment 
options available for the treatment of CML is beneficial, there is concern that this may increase 
temptation of rapid succession of treatment changes because of perceived suboptimal response or 
adverse events.42  This practice should be avoided.  The expected long-term outcome with the current 
treatment needs to be compared with the expectations of a newer agent before changing therapy.42    
New treatment options have become available after the study period for second-line use.  
Therefore, the results of this study may not reflect practice today.  Although there is clinical rationale 
to support starting patients on either a first or second-generation TKI as frontline therapy, the 
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availability of additional second-line therapies may influence treatment decisions for frontline 
treatment.  Further, physicians may be more willing to start patients on a second-generation TKI now 
that three year follow-up data are available for both dasatinib and nilotinb (i.e. DASISION and 
ENESTnd) and additional second-line agents are available for patients who have suboptimal response 
to nilotinib and dasatinib when used as first-line therapy.  
6.5 Policy implications 
This study was a first step in evaluating treatment patterns and economic outcomes among 
patients newly initiating first and second-generation TKI therapies for the treatment of CML.  With 
the availability of several treatment options and imatinib becoming generically available in 2015, 
payers and providers are faced with more considerations when managing patients with CML.  
Although oncology is a CMS protected class and these therapies must be covered by Part D sponsors, 
payers will consider more restrictive preferred therapies and will drive generic utilization with 
imatinib.  Recent guidance issued by the National Institute for Health and Clinical Excellence (NICE) 
recommends imatinib and nilotinib, both made by Novartis, for first-line treatment of CML.24  
Dasatinib, made by Bristol-Myers Squibb, is not recommended.  NICE concluded from indirect 
comparisons that dasatinib and nilotinib could be considered equally effective in treatment of CML 
and accepted an undisclosed patient access scheme reducing the cost to approve nilotinib on the 
formulary in the United Kingdom.  U.S. payers may consider a similar approach and have a preferred 
second-generation TKI (i.e. nilotinib or dasatinib). 
Physicians will not only consider efficacy but adherence as well as cost when recommending 
frontline therapy for the treatment of CML.  This will become increasingly important when imatinib 
becomes generically available in 2015.  Furthermore, the argument of initiating older patients on 
imatinib is further strengthened by the results of this study.  Patients who initiated therapy with 
imatinib had lower rates of treatment interruption, higher mean adherence, fewer inpatient and ER 
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visits, and overall healthcare costs during the follow-up period compared to patients who were 
initiated on second-generation TKIs. 
6.6 Future Research 
The first-line treatments available today have been studied in isolation and only address the 
issue of what drug is better.9,11,57  These studies do not address how to adequately treat patients with a 
suboptimal response on first-line therapy.  Future research is needed to determine which strategy is 
better: use of second-generation TKIs as initial therapy or after failure of imatinib.42  Additionally, 
comparative effectiveness analyses with larger sample sizes are needed to determine whether 
initiating a first versus second-generation TKI is preferred and for those patients who switch, the best 
sequencing for second-line and third-line agents.  Comparative effectiveness research using real 
world data should continue to be used to inform formulary decision making and help physicians 
identify which patients may benefit from a particular therapy. 
6.7 Conclusion 
Using a large dataset of privately insured and Medicare patients, this study demonstrated that 
the majority of patients were initiated on a first-generation TKI compared to a second-generation TKI 
as first-line treatment.  Initiating therapy on a first-generation TKI was associated with lower risk of 
treatment interruption.  Although mean adherence was higher for patients initiating imatinib 
compared to a second-generation TKI, adherence to therapy is suboptimal.  Initiating therapy on a 
first compared to a second-generation TKI was associated with fewer inpatient hospital stays, 
emergency room visits, and overall lower healthcare costs during the follow-up period.   
 For analyses assessing intended drug effects, it is often the case that many important 
confounders are unmeasured.  Although we attempted to reduce selection bias and strengthen causal 
inference by using a new user design with multivariate regression modeling, the results from this 
study should be interpreted with caution due to the potential of unmeasured confounding.  
Specifically, this study found statistically significant differences for some study outcomes for patients 
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initiating first versus second-generation TKI therapy.  Although this study adjusted for CML phase, 
patients with accelerated CML were more likely to initiate therapy on a second-generation TKI 
therapy.  Therefore, the possibility of residual confounding by disease severity cannot be excluded.  
Instrumental variable methods have been proposed as a potential approach to control for confounding 
by disease severity in non-experimental studies and should be considered for future research 
comparing CML therapies. 
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